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Abstract 
Natural Killer (NK) cells are innate cells of the immune system and constitute 
10% of lung lymphocytes. Increasing evidence implicates a role for innate 
immunity in the pathogenesis of asthma and although there is evidence of a role 
for NK cells in the development of allergic inflammation, the mechanisms by 
which NK cells contribute to allergy is not known.  
To characterise the NK cell response and determine the phenotype of NK cells in 
allergic pulmonary inflammation we employed a model in which mice are dosed 
intranasally 3 times a week for 3 weeks with house dust mite (HDM) extract. 
Numbers of NK cells in the bronchoalveolar lavage (BAL) increased over the 
time course of HDM challenge and followed a similar trend to eosinophils and 
Th2 cells. Airway NK cells were activated and expressed NKG2D and granzyme 
B. In addition, expression of the NKG2D ligand (MULT-1) was upregulated in 
the lungs of mice treated with HDM. 
To determine the importance of the NKG2D receptor in allergic inflammation, the 
HDM model was tested on NKG2D knock out (KO) mice. There was a dramatic 
reduction in the extent of the inflammatory response in the absence of this 
receptor, including a reduction in BAL eosinophilia, Th2 responses and serum 
IgE. Adoptive transfer of wild type (WT) NK cells into NKG2D KO mice 
restored allergic inflammatory responses to HDM, whereas transfer of granzyme 
B-/- NK cells did not, demonstrating the requirement for NK cell expression of 
NKG2D and granzyme B. 
Detailed phenotypic analysis of NKp46+ cells in the HDM model showed that 
NKp46+ cells in BAL and lung consisted of RORγt+ and RORγt- subsets. 
NKp46+RORγt- cells resembled conventional NK cells as they express NKG2D 
and granzyme B, however NKp46+RORγt+ had similar phenotype to type-3 innate 
lymphoid cells (ILC3) cells and produced Th2 cytokines upon HDM challenge. 
We have shown for the first time that NK cells promote allergic lung 
inflammation via NKG2D and granzyme B production. We have also described 
for the first time the presence of NKp46+RORγt+ cells in the airways and lung 
which identifies potential novel therapeutic targets. 
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Chapter One – Introduction 
1.1 Asthma 
Asthma is a complex disease with many clinical phenotypes in both adults and 
children. The prevalence of asthma is rapidly increasing to epidemic proportions. 
There are now an estimated 300 million sufferers worldwide and this number is 
expected to significantly increase over the next 15-20 years [1]. Despite the advances 
in effective therapy, asthma still has enormous healthcare expenditure and economic 
burden associated with it [2]. The majority of asthma related hospitalisations are due 
to exacerbation, which is strongly associated with respiratory viral infections and 
asthmatics experience more severe and longer-lasting symptoms following infection 
[3].  
 
Asthma is a heterogeneous condition, defined as a chronic inflammatory disease of 
the airways in which many cell types play a role.  It is characterised by reversible 
airway obstruction, airway inflammation, airway hyperresponsiveness (AHR), mucus 
hypersecretion, and airway remodelling [4]. For many patients the disease has its 
roots in infancy, and both genetic factors and environmental factors such as viruses or 
allergens, contribute to its initiation and evolution [5]. In the majority of cases, this 
occurs through the selective expansion of  T lymphocytes (specifically Th2 cells) that 
secrete a plethora of type-2 cytokines such as IL-4, IL-5, IL-13 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [6].  
 
The most common form of the disease is allergic asthma, which has been the major 
focus of treatment and research [7, 8]. Current therapies are of limited efficacy, so 
there is a pressing need for further understanding of the immune pathways that drive 
allergic lung disease. Atopy is a genetic predisposition in which an atopic individual 
mounts an allergen-specific IgE response and has positive skin prick tests to common 
allergens. One of the common allergens associated with atopy and asthma is house 
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dust mite (HDM) [9-11] and 50 to 85% of atopic asthmatics are allergic to HDM 
[12]. 
1.2 AHR and airway remodelling 
Clinically asthma is characterised by attacks of wheezing and breathlessness due to 
bronchoconstriction [13]. Asthmatics exhibit a dramatic heightened responsiveness to 
innocuous stimuli leading to constriction of conducting airways and decline in lung 
function known as AHR [14]. AHR is mediated by impaired function and contraction 
of the underlying airway smooth muscle and in the majority of cases this can be 
improved by use of smooth muscle relaxants such as β-agonists [15]. The specific 
causes leading to altered airway responsiveness in asthmatics are still unclear [16]. 
Airway inflammation can change airway smooth muscle behaviour; however the 
extent of airway inflammation does not correlate with the degree and severity of 
AHR [17-20].   
 
In addition to AHR and airway inflammation, asthma is also associated with airway 
remodelling. This represents complex structural changes [21, 22] which include 
epithelial detachment and compromised function, sub-epithelial fibrosis, increased 
fibroblast proliferation [23, 24], goblet cell hyperplasia and angiogenesis [25, 26]. 
Current asthma therapies, such as inhaled corticosteroids which are the most effective 
anti-inflammatory therapy for asthma, have minimal impact on airway remodelling 
[27, 28]. The mechanisms that regulate airway remodelling and the precise sequence 
of events that occurs in the course of the remodelling process are not fully understood 
[16]. Previously it was believed that the repair process in response to airway injuries, 
as a result of sustained airway inflammation, causes airway remodelling [29-32]. 
However, recent evidence indicates that inflammation and remodelling occur in 
parallel rather than as sequential events [33, 34]. In addition, studies of childhood 
asthma indicates that structural changes occurs at early stages of the disease and that 
remodelling may precede the development of chronic inflammation; making it a 
crucial component for the development of asthma [35].  
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1.3 Immunopathogenesis of allergic asthma  
Allergic asthma is an aberrant immune response to non-pathogenic stimuli. Airway 
inflammation is the cause of airway pathophysiology and dysfunction in asthma. The 
inflammatory immune response in asthma is complex and heterogeneous and 
involves both innate and adaptive cells of the immune system. 
1.3.1 Initiation of allergic asthma 
There is a growing interest in the role of innate cells in the initiation of allergic 
airway inflammation. Allergens, including those of HDM, can trigger pattern 
recognition receptors (PRRs) on antigen presenting cells (APC) and structural cells, 
such as respiratory epithelial cells [36-38].  
1.3.1.1 Airway epithelium and HDM 
The airway epithelium is one of the first points of contact between the allergen and 
the immune system [39]. The relationship and interactions between the pulmonary 
innate immune system and surrounding tissue are essential for allergen sensitisation 
[40]. In fact, a number of recently identified asthma susceptibility genes are 
expressed in the epithelium [41, 42].  
 
Airway epithelial cells express PRRs which respond to pathogen-associated 
molecular patterns (PAMPs) and damaged-associated molecular patterns (DAMPs). 
Activation of these receptors leads to release of mediators such as cytokines and 
chemokines. This leads to the activation of innate immune cells, including type-2 
innate lymphocytes, γδ T cells, NKT cells and dendritic cells (DC) which promote 
Th2 immune responses [43-46] (Figure 1.1). 
 
Many allergens such as HDM contain proteolytic allergens and microbial 
contaminants. Protease activity of the group 1 mite allergens Derp1 and Derp2 
contributes to HDM allergenicity by cleaving epithelial tight junctions allowing 
allergen delivery from airway lumen to APCs [47, 48]. Furthermore proteases can 
also react with cell surface protease activated receptors (PARs) in the airways to 
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initiate an inflammatory response [49]. In addition to this, HDM contains microbial 
compounds such as LPS, β-glucans and chitin, a glucosamine-based polymer forming 
the mite exoskeleton and also found in fungal cell walls. These components can act 
on PRRs such as TLRs and C-type lectins on epithelial cells and contribute to 
allergenecity of HDM [50] (Figure 1.1). Furthermore, DAMPs such as adenosine 
triphosphate (ATP) and uric acid are able to trigger immune responses and have been 
shown to be increased in the airways of asthmatic subjects following allergen 
exposure [51, 52]. In HDM induced allergic inflammation in mice, uric acid has been 
shown to be important in Th2 inflammation, AHR and eosinophilia and DC 
activation [52].  
 
Epithelial cells can activate DCs through direct interaction or via the release of 
mediators [53]. Hammad et al. [43] demonstrated that epithelial cell activation 
through PPRs, is a key event in activation of DCs and propagation of the immune 
response. Complex allergen such as HDM can directly stimulate the production of 
thymic stromal lymphopoietin (TSLP), IL-25, IL-33 and CCL20/MIP-3α from airway 
epithelial cells [54]. Interestingly TLR4 signalling requires a cofactor MD2 which has 
low expression in airway epithelial cells, however the Derp2 component of  HDM has 
molecular similarity to MD2 which facilitates TLR4 signalling in absence of MD2 
[50]. 
1.3.1.2 DCs and inhaled allergen 
DCs, residing in the airway mucosa are essential APCs for priming, initiation and 
maintenance of Th2-driven inflammation following allergen exposure. In addition to 
expressing innate immune receptors, DCs can take up allergen, processing them into 
small peptides and presenting them through major histocompatibility complex (MHC 
class I and class II) to T cells. Rapid recruitment of DCs into the bronchial mucosa 
has been observed in animal studies [55] and in human subjects in response to 
allergen challenge [56]. The presence of GM-CSF released from epithelial cells in the 
presence of IL-4 and TNF-α leads to DC maturation and fully competent APCs. DC 
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maturation involves the upregulation of co-stimulatory molecules and enables DCs to 
migrate to the draining lymph nodes (LNs) to prime an antigen-specific T cell 
response [57, 58].  
 
The role of DCs in initiation of Th2 immunity was demonstrated by CD11c-DTR 
mice, where depletion of CD11chigh  DCs abolished Th2 immunity to HDM [44].  
DCs have many subsets with distinct surface marker expression, function and 
development [59]. Common DC progenitor gives rise to pre-conventional DCs and 
plasmacytoid DCs (pDCs) [60]. Pre-conventional DCs in the lung are CD103 or 
CD11b expressing [61]. CD103+ DCs are involved in viral antigen cross-presentation 
to CD8 cells [62, 63] and CD11b+ DCs present soluble antigen to CD4 T cells and are 
shown to produce pro-inflammatory chemokines [64, 65]. pDCs, however, are known 
to have a regulatory role in allergic lung inflammation [66]. 
Interestingly, Plantinga et al. [67] have demonstrated that different subsets of DCs are 
responsible for initiation and maintenance of allergic responses in the lung. They 
identified migratory CD11b+ conventional DCs as the subset that initiates Th2 
responses in the LN. Furthermore they demonstrated that Flt3l knockout (KO) mice, 
which lack conventional DCs, can mediate Th2 responses via monocyte derived DCs, 
if a high dose of HDM is used and these cells are the subset responsible for 
production of pro-inflammatory chemokines and antigen presentation in the lung.  
 
The mechanism of Th2 differentiation from naïve T cells in the LN is still poorly 
understood. In the case of Th1, IL-12 production by DCs is sufficient to initiate 
differentiation of T cells. Therefore it was proposed that Th2 differentiation is a 
“default mechanism” [68], occurring in the absence of strong Th1 or Th17 promoting 
cytokines, or when the strength of the MHC II–TCR interaction or co-stimulation is 
weak [69-72]. It was believed that the absences of IL-12 signalling in DCs drives 
them to induce Th2 responses. However DCs activated by papain which do not 
produce IL-12, fail to induce Th2 responses and in return induce weak Th1 responses 
[73].  
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Another school of thought is that the prerequisite of Th2 differentiation is an 
obligatory source of IL-4 which activates transcription factor STAT6 and GATA3 
and a source of IL-2, IL-7, or TSLP to activate the transcription factor STAT-5 [68, 
74-77]. Despite this, DCs have never been demonstrated to produce IL-4. There is 
some evidence that cellular sources of IL-4 could be mast cells or basophils [78, 79]. 
Van Panhuys et al. [80]  and Perrigoue et al. [81] demonstrated that in helminth 
infection, basophils migrate into the LN and act as APCs and a source of IL-4.  
Furthermore it was also reported that in papain injection models, expression of MHC 
class II on DCs was not sufficient to induce Th2 immunity [78]. However, Hammad 
et al. [44] demonstrated lung inflammatory DCs but not basophils are necessary and 
sufficient for Th2 development in the HDM mouse model where exposure occurs by 
inhalation. Development of Th2 response to inhaled HDM was recently shown to 
depend on its protease activity, its potential to induce TLR4 signalling and triggering 
of C-type lectin receptors on DCs and bronchial epithelial cells [82-85]. These 
findings lead to a new proposal where TLR4 triggering and C-type lectin triggering 
on epithelial cells or damage by microbes or allergens could direct DCs migration, 
trafficking and activation via the release of innate pro-Th2 cytokines like GM-CSF, 
TSLP, IL-25, and IL-33 and production of chemokines like CCL2 and CCL20 [43, 
53, 86]. Chemoattractants such as CCL20, CCL19 and CCL27- the ligands for CCR6, 
CCR7 and CCR10 respectively, direct DC migration toward the epithelium and 
submucosa [44]. 
1.3.1.3 Pro-Th2 innate cytokines and initiation of Th2 response 
IL-25, IL-33 and TSLP are innate cytokines, central to the recruitment and activation 
of DCs and the initiation of Th2 responses. These epithelial derived cytokines are 
able to cause eosinophilia, Th2 cytokine production and AHR [87-89].  Mice that 
lack IL-25 and IL-33 and corresponding receptors show delayed onset of Th2 
immunity [90-92]. IL-25, its receptor (IL-17RB) transcripts and the number of cells 
expressing TSLP have been shown to be elevated in biopsies of asthmatic individuals 
[93-95].  
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TSLP is a cytokine of the IL-7 family and is a powerful stimulus of Th2 immunity 
[96, 97]. TSLP can activate DCs by upregulation of OX40L and lead to Th2 
polarisation, which is further enhanced by IL-25 produced by epithelial cells, 
basophils and eosinophils [94]. In mice, TSLP mRNA expression is higher in the 
lungs of ovalbumin (OVA)-treated mice and lung-specific expression of TSLP 
induces airway inflammation and AHR [89]. Overexpression of TSLP in lung 
epithelial cells leads to enhanced Th2 responses to inhaled antigen [98] and TSLP 
mRNA and protein levels are high in bronchial biopsies of severe asthmatic patients 
[59]. Furthermore genetic polymorphisms in the promotor region of TSLP are 
associated with asthma [99].  
 
IL-25 is a member of the IL-17 cytokine family [100] and is produced from a variety 
of cells including epithelial cells [87] and mast cells [101], activated eosinophils and 
basophils [87, 102]. In mouse models of asthma, IL-25 amplifies Th2 cytokine 
production and eosinophilia and acts on both the innate and adaptive immune systems 
to amplify Th2 responses [103-106]. IL-25 deficient mice show significant reduction 
of eosinophils, pro-inflammatory mediators and AHR [107]. Greater IL-25 levels are 
detected in the bronchial submucosa of asthmatics compared to non-asthmatics [93, 
94].  
 
IL-33 is a member of the IL-1 cytokine family and is expressed by airway epithelial 
cells, fibroblasts, smooth muscle cells, macrophages, DCs, basophils and mast cells 
[108, 109]. IL-33 is known to be a key player in initiation of allergic asthma as higher 
tissue concentrations and polymorphisms in IL-33 have been associated with asthma 
[110]. 
IL-33 is sequestered in the cell nucleus and has also been shown to be released from 
necrotic cells, acting as a pro-inflammatory endogenous danger signal [111]. 
Therefore, in addition to its pro-inflammatory role, IL-33 could also act as a DAMP 
or an ‘alarmin’ [112]. The IL-33 receptor ST2 has been strongly associated with the 
promotion of Th2 responses [108]. Interaction of IL-33 with ST2 on a range of 
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different leukocytes promotes a number of key inflammatory pathways that have the 
potential to initiate and propagate allergic inflammation and blockade of IL-33 
signalling by soluble T1/ST2 leads to abolished Th2 immunity induced by 
inflammatory DCs [71] (Figure 1.1).  
 
It is not yet clear which signals lead to release of these cytokines from airway 
epithelial cells, however a recent study demonstrated that IL-1α release induced by 
TLR4 signalling, acts in an autocrine manner and leads to release of DC activating 
cytokine and chemokines [46]. 
 
Epithelial cytokines also activate innate immune cells such as basophils, mast cells, 
eosinophils and the recently described innate lymphoid cells (ILC) [92, 100, 113-
115].  
1.3.1.4  ILC2 
Discovery of IL-25 and IL-33 as potent inducers of Th2 cytokines soon was followed 
by discovery of cells responding to these cytokines. In addition it was shown by 
Voehringer [116] that the essential source of IL-13 in Th2 immunity is not CD4+ T 
cells, suggesting that a non-T cell source of IL-13 exists. In addition, Fallon et al. 
[64] identified an innate source of type-2 cytokines that were dependent on IL-25.   
 
A group of studies carried out in the gut defined a new group of innate lymphocytes 
and variously termed them nuocytes [92], natural helper cells [113] and innate helper 
cells [117]. Saenz et al. showed that injecting IL-25 into mice, leads to expansion of 
cells that produce IL-4 in gut-associated lymphoid tissues [114]. Neil et al. 
demonstrated that injection of IL-25 and IL-33 leads to expansion of IL-13 producing 
cells in gut associated lymphoid tissue, mesenteric LNs and spleen that are important 
in clearance of helminth infection [92].  Moro et al. identified IL-33 responsive cells 
that have morphology similar to lymphocytes which were present in fat associated 
Page 27 of 194 
 
lymphoid clusters in mesenteric tissue of mice and were implicated in helminth 
expulsion [113].  
 
These cells are characterised by their lack of conventional lineage markers and 
expression of molecules such as ICOS, CD90, ST2, CD25 and CD127 and are now 
classified as ILC2s [118]. IL-33 and IL-25 responsive population of ILCs produce IL-
5 and IL-13 and have recently been shown to contribute to virus induced AHR, goblet 
cell metaplasia, atopic dermatitis and allergic airway inflammation [119-121] (Figure 
1.1).  
Barlow et al. [122] showed that IL-13 producing ILC2 increased during allergic 
inflammation induced by OVA and contributed to airway hyperactivity and Bartemes 
et al. [123] evidenced that IL-33 responsive ILC are critical for a type-2 response to 
fungal allergen. Halim et al. [124] also demonstrated type-2 cytokine production by 
ILC in protease allergen induced airway inflammation. In addition IL-33 responsive 
ILC2 have been shown to contribute to pulmonary eosinophilia in intestinal nematode 
infection [125].   
 
Recently the presence of ILC2 in the human lung has been reported. Mjosberg et al. 
defined ILC2 as CRTH2 (prostaglandin D2 receptor) and CD161 expressing cells. 
These cells respond to IL-25 and IL-33 and produce IL-13 [126]. Furthermore, the 
same authors reported ILC2 cells in nasal polyps of patients with rhinosinusitis which 
is characterised by eosinophilia, further implying ILC2 in mediating Th2 immunity. 
A recent paper has demonstrated that activation of CRTH2 by prostaglandin D2 
(PGD2) lead to migration and production of Th2 cytokines in human ILC2s, 
rendering this receptor as a potential therapeutic target [127]. 
 
Monticelli et al. defined ILC2 in humans by expression of Thy-1 (CD90), IL-2 
receptor α-chain (CD25), IL-7 receptor α-chain (CD127) and T1-ST2. Furthermore, 
this group demonstrated that these cells were recruited to the airways following 
influenza infection and their depletion lead to diminished lung function and impaired 
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airway remodelling [120]. Chang et al. demonstrated that ILC2 mediate AHR 
following influenza infection independent of adaptive immunity through IL-13 
production by these cells [119] and Kim et al. reported the same results in glycolipid 
induced AHR [128].  
 
 
  
Figure 1.1 Initiation of Th2 response to inhaled allergen: Allergens such as HDM contain cystein 
proteases and endotoxin, which can activate epithelial cells through PARs, and PRRs. The epithelium 
releases IL-25, IL-33 and TSLP which activate ILC2. ILC2 release type-2 cytokines such as IL-4 and 
IL-13 and contribute to initiation of allergic inflammation. Adapted from Lloyd & Hessel [129]. 
 
 
ILC2 require transcription factor inhibitor of DNA binding 2 (Id2) and CD127 (IL-
7R) for their development and are not dependent on transcription factor RORγt [130]. 
Recently transcription factor RORα has been identified for development of ILC2 
[131] and interestingly RORα deficient mice are partially protected from AHR [132]. 
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From the evidence above it appears ILC2 are the predominant cell type that responds 
to epithelial derived pro-Th2 cytokines such as IL-33 and IL-25. Following their 
activation they produce Th2 cytokines which lead to initiation of Th2 immunity and 
inflammation. 
1.3.2 Cells and mediators 
The allergic inflammatory response involves allergen-specific IgE binding to high-
affinity Fcε receptors on the surfaces of  peripheral blood basophils and tissue mast 
cells [133] resulting in an immediate release of mediators, including leukotrienes, 
prostaglandins and histamine, which are capable of contracting airway smooth 
muscle cells and inducing oedema and mucus secretion, leading to narrowed, 
constricted airways.  
 
Mast cell degranulation leads to release of mediators that have a broad range of 
effects including: recruiting eosinophils, encouraging their survival (primarily via IL-
5 and GM-CSF), the stimulation and continued production of IgE by B cells, and the 
induction of vascular cell adhesion molecule- 1 by endothelial cells by release of IL-4 
[4]. 
 
Eosinophils are one of the predominant inflammatory cells found in both the lung 
tissue and the BAL fluid of asthmatic patients [134, 135] and are recruited from the 
bone marrow following the release of eotaxin-1/CCL11, eotaxin-2/CCL24 and 
eotaxin-3/CCL26 acting via CCR3 [136-138]. Although eosinophilia is the most 
characteristic type of inflammation in asthma, this is neither an exclusive feature nor 
the only type of inflammation observed and eosinophilic asthma is now considered a 
distinct phenotype of asthma associated with thickening of the basement membrane 
and by corticosteroid responsiveness [139]. Once present, eosinophils release a 
collection of toxic granules such as major basic proteins (MBP) and eosinophils 
peroxidise (EPO), which are toxic to the lung microenvironment and cause prolonged 
bronchoconstriction and damage to epithelial layers. In addition, neutrophilia is also 
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observed in asthmatic patients especially in the case of severe asthma [140], 
exacerbated [141] and non-atopic asthma [142].  
 
Basophils are implicated in the development of Th2 inflammation [143] and 
recruitment mechanisms of basophils are very similar to eosinophils [144]. Basophils 
express FcεRI and degranulate and release eicosanoids and histamines contributing to 
the local symptoms of inflammation and AHR [145]. Basophils have also been shown 
to promote Th2 inflammation via the release of cytokines such as IL-4 [146] and by 
possessing antigen presenting function [78, 79, 81]. 
1.3.2.1 T cell subsets in allergic inflammation 
Bronchial biopsy specimens from asthmatic individuals indicate an increase in 
effector Th2 lymphocytes [147]. Phenotypically, Th2 cells are defined by expression 
of T1/ST2 [148, 149] and the CCR3 [150], CCR4 and CCR8 receptors [151]. Th2 
cells that are polarised in the LN, migrate back to the airways under the influence of 
the chemokines thymus and activation regulated chemokine (TARC)/CCL17 and 
monocyte-derived chemokine (MDC)/CCL22, which interact with the receptor CCR4 
[152, 153]. Th2 cells promote allergic immunopathology by production of a variety 
of mediators including IL-4, IL-5, IL-9, IL-13 and IL-25 which together promote IgE 
production, AHR, inflammation and tissue remodelling [34, 154]. IL-4 and IL-13 are 
involved in the class switching of B cells to produce IgE [155]. Th2 cytokines are 
also involved in recruitment of mast cells (IL-4, IL-9 and IL-13) [156] and basophils 
(IL-4) [145], whilst IL-5 is important in growth, differentiation, and activation of 
eosinophils [138]. IL-13 is also strongly linked to the development of AHR [157-
159].  
 
IFN-γ producing Th1 cells have been detected in the airways and serum of asthmatic 
patients [147, 160]. The exact role of Th1 cells in asthma is not clear as the 
transcription factor for Th1 cells, T-bet, is under-expressed in the asthmatic airway 
[77] and Th1 related cytokines have been shown to inhibit allergic airway 
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inflammation by inhibiting Th2 response in vivo [161], indicating a possible 
regulatory role.  
 
Th17 cells, identified by the transcription factor RORγt as a distinct linage of Th 
cells, have recently been implicated in neutrophil-dominated asthma and 
corticosteroid insensitivity [162-165]. These cells produce IL-17A, IL-17F and IL-22 
[166-168]. IL-17 levels have been shown to be elevated in the asthmatic airway 
[169], however despite some emerging genetic evidence and the potential role for IL-
17A and IL-17F in moderate to severe disease, their role in asthma is controversial 
[170, 171]. In the mouse, allergic sensitisation followed by challenge leads to a strong 
Th17 response in association with airway neutrophilia and AHR; this response is 
absent in IL-17F KO mice [172]. In another study, IL-17 is essential during 
sensitisation, but in mice already sensitised to allergen, IL-17 attenuates allergic 
inflammation [173]. Interestingly IL-17A can cause steroid insensitivity in bronchial 
epithelial cells [174] which could explain why severe asthmatics do not respond to 
therapy. 
 
Although differentiation of Th effector cells was originally considered a terminal 
event [175, 176] recent identification of Th9 effector cells lead to a revision of this 
view. Th9 cells were induced from differentiated Th2 cells, suggesting a functional 
plasticity within the Th subsets [177, 178]. IL-9 was previously thought to be a Th2 
derived cytokine however it has been shown that T cells producing IL-9 lack the 
defining transcription factors for Th1 and Th2 (T-bet and GATA3 respectively), 
instead these cells express transcription factor PU.1 and interferon regulatory factor 4 
[179]. However expression of these by other myeloid lineages argues against Th9 as a 
separate lineage.  
In the initial mouse studies, overexpression of IL-9 in the lung led to increased 
airway inflammation, remodelling and AHR. This response was reversed by blocking 
IL-9 [180, 181]. HDM exposure in mice causes rapid Th9 differentiation and 
expansion, and adoptive transfer of Th9 cell enhances pathology [182]. In humans IL-
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9 secretion has been demonstrated in lymphocytes in asthmatic patients [183]. Th9 
numbers have been shown to be increased in peripheral blood of atopic patients 
compared to controls [182].  
 
Allergic inflammation is thought to be an abnormal immune response to harmless 
airborne particles [184]. In homeostasis, these reactions are supressed by regulatory 
mechanisms such as regulatory T cells (Tregs) and cytokines. Tregs and regulatory 
cytokines such as IL-10 and TGF-β are central in maintaining tolerance. In asthmatic 
patients there is a breakdown of regulatory mechanisms [185]. In mouse models, 
transfer studies showed that IL-10 producing Tregs are capable of suppression of 
allergic inflammation and AHR [186]. Furthermore blockade of CD25 leads to 
enhancement of these responses [187]. In experimentally induced asthma, Tregs have 
been shown to supress the activation of pulmonary DCs and therefore be protective 
against asthma development [187]. 
In allergic rhinitis patients, CD4+CD25+ T cells from peripheral blood mononucleated 
cells (PBMCs) were less effective in suppressing allergic T cell responses [188]. In 
asthmatic patients, although the frequency of pulmonary CD4+CD25+Foxp3+ cells 
was increased, they still demonstrated enhanced Th2 responses to allergen challenge, 
which could indicate that suppression of Th2 responses by Tregs are defective [189]. 
In addition, Tregs from BAL fluid and peripheral blood of asthmatic children were 
also less effective in suppressing Th2 proliferation and cytokine production compared 
to controls [190].  It has been proposed that increased TSLP levels in asthmatic 
patients, and the suppressive effect of these cytokines on Tregs, could explain the 
defect in Treg function in asthma [60].  
Interestingly, allergen specific immunotherapy is associated with development of 
allergic specific Tregs and suppressive cytokines such as IL-10 and TGF-β [191-195].  
 
CD8+ T cells are present in the airway of asthmatics and bronchial biopsies of atopic 
and non-atopic asthmatics contains CD8+ T cells [136]. Patients who died from 
asthma have a higher frequency of CD8+ T cells [196]. It has also been shown that 
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sputum-derived CD8+ T cells from asthmatic patients spontaneously produce IL-4, 
IL-5 and IFN-γ [197]. However the behaviour of peripheral blood derived CD8 cells 
is different to that of airway CD8 cells which could be due to exposure to the local 
airway environment. In sensitised rats, depletion of CD8a+ cells enhanced airway 
inflammation and remodelling parameters [198]. However transfer of CD8+ T cells 
worsens the symptoms [199]. In mouse models, the role of CD8+ T cells in allergic 
inflammation of the lung is debatable. CD8 deficient mice are less susceptible to 
allergic inflammation but transfer of in vitro primed CD8+ T cells into sensitised CD8 
mice increased AHR and airway inflammation [200, 201].  It is still not clear whether 
CD8+ T cells play an active role in asthma or act as bystanders. 
 
NKT express an invariant T cell receptor which recognises glycolipids instead of 
peptides in the context of MHC class I like molecule CD1d [202]. Activation of NKT 
cells leads to release of a number of cytokines such as IL-4 and IFN-γ. Animal 
studies suggest the importance of NKT cells in allergic inflammation of the lung and 
it is hypothesised that allergens somehow change the mucosal environment in the 
lung, which exposes the self glycolid antigens that are recognised by NKT cells and 
this leads to activation and cytokine production of NKT cells [203]. NKT deficient 
mice do not develop AHR [204]. However instillation of NKT cell TCR ligand α-
GalCer induces production of IL-13 and TSLP in NKT cells and promotes AHR 
[205]. Furthermore exposure of mice to α-GalCer in the presence of allergen leads to 
NKT cell dependant allergen sensitisation [206]. Although NKT cells are elevated in 
asthmatics following allergen challenge [207, 208], the role of NKT cells in asthma 
remains highly controversial as the frequency of NKT cells in human asthma ranges 
from 2% to 60% [209, 210]. However, recently it has been reported that the most 
sterile HDM extract contains antigens that are able to activate both mouse and human 
NKT cells [211]. Further studies would shed light into the importance of NKT cells 
in asthma.  
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γδT have an immune surveillance role in the lung. They reside in close proximity to 
lung epithelium responding to stress signals and tissue damage [212, 213]. In 
asthmatic patients the proportion of γδT is higher and they produce IL-4 compared to 
healthy controls [214]. In mouse models there are two distinct populations of γδT: 
Vγ1+TCR expressing γδT that are pro-inflammatory and produce IL-5 and IL-13 
[215], and Vγ4+ that are suppressive and produce IL-17A [169, 216]. IL-17A 
produced by γδT has been shown to be important in resolution of allergic 
inflammation, emphasising that the source of IL-17 is important in its function [129]. 
Furthermore non-allergic γδT deficient mice exhibit AHR, implicating these cells in 
maintenance of normal lung function [217]. The function of γδT cells is yet to be 
studied in the lung of allergic patients. 
Involvement of inflammatory cells in allergic inflammation and asthma is 
summarised in Figure 1.2. 
 
 
 
Figure 1.2. Inflammatory cells in asthma: contribution of different inflammatory cells is shown, 
especially T cells and their role in allergic inflammation. Adapted from Lloyd & Hessel [129]. 
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1.4 NK cells  
NK cells are large granular lymphocytes and are innate cells of the immune system 
which are widely distributed throughout the body. They were initially described 
between 1974 and 1977 as non-T and B cells that are capable of killing tumours in 
the absence of prior sensitisation [218].  
Recently, NK cells were officially classified as type-1 ILCs which are defined by 
their capacity to produce IFN-γ [118, 219]. NK cells are involved in tumour immune 
surveillance, in the early control of microbial infections and in pregnancy [220].  
1.4.1 NK cell receptors 
Human NK cells are defined as CD3-CD56+ lymphocytes. Two major subsets of NK 
cells are found in humans; CD56dim and CD56bright. NK cells expressing high levels of 
CD56 are present in LNs and have high cytokine production and diminished 
cytotoxicity compared to CD56dim cells which are fully mature and are the major 
subset in the periphery [221].  Mouse NK cells are primarily defined as CD3-NKp46+, 
however many also have defined them as CD3-NK1.1+ or DX5+ cells. NKp46 is 
stably expressed on all NK cells and detected only on extremely discrete T cell 
subsets and a subset of ILCs (ILC3) [222, 223]. Similar to human CD56bright NK 
cells, mouse CD27high NK cells are potent producers of IFN-γ and are less cytotoxic 
[224].  
 
NK cells express an array of different activating and inhibitory receptors, of which 
many of their ligands are still unknown. They are activated through the balance of 
signals received from activating ligands (such as stress induced ligands) and 
inhibitory ligands (typically MHC class I) expressed on the target cell surface [225]. 
Human and mouse NK cell inhibitory receptors have divergent structural differences 
but perform the same function. Engagement of the inhibitory receptor by MHC class I 
molecule or related molecules is essential to inhibit NK cells activation. MHC class I 
down regulation, often occurs during viral infection or in tumours as means of 
immune evasions and to prevent recognition by cytotoxic T cells. This is called the 
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“missing self” hypothesis, where absence of these molecules on the surface of a cell, 
would lead to NK cell activation and killing of the cell [226].  
 
Principle inhibitory receptors include killer immunoglobulin-like receptors (KIRs) on 
human and Ly49 receptors on mouse NK cells. KIRs are polymorphic type I proteins 
that have immunoglobulin like domains, which recognise subsets of MHC class I 
(HLA-A, HLA-B and HLA-C). Ly49s are polymorphic type II proteins with C-type 
lectin domains that bind H-2 molecules [227, 228]. Both mouse and human express 
the NKG2A:CD94 inhibitory receptor whose ligand is the non-classical MHC class I, 
Qa-1b in mouse and HLA-E in humans [229]. Each individual has a repertoire of 
different NK cells that express different subsets of inhibitory receptors increasing the 
variability of ligand recognition within human and mouse populations [230].  
 
The Ly49H receptor is crucial for protection against murine cytomegalovirus 
(MCMV) in C57BL/6 mice as it binds to viral m157 protein and controls infection 
[231]. The function of inhibitory receptors, apart from controlling infection, is to 
counteract activatory receptors and tolerise NK cell response toward normal cells; 
however inhibitory receptors are also implicated in “education” of NK cells which 
will be discussed later. 
 
Activating receptors include the natural cytotoxicity receptors (NCR), such as 
NKp30, NKp46, NKp44, Fc receptor CD16 (FcγRIIIA) and NKG2D.  
NKp30 expressing NK cells are implicated in chronic HCV infection [232]. NKp46 
interacts with influenza hemagglutinin and in murine models this is crucial for control 
of infection [233]. CD16 triggers antibody-dependant cellular cytotoxicity (ADCC) 
[229].  NKG2D and NCR however, stimulate responses to tumour target cells.  
1.4.2 NKG2D 
NKG2D is a major activating receptor expressed on all mature NK cells, NKT cells 
and subsets of γδ and αβ T cells [234, 235]. NKG2D is a homodimer with type II 
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transmembrane receptor sequences that are similar to C-type lectins. NKG2D lacks a 
signalling motif and is associated with DNAX-activating proteins of 10kDa (DAP10) 
and DAP12 signalling molecules [235]. In NK cells, NKG2D can associate with 
either DAP10, signalling through PI3K in a Syk-PTK−independent fashion or the 
ITAM-containing DAP12, signalling through a Syk-PTK dependent pathway. Both 
signalling pathways can trigger cytotoxicity, but only the DAP12 pathway results in 
induction of cytokine [235]. (Figure 1.3) 
 
In mouse NKG2D is expressed by all NK cells [236] whereas in human most NK 
cells express NKG2D and expression is increased in exposure to IL-15 [237]. 
NKG2D recognises several surface molecules that are distantly similar to MHC class 
I. The NKG2D receptor mediates the ‘stress surveillance’ function of NK cells and 
recognises ligands Histocompatibility-60 (H60), Murine ULBP-like transcript-1 
(MULT-1) and the Retinoid acid early inducible-1 (Rae-1) families in mice and MHC 
class I chain-related molecules (MICA or MICB) and UL16-binding proteins 
(ULBPs) in man, which are induced in response to DNA damage and on transformed 
cells [238, 239]. Engagement of NKG2D on NK cells cause lysis of ligand expressing 
cells and cytokine production such as IFN-γ [240]. NKG2D has been implicated in 
tumour clearance, graft rejection, atherosclerosis, autoimmunity and infection [239, 
241-246].  
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Figure 1.3. NKG2D signalling in NK cells: NKG2D signals though DAP10 and DAP12. DAP10 
signalling leads to cytotoxicity and DAP12 leads to both cytotoxicity and cytokine production. 
Adapted from Trinchieri [247]. 
 
NKG2D ligands expression in normal adult cells is generally absent or at low levels 
both in human and mice [248]. However in pathological conditions or in response to 
activation of cellular stress pathways, their expression is upregulated. Upregulation of 
the self-encoded ligand for the activatory receptor is termed “induced self-
recognition” [249] which is different to “missing self-recognition” described above 
where an inhibitory receptor senses the absence of MHC class I. 
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In man during homeostasis MICA and MICB expression is only found on intestinal 
epithelial cells, probably due to presence of bacterial flora [250] however their 
expression is upregulated by many tumour cells of epithelial origin [251]. Similarly 
Rae-1 and H60 upregulation are reported in tumour cell lines [252] and in skin tissues 
treated with carcinogens [253]. In contrast, ULBP molecules in humans and  MULT-
1 in mice are expressed by many cells at the mRNA level but surface expression is 
very low [239] due to post-translational regulation by ubiquitination and degradation 
which is reduced in response stress [254]. However cell surface expression of ULBP 
and MULT-1 is reported in tumour cell lines or cells exposed to stress [255-257].   
Human MICA and MICB were shown to be upregulated by heat shock [250, 258] and 
genotoxic stress was shown to upregulate the NKG2D ligand in fibroblasts [259]. 
Interestingly, NKG2D ligand Rae-1 and MULT-1 have been shown to upregulate on 
renal tubular epithelial cells in response to TLR4 engagement on these cells [260] and 
TLR3 signalling also induced Rae-1 expression by mouse intestinal epithelial cells 
[261]. 
 
In addition to expression of NKG2D ligand on tumour cells or cells undergoing 
stress, NKG2D ligands have also been shown to be upregulated in cells infected with 
pathogens such as mouse fibroblast infected with MCMV [262]. However expression 
of the NKG2D ligand has also been documented in other inflammatory and disease 
conditions. NKG2D ligand is implicated in human autoimmune disorders [263] 
which supports the immunoregulatory role of NK cells. In mouse NKG2D ligand 
expression has been shown on activated T cells and macrophages [264, 265]. 
Interestingly NKG2D ligand Rae-1 has been shown to be upregulated on airway 
epithelial cells in a mouse model of chronic obstructive pulmonary disease (COPD) 
exacerbation [266]. In human, expression of MICA and MICB by DCs induced by 
IFN-α and [267] expression of NKG2D ligands on antigen activated T cells are also 
reported [268]. Expression of NKG2D ligand on other immune cells would make 
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these cells susceptible to NK cells lysis which highlights the immunoregulatory role 
of NK cells as well as their ability to shape adaptive immunity. 
1.4.3 NK cells origin and development 
NK cells have characteristics of innate immune cells, as they lack antigen recognition 
receptors and are not dependent on the recombination activating gene (RAG), yet 
have some characteristics of the adaptive response. NK cells develop in the bone 
marrow as disruption in intact bone marrow leads to abrogation of NK cells 
development and function [269].  NK cells are the third major lineage of lymphocytes 
[270, 271] and recent evidence indicates that NK cells are educated and selected 
during their development. Furthermore there are reports of NK cells clonal expansion 
and generation of long lived memory during infection [272-274].  
 
NK cells originate from the common lymphoid progenitor and require cytokines such 
as IL-15, which signal via receptors containing the common γ-chain, for their survival 
and homeostasis [275]. Different states of maturation exist for NK cells based on 
their expression of CD11b and CD27 and the signal required for this maturation is 
still under investigation [276]. Interestingly, recent evidence indicates that monocytes 
provide a maturation signal to NK cells sustaining their transition from immature NK 
cells (CD11b+CD27+) to mature stage (CD11b+CD27-) by trans-presenting IL-15 
through IL-15Rα chain to NK cells [277]. 
 
NK cells require tuning of their activation so that they can exert effector function in 
disease but stay tolerant to the host. NK cells responsiveness depends on whether NK 
cells are “educated”, “licenced” or “armed”. The mechanisms of responsiveness are 
debated but briefly described below. 
 
Developing NK cells are educated and selected by engagement of their receptors with 
many MHC class I ligands. During their development, immature human and mouse 
NK cells express inhibitory receptors KIR and Ly49 receptors respectively, which 
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allows establishment of efficient “missing-self” recognition [226, 278]. Engagement 
of inhibitory receptors with cognate MHC class I, leads to generation of functional 
NK cells [279, 280]. In addition, NK cells vary their responsiveness through a 
process in which they tune their ability to react which is dependent on the number of 
inhibitory receptors for autologous MHC class I molecules that they express. Failure 
to engage the inhibitory receptor during development results in peripheral NK cells 
that are hyporesponsive [280]. However reactivity of NK cells is very plastic and NK 
cells adapt their responsiveness in a given environment [281].  
 
Recently, the transcription factor E4BP4 (nfil3) is identified as an essential factor in 
early development of NK cells in the absence of infection as mice lacing E4BP4, 
exhibit severe loss of mature NK cells [282, 283]. It is believed that E4BP4 works 
downstream of IL-15R and controls the expression of GATA3 and Id2 [282, 284]. 
Interestingly a recent study suggest that E4BP4 is only important in early 
development of NK cells as E4BP4 deficient mice develop Ly49H expressing NK 
cells, following viral infection [285]. It is important to note that E4BP4 also 
influences the development of subsets of DCs and regulation of Th2 cell responses 
and B cells class switching [286-288].  
 
Once they leave bone marrow, mature NK cells either circulate in blood or reside in 
both lymphoid and non-lymphoid tissues. NK cells express many chemokine 
receptors, such as CCR2, CCR5, CXCR3 and CX3CR1 thus responding to large 
arrays of chemokines and are recruited to distinct sites of inflammation [289] in 
response to infection [290] or allergic inflammation [291]. 
 
Some recent evidence has shown that a subset of NK cells can become long-lived and 
exhibit memory like responses to specific antigens, however it is still to be 
established whether this is an organ specific mechanism that occurs under a specific 
mode of activation or signal [272, 292, 293]. 
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NK cells require priming by various factors, such as IL-15 presented by DCs [294] or 
macrophages [295], IL-12 [296] or IL-18 [297], highlighting the constant interactions 
between NK cells and other components of the immune response. Cytokines such as 
IL-15 and IL-18 continue to be important in the survival of peripheral NK cells. In 
the absence of IL-15, adoptively transferred NK cells had a significantly shorter half-
life [298] and it has been shown that resting splenic NK cells that were not able to 
receive IL-18 signals were defective in cytotoxicity and cytokine secretion [299].  
1.4.4 NK cell functions 
NK cells patrol through the body and fight infection by directly killing infected cells 
or transformed cells that down regulate MHC class I, normally expressed on nearly 
every healthy cell [226] (Figure 1.4). People who lack NK cells exhibit increased 
susceptibility to viral infection and increased tumour incidence [300]. 
NK cells can direct cytolytic granules containing mediators such as perforin and 
granzyme, towards the synapse which perforate the plasma membrane and trigger 
apoptosis to directly kill a target cell [301, 302].  
 
In addition, NK cells get activated during infection by pro-inflammatory cytokines 
such as IL-12 and type I interferon and produce large amount of IFN-γ, TNF-α and 
GM-CSF [225] as well as IL-10 and many chemokines such as CCL2, CCL3, CCL4, 
CCL5, CXCL1 and CXCL8 [225, 303] (Figure 1.4).  
Furthermore it has been reported that IL-17, IL-22 and Th2 cytokines can be 
produced by NK cells, however with recent identification of ILCs, it is possible that 
the source of these cytokine are in fact ILCs which share surface markers with NK 
cells [169, 304, 305].  
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Figure 1.4. NK cell functions: NK cells have dual functions: cytotoxicity and cytokine production. 
 
NK cell cytotoxicity and cytokine production impact both innate cells such as DCs, 
macrophages, and neutrophils [306-311] and adaptive immunity, affecting subsequent 
antigen-specific T and B cell responses [312-314]. For instance, during viral 
infection, NK cells enhance antigen specific T cell response in modest viral doses but 
also limit excessive T cell responses on exposure to high viral doses [314]. 
IFN-γ is essential for development and cytotoxic function of T cells against infection. 
In addition macrophages activation is dependent on IFN-γ. In the absence of NK 
cells, priming of CD4 and CD8 T cells was impaired [315].   
 
Evidence from both human and mouse studies suggests that NK cells may also 
participate in the adaptive immune responses by modulating DC function or by 
producing IFN-γ [316]. For instance, NK cells have been shown to regulate T cells 
responses by killing MCMV-infected APCs [312] and NK cells can attract immature 
DCs to LNs, possibly by producing CXCL1, CCL3, CCL4 and CCL5 [317].  
Conversely APCs can release IL-10 and TGF-β which can diminish IFN-γ production 
by NK cells [318].  
In vitro human NK cells can either kill immature DCs or induce their maturation and 
the production of IL-12, thereby promoting Th1 polarization [310, 313, 319]. In mice 
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it has been shown that NK cells are rapidly recruited to LNs upon activation and are 
an early source of IFN-γ for the induction of Th1 responses possibly by a direct 
interaction with naive T cells [320]. Furthermore, human NK cells can enhance T cell 
polarisation by IFN-γ production [321]. 
 
More recent studies have reinforced the role of NK cells in shaping adaptive 
responses. It is well known that early resistance of C57BL/6 mice to MCMV 
infection is down to NK cells recognition of viral protein m157 expressed on infected 
cells on their activatory receptor Ly49H leading to their lysis. However it has been 
reported that NK cells also accelerate CD8+ T cells responses, recovery of 
conventional DCs and T cells priming in this infection model [322].  
1.4.5 NK cells in the airways 
The role of NK cells in mediating inflammatory conditions in different organs is 
complex. In some disease conditions NK cells are known to be inflammatory and 
pathological but in others they seem protective. This could be due to organ specific 
factors and cellular interactions as well as specific microenvironments influencing the 
NK cell response. In addition, NK cells respond to a large array of chemokines and 
therefore are recruited to the site of infection [289].  
At steady state, NK cells represent about 10% of lung lymphocytes in both humans 
and mice [289]. This relatively high frequency supports a prominent role of NK cells 
in airway immunology [289, 304]. Due to the critical physiological role of the lung, 
during infection innate immune responses in the lung must be initiated quite rapidly 
but inflammation needs to be controlled to prevent damage to the lung and airways 
thus avoiding impaired gaseous exchange. Inflammation in the lung is controlled by 
IL-10 and TGF-β produced by alveolar macrophages. This raises the activation 
threshold that needs to be overcome for immune response to occur [323]. In 
homeostasis lung NK cells are supressed and impaired in their cytotoxic capacity 
[324-326]. Pulmonary NK cells can become activated in the presence of type I IFN 
Page 45 of 194 
 
and conversely supressed in presence of BAL fluid or alveolar macrophages [327, 
328].   
 
Genetic defects in NK cells have severe consequences in pulmonary health. For 
instance individuals with NK deficiency have recurrent viral and bacterial infection in 
the upper and lower respiratory tracts [300, 329]. Additionally, in conditions where 
NK cells are poorly regulated NK cells are chronically activated and form lesions in 
the lung and skin [330, 331].  
 
NK cells play a pivotal role in control of respiratory infection such as RSV and 
influenza. NK cells are recruited to the airway within the first few days of influenza 
infection in humans and mouse [332, 333] and in addition to producing IFN-γ they 
shape the adaptive immune response by activating cytotoxic T lymphocytes [334].  
Depletion of NK cells during influenza infection leads to enhanced susceptibility to 
severe infection [334, 335].  
NKp46 is critical in protecting mice against lethal influenza infection and it is known 
to directly bind viral glycoprotein which is thought to make them cytotoxic toward 
infected cells  [336]. In fact, NKp46 deficient mice exhibit enhanced susceptibility to 
lethal influenza infection [336]. 
 
NK cells also play an important role in viral clearance following RSV infection [337, 
338]. During RSV infection NK cells are responsible for lung injury either alone 
[339] or in combination with IL-18 [337]. Failure to generate robust NK cell 
responses is demonstrated in severely RSV-infected infants [340-342]. A recent study 
in BALB/c mice demonstrates that NK cell deficiency during primary RSV infection 
results in the suppression of the early IFN-γ expression and the development of an 
RSV-specific Th2 response. Interestingly, this Th2 response was dependent on IL-25 
expressed by airway epithelial cells [343]. 
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NK cells have also been shown to be protective in mouse pulmonary bacterial and 
fungal infection. NK cells IFN-γ production is found to be crucial for early anti-
microbial immunity [344].  
1.5. NK cells in asthma 
Although a body of evidence exists for a role of NK cells in Th1 immunity, NK cells 
in allergic disease have gained less attention. Increasing evidence implicates innate 
immunity in the pathogenesis of asthma and the ability of NK cells to shape adaptive 
response highlights the importance of studying these cells in allergic disease.  
 
Here I discuss clinical and murine studies that implicate the NK cell in allergy and 
asthma. 
1.5.1 Clinical evidence  
Early clinical studies reported that PBMC from asthmatics exhibit enhanced NK 
activity and this activity is reduced after allergen challenge. The reduction in NK 
cells activity may be due to migration of circulating NK cells into the lung [345]. 
Furthermore in asthmatic children undergoing acute exacerbation, an increased 
frequency of NK cells was reported in PBMCs [346]. Atopic asthmatic PBMC 
derived NK cells which are activated ex vivo showed a higher frequency of IL-4 
producing NK cells (identified by CD56+) than IFN-γ producing NK cells [347, 348]. 
In addition, peripheral blood NK cells from patients with atopic dermatitis released a 
high amount of IL-4, IL-5, IL-13 as well as IFN-γ [349]. Patients with either allergic 
rhinitis, or rhinitis and intermittent asthma, are impaired in their ability to produce 
IFN-γ from their NK cells [309]. The cytotoxic capacity of NK cells in allergic 
rhinitis patients was higher compared to healthy controls [350]. 
 
Although it is not clear how NK cells in human switch their cytokine production from 
type-1 to type-2, evidence in literature indicates that the phenotype of NK cells is 
dependent on the environmental milieu that they are exposed to [304]. For instance, 
ex vivo stimulation of NK cells in presence of IL-4 leads to type-2 cytokine 
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production and is inhibited by IL-12 and IL-10 [351-353]. This is also demonstrated 
in mouse RSV infection. During Th1 responses to a respiratory viral infection, NK 
cells produce IFN-γ, however this was reduced in Th2 response induced by priming 
with an RSV G protein [338]. Other factors that could influence NK cell phenotype in 
asthma are other mediators released in this condition. For example PGD2 produced 
by mast cells has been shown to inhibit IFN-γ production in NK cells and reduce their 
cytotoxicity activity [354]. Asthmatics are also deficient in type I IFNs, which are 
potent activators of NK cells and IFN-γ production in these cells. Whether lack of 
these cytokines influence NK cell phenotype remains to be established [355].   More 
recently, the crosstalk between NK cells and DCs was shown to be less efficient with 
NK cells isolated from allergic patients compared to non-allergic patients. This defect 
led to reduced capacity of NK cells to produce IFN-γ in response to DC stimulation 
[309].  Another proposed function of NK cells- ‘dendritic cell editing’- involves 
removal of DCs which would otherwise promote Th2 responses or tolerance during 
an immune response [316]. NK cells activated with IL-4 do not perform this function, 
and possibly promote T cell anergy or Th2 responses [296]. Furthermore, in patients 
suffering from rhinitis and asthma, not only was the proportion of CD56bright NK cells 
low, but also following co-culture with DCs, NK cells showed impairment in IFN-γ 
production and promoting DC maturation [309].  
 
More recent evidence highlights the importance of NK cells and their receptors in 
asthma. In severe asthma, peripheral blood NK cells express high levels of NKG2D 
and CD69 (a marker of activation) which correlates with blood eosinophilia [356]. 
Furthermore, NKG2D ligands MICA and ULBP-2 are elevated in the serum of 
children with respiratory symptoms of HDM allergy [357]. A recent genome-wide 
association study meta-analysis with self-reported cat, dust-mite and pollen allergies 
identified MICA as being associated with allergy [358]. Interestingly, allergen 
challenged asthma patients have elevated level of granzyme B in their airway [359, 
360]. 
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1.5.2 Murine studies  
In a mouse model of allergic airway inflammation, NK cell depletion by NK1.1 
antibody (Ab) administration before immunisation inhibited lung eosinophilia, cell 
infiltrate and OVA-induced levels of IL-4, IL-5 and IL-12 in the BAL of C57BL⁄6 
mice [361]. However anti-NK1.1 also depletes NKT cells which are implicated in 
allergic airway disease [362]. Recently in an OVA model of allergic inflammation, 
depletion of NK cells by the ASGM1 Ab lead to a decrease in BAL eosinophilia 
[363]. However in a recent paper it was shown that the anti-ASGM1 Ab also depletes 
basophils [364]. This finding raises concern about the possibility that certain 
functions of basophils might have been interpreted as those of NK cells.  Recently it 
has also been proposed that NK cells are involved in resolution of allergic 
inflammation. In this paper it has been shown that after cessation of allergic 
challenge, eosinophils and T cells were cleared concomitant with increased number 
of NK cells in the lung and mediastinal LNs and that eosinophils and CD4 T cells 
expressed NKG2D ligands during resolution [365]. However recent evidence in 
murine models, shows that activation of skin intraepithelial lymphocytes via NKG2D 
can promote systemic atopy [257]. 
1.6. Viral infection and exacerbation 
Respiratory virus infection is thought to be a major risk factor in asthma development 
and exacerbation. It has been suggested that release of inflammatory products and 
enhanced viral shedding could provide stimulus for recruitment of DCs and allergen 
sensitisation [366]. Bronchiolitis following infection with RSV and rhinovirus in 
early life is associated with wheezing and development of asthma at early age [367, 
368] and 40-50% of children who experienced severe RSV bronchiolitis are 
eventually diagnosed with asthma [369]. Furthermore in a neonatal mouse RSV 
infection, reinfection in adulthood leads to more aggressive airway inflammation 
compared to delayed initial virus infection [370]. 
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A recent study supports the hypothesis that virus and allergen interaction plays a role 
in development of asthma. Neonatal mice infected with influenza were subsequently 
exposed to HDM, and co-current exposure of allergen and virus lead to allergen 
specific immunity, inflammation and remodelling which was absent in mice 
challenged with HDM only. This remodelling persisted to adulthood and lead to 
impairment of lung function [371]. It is yet unclear how virus infection in early life 
renders the host susceptible to development of asthma in adulthood. Interestingly 
impairment of Tregs following RSV has shown to increase susceptibility to allergic 
asthma [372]. More recently Durant et al. demonstrated that depletion of Tregs lead 
to Th2 and eosinophilic responses following RSV infection in mice [373]. 
 
Asthma exacerbations are strongly associated with respiratory viral infections and 
asthmatics experience more severe and longer-lasting symptoms following infection 
[374]. Inappropriate or poor activation of NK cells in asthma could enhance 
susceptibility to these infections. A possible mechanism for this is that asthmatics 
produce less type I IFN in response to respiratory viruses, which could impact on NK 
cell activation [375]. Moreover deficiencies in NK cell function have been associated 
with recurrent respiratory infections, and polymorphisms in genes for NK cell 
receptors have been linked to infectious disease progression [329]. 
1.7. ILC3 
ILCs are central players in immunity during homeostasis and disease, particularly at 
mucosal surfaces [219, 376]. While our knowledge of innate lymphocytes is rapidly 
developing, we still do not have a full understanding of their diverse roles at different 
sites. 
 
ILCs are RAG-independent lymphocytes which require both the transcriptional 
repressor Id2 and the common γ-chain of the IL-2 receptor (IL2Rγc) for their 
development. ILCs have been classified into three groups, which broadly correspond 
to the T helper cell subsets, based upon transcription factor and cytokine expression 
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[118]. Group 1 ILCs include conventional NK cells and the mucosal ILC1 which 
predominantly produce IFN-γ [377-379]. ILC2 are a potent source of IL-5 and IL-13 
in the gut and lung in allergic inflammation and helminth infection [92, 113]. Group 3 
ILCs include lymphoid tissue inducer cells (LTi cells) which are essential in 
formation of the LNs during embryogenesis [380] and ILC3 [219] (Figure 1.5).  
 
ILC3 have been found mainly at mucosal sites and are defined by their capacity to 
produce IL-17A and /or IL-22, express RORγt and require transcription factor Id2 
and aryl hydrocarbon receptor (AhR) [219].  
 
A group of ILC3 are characterised by NKp46 (in mouse) and NKp44 (in human) and 
RORγt [381] expression and produce IL-22 [382-384]. These cells were previously 
described as NK22 and have important effector functions during the early stages of 
immunity to microorganisms [385]. Natural cytotoxicity receptor (NCR)+ ILC3 are 
mainly found on mucosal sites both in mouse and human such as gut lamina propia, 
Peyer’s patches, mesenteric LNs and tonsils [386]. Recently, transcription factor T-
bet is implicated in maturation of NCR+ ILC3 [387] whereas GATA3 has been shown 
to be important in early development of gut RORγt+ ILC3s [264]. 
 
These NCR+ ILC3 lack cytotoxic effector molecules such as perforin and granzyme 
and do not produce IFN-γ or TNF [382, 388, 389]. Furthermore NK cells require IL-
15 signalling for their development and survival, whereas NCR+ ILC3 are dependent 
on IL-7 [390]. Fate mapping studies have demonstrated that these cells are distinctly 
different from conventional NK cells [222, 391, 392]. 
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Figure 1.5. ILC subsets: 3 groups of ILCs and their phenotype and cytokine production in mouse and 
human is shown. Adapted from Walker [219] 
 
 
ILC3 depend on the presence of the microflora for their development [389] and guard 
against commensal and pathogenic bacteria via IL-22, which protects epithelial 
surfaces and induces anti-microbial peptides [382, 393, 394]. Mice lacking NCR+ and 
NCR- ILC3 cells due to AhR, RAG and γc deficiency are unable to fight microbial 
infection in the gut [382, 395]. Notably IL-22 deficient mice exhibit increased 
inflammatory infiltration and mucosal hyperplasia and erosion of the epithelium in 
the gut [394]. However there is also evidence of the pro-inflammatory role of IL-22 
in the gut [396]. IL-23 is known to regulate IL-22 production in ILC3s in mice and 
human [382, 389, 397]. In human engagement of NKp44 on ILC3s leads to TNF 
production and pro-inflammatory phenotype of these cells, suggesting these cells can 
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activate without cytokine stimuli and switch from IL-22 production to TNF 
production [398].  
 
The role of ILC3 in the lung is not known, however IL-22 is shown to be elevated in 
asthmatics [399]. There are also increased numbers of cells expressing IL-22 in the 
blood and bronchial mucosa of asthmatics but the source of IL-22 apart from  ILC3 
could be T cells such as Th17 cells [400]. 
In the allergic asthma model, the predominate source of IL-22 was Lin-
Thy1.2+Sca1+RORγt+ cells [401]. IL-22 may have dual effects in the lung. It is 
protective during inflammation but required for the onset of allergic asthma in mice 
[402]. In an allergen induced airway inflammation study, neutralization of IL-22 
enhanced Th2 cytokine production, eosinophil recruitment, and goblet cell 
hyperplasia, and administration of recombinant IL-22 attenuated eosinophil 
recruitment into the airways following allergen challenge. Interestingly, IL-22 
neutralisation enhanced IL-25 production in the airways following allergen challenge, 
and IL-25 Ab reversed the enhancing effect of IL-22 Ab on eosinophil recruitment 
into the airways [400]. Conversely, a recent study reported an immunopathogenic 
role for IL-22 during fungal allergy [403]. 
 
Identification of ILCs and specifically ILC3 that share expression of the NKp46+ 
receptor with NK cells, make it vital to study these cells further and establish whether 
the current knowledge on NK cells- acquired by using these common markers- is still 
valid.  
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1.8. Hypothesis and aims 
 
Hypothesis: 
Alteration of NK cell function in allergy could have important clinical implications. 
Experimentally, there is evidence that NK cells are required for the development and 
maintenance of allergic inflammation. However, the mechanisms by which NK cells 
contribute to allergic inflammation remain unclear. We hypothesised that NK cells 
contribute to allergic inflammation through their cytotoxicity and cytokine 
production. 
 
Aims: 
We aimed to: 
1. Phenotype NK cells within the lung environment in naïve mice and in HDM  
induced pulmonary inflammation  
2. Determine the mechanisms by which NK cells influence HDM induced allergic 
inflammation 
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Chapter Two – Materials and Methods 
2.1 Animals 
Female wild type (WT) BALB/c, C57BL/6 and granzyme B KO (gzmb-/-) mice were 
purchased from Jackson Labs (Kent, UK) and were used at age 6-8 weeks in all 
experiments.  NKG2D deficient ((klrk1-/-) hereafter named NKG2D KO) mice were 
originally generated by Dr Nadia Guerra [243] (Imperial College London) by gene 
targeting. Six exons of the Klrk1 gene were replaced with a neo cassette in the Bruce-
4 embryonic stem cell line derived from inbred C57BL/6 mice. These mice were 
kindly genotyped by Dr Chiara Triulzi (Imperial College London). Animals were 
housed at Imperial College animal facility with food and water ad libitum.  UK Home 
Office guidelines for animal welfare based on the Animals (Scientific Procedures) act 
1986 were strictly observed. For experiments involving NKG2D KO mice, WT 
control animals were age and sex matched littermates (klrk1+/+).     
2.2 Genotyping NKG2D mice 
NKG2D KO mice were bred and genotyped in collaboration with Nadia Guerra’s 
laboratory. Briefly, mice were bred by mating heterozygotes. Offspring were 
genotyped by collecting ear punches and digesting with lysis buffer (25mg/ml 
protease K (Sigma, UK), 0.5M EDTA, 1M Tris, 5M NaCl, 10% SDS) overnight 
(ON) at 55oC. DNA was then extracted by spinning the tubes at full speed for 5 
minutes (mins) at 4oC and collecting the supernatant. 100% ethanol was added to the 
supernatant and tubes were inverted until white DNA material was observed. After 
storing the tubes at -20oC for 20 mins, the DNA was pelleted by centrifuging at full 
speed for 5 mins at 4oC. 70% ethanol was added to the pellet and tubes spun as 
before.  The pellet was then allowed to air dry at room temperature (RT) and the 
pellet was dissolved in TE buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0) for 20 mins 
at 55oC. Polymerase chain reaction (PCR) was performed using following primers: 
Common: 5'- CAA GTA GTG TGC ATT TCA TTC AG -3', WT: 5'- CAG AGC 
AAG CTT CCT GTT TGT CTC A -3', KO 5'- ATT GCT CCC TGT CTC ATT CTC 
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TT -3'. The amplification was carried out as follows: 94oC for 4 mins, followed by 36 
cycles of 94oC for 30s, 56oC for 45s, 72oC for 1 min 10s, and a final step at 72oC for 
7 mins. When resolved on a 2% agarose gel, the PCR yielded bands of 400 bp for the 
WT allele and 350 bp for the mutant allele. 
 
2.3 Allergen challenge  
House dust mite (Dermatophagoides pteronissinus) extract (HDM, Greer 
laboratories, USA) was used as allergen to induce allergic airway disease in mice. 
Approximately 10% of the protein in the extract is the major epitope, Derp1. LPS 
content was 4 EU/mg of protein. Mice were challenged by intranasal (i.n.) instillation 
of a 1mg/ml solution of whole HDM allergen extract in phosphate buffer saline 
(PBS) under inhalational isoflurane anaesthesia. Control mice received PBS. Mice 
were challenged with 25µl of HDM, 3 times a week for 3 weeks [404, 405].  In other 
experiments, mice received a single dose of 70μg of HDM extract. Mice were 
harvested 24 hours (hrs) after the last challenge. 
2.4 NKG2D blocking mAb 
NKG2D blocking Ab (anti-mouse CD314, MI6) was purchased from e-Biosciences. 
For the prophylactic regimen, 2 days prior to HDM challenge mice were injected with 
200µg (200µl) of the Ab or isotype control (IgG2ak) i.p. This was followed with 
weekly injections of 100µg (100µl) of the Ab or isotype control i.p. Mice were 
treated with HDM as described above and culled 24 hrs after the last challenge.  
400 
350 
Het WT NKG2D KO 
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For the therapeutic regimen, mice were challenged with HDM for 2 weeks and 
treated with 200µg NKG2D blocking Ab (i.p) at the start of week 3. Mice were then 
challenged 3 more times in the last week and culled 24 hrs after the last challenge. 
2.5 Adoptive transfer of NK cells or CD3+ lymphocytes in vivo 
Single cell suspensions of spleen cells from donor animals (WT, NKG2D KO and 
gzmb-/- mice) were prepared as described in section 2.8.2.  Splenic NK cells (CD3-
NKp46+ lymphocytes) or CD3+ lymphocytes (which included CD4+, CD8+, NKT and 
γδ T cells) were sorted on a FACSAria III (Becton Dickenson). Dead cells and 
doublets were excluded. Purity was confirmed by flow cytometry and was found to 
be typically over 97%. 0.5x106 cells were transferred intravenously (i.v.) per mouse 
24 hrs before the first HDM challenge. Recipient mice were place in a hot box at 
37oC for 5 mins to cause vasodilation facilitating i.v. delivery of purified cells in 
100µl sterile PBS.  NKG2D KO NK or CD3+ cells were injected to NKG2D KO mice 
to control for cell isolation and sorting.  
2.6 Conjugated OVA administration 
Mice were given 100µg of AlexaFluor 647 conjugated OVA (Invitrogen) with or 
without 50µg of HDM i.n. Mice were then culled 24 hrs post challenge and lung and 
mediastinal lymph node (MLN) were collected.  
2.7 RSV infection 
RSV strain A2 (ATCC) was grown in HEp-2 cells as previously described [406]. 
Mice received 106 plaque forming units (PFU) or control HEp-2 cell lysate, 
intranasally in 50μl. Mice were weighed daily and responses analysed 4 days after 
infection. 
2.7.1 Growing HEp-2 cells 
HEp-2 cells were cultured using complete RPMI medium in 175cm2 flasks. The 
medium was changed when necessary and cells were passaged when 80-90% 
confluent. To passage the cells, they were washed with 10 ml PBS after removing the 
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media. 10ml of cell dissociation solution was added to the cells and they were 
incubated at 37°C for 5 mins. The cell dissociation solution was neutralized by 
adding complete medium and spun down for 5 mins at 1,500 rpm. Cells were 
thoroughly resuspended to inhibit the formation of cell clumps, and transferred to 
flasks containing fresh complete medium. 5x105 cells per flask were seeded and 
incubated at 37°C and 5% CO2 in a humidified incubator. 
2.7.2 Growing RSV 
Human RSV A2 strain was cultured in HEp-2 cells in complete RPMI. The day 
before infection, 5x106 HEp-2 cells were seeded in 150cm2 flasks containing 30ml of 
complete medium. Cells were left to grow to 50% confluence ON at 37°C and 5% 
CO2. The next day, the medium was removed from the flask, and the monolayer was 
washed with 10ml of serum free medium. Cells were then infected with 1x106 PFU of 
RSV in 3ml of serum free medium (multiplicity of infection (MOI) of 0.1 PFU/cell). 
In a control flask 3ml of serum free medium alone was added. The flasks were left at 
37°C for 2 hrs with gentle shaking, after which 27ml of complete medium was added 
into each flask. The flasks were left for 24 hrs at 37°C and 5% CO2 and then 25ml of 
the media were taken out of the flask and spun down on 1,500 rpm for 5 mins. The 
supernatant was discarded and the pellet was resuspended in 25ml of serum free 
medium and added back into the flask to reduce the total foetal calf serum (FCS) 
level to 2%. Cells were then left for further 24-48 hrs at 37°C and 5% CO2. When 
50%-70% of the cells were detached, the cells were harvested using a cell scraper and 
transferred into a 50ml falcon tube. Cells were sonicated for 3 mins at 4°C, and were 
centrifuged at 1,500 rpm for 5 mins at 4°C. Supernatants containing the virus were 
then pooled from each flask and 1ml aliquots placed into cryovials that were snap 
frozen in liquid nitrogen. The virus was stored in liquid nitrogen until further use. The 
same batch of RSV was used throughout this project for all experiments. 
2.7.3 RSV plaque assay 
To determine the titre of the grown virus, plaque assay was used. 2x104 HEp2 
cells/well were seeded into a flat-bottomed, 96-well plate in complete medium and 
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incubated ON at 37 °C, 5% CO2. The following day, the medium was removed from 
the plate; 50μl of virus stock was titrated in serum free medium and added to the 
cells. These were then incubated for 2 hrs and 150μl of complete medium was added 
to each well. Cells were then further incubated for 24 hrs, after which they were fixed 
in methanol containing 2% H2O2 for 20 mins. 100μl of titrated biotinylated goat anti-
RSV Ab was added to each well and incubated for 1 hr at RT. Plates were washed 
twice with PBS 1% FCS, 100μl of 1:500 diluted streptavidin peroxidase was added to 
each well and incubated at RT for 30 mins. Plates were washed twice with PBS 
containing 1% FCS and 50μl of DAB (3,3´-diaminobenzidine) substrate (Sigma) was 
added to each well for 10-60 mins. The reaction was stopped by washing the plates 
with PBS and infectious units were counted under light microscopy. 
2.8 Exanguination and serum isolation 
Mice were bled under terminal anaesthesia by cardiac puncture, recovering 
approximately 0.5-1ml per mouse. After overnight clotting, samples were centrifuged 
at 13,000rpm for 20 mins at 4oC, serum removed and stored at -80oC for use in 
ELISA.  
2.9 Cell recovery  
Complete media; RPMI containing 10% FCS, 2mM L-glutamine, 100U/ml 
penicillin/streptomycin (Sigma), was used throughout all leukocyte preparations. 
2.9.1 BAL of airway lumen   
BAL was performed by flushing out the lungs three times with 1ml of phosphate 
buffered saline (PBS) containing 5mM EDTA, via a tracheal canula. The fluid 
collected was centrifuged (1,200 rpm, 5 mins, 4oC) and the recovered supernatant 
was stored at -80oC for cytokine and immunoglobulin (Ig) analysis.  Recovered cells 
were resuspended in complete media after lysis of red blood cells by ACK buffer 
(0.15 M NH4Cl, 1mM KHCO3, 0.1mM Na2EDTA, pH 7.2). 
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2.9.2 Lung parenchyma   
Lung vasculature was perfused in situ with PBS via the right atrium. Lung tissue was 
removed and placed in C-tubes (Miltenyi Biotech, UK) containing 2.5ml of 0.5mg/ml 
collagenase (Sigma) in media and agitated on GentleMACS (Miltenyi Biotech).  The 
tubes were then incubated for 1 hr at 37oC and agitated on the GentleMACS after 
which the cells were resuspended in ACK buffer and washed with medium. Cells 
were then recovered by filtration through a 70µm nylon sieve (Falcon, Marathon Lab 
Supplies, UK), washed twice by centrifugation (1,500 rpm, 5 mins, 4oC) and 
resuspended in complete media.  
2.9.3 Spleen and LNs 
Spleen and MLN were collected and placed in tubes containing complete media. 
Single cells suspensions, obtained by passing tissue through a 70µm nylon sieve, 
were washed twice by centrifugation (1,500 rpm, 5 mins, 4oC) and resuspended in 
complete media after lysis of red blood cells by ACK buffer. 
2.10 Total and differential leukocyte counts 
Following isolation of leukocytes from each tissue, total cell counts were carried out 
on a FACSCanto flow cytometer (BD, Oxford, UK) using CountBright (Invitrogen, 
Paisley, UK) counting beads according to the manufacturer's instructions.  BAL 
leukocytes were applied to glass slides by centrifugation (Cytospin II, Shandon), 
slides were allowed to air dry and were fixed and stained with Quick-Diff (Reagena, 
Finland). Percentages of macrophages, lymphocytes/mononuclear cells, eosinophils 
and neutrophils were determined under light microscopy (40 x objective lens) by 
counting cells in 8 randomly selected fields and dividing this number by the total 
number of cells counted.  To obtain absolute numbers, this percentage was multiplied 
by the total number of cells recovered in the BAL fluid. 
2.11 Staining of leukocytes and flow cytometric analysis  
2.11.1 Antibodies   
Directly labelled anti-mouse antibodies used for this work are listed in Table 1. 
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Table 1. Antibodies used for flow cytometry  
Antibody Clone Fluorescent label Company 
CD4 GK1.5 Alexafluor 700 or APC-H7 BD Biosciences 
CD8 35-6.7 Pacific Blue BD Biosciences 
NKp46 29A1.4 Alexafluor 700 or percp-cy5.5 BD Biosciences 
LY49G2 4D11 PE-CY7 BD Biosciences 
CD16 2.4G2 PerCP-Cy5.5 BD Biosciences 
CD107a 1D4B PE BD Biosciences 
CD27 LG.3A10 APC or V450 BD Biosciences 
γδTCR GL3 FITC BD Biosciences 
CD49b DX5 V450 BD Biosciences 
CD127 SB/199 Alexafluor 488 BD Biosciences 
LY6G 1AB Percp-Cy5.5 BD Biosciences 
IFN-γ XMG1.2 FITC or PE-Cy7 BD Biosciences 
RORγt Q31-378 PerCP-Cy5.5 BD Biosciences 
IL-17 TC11-18H10 Alexafluor 488 BD Biosciences 
CD11b M1/70 V450 or PE-Cy7 BD Biosciences 
CD11c HL3 V450 BD Biosciences 
CD117 2B8 Pe-Cy7 BD Biosciences 
CD94 18d3 FITC eBiosciences 
CD3 17A2 APC-efluor780 or Alexafluor 700 eBiosciences 
NKG2D CX5 PE eBiosciences 
CD69 H1.2F3 PE-Cy7 eBiosciences 
NK1.1 PK136 APC eBiosciences 
CD19 1D3 APC or Percp-Cy5.5 eBiosciences 
CD25 PC61.5 APC eBiosciences 
Foxp3 FJK-16s FITC or V450 eBiosciences 
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IL-4 11B11 APC eBiosciences 
IL-13 eBio13A FITC or PE eBiosciences 
IL-22 1H8PWSR PE eBiosciences 
CD45 30-F11 Alexafluor 700 Biolegend 
EpCAM G8.8 PE-Cy7 Biolegend 
F4/80 BM8 APC or Percp-Cy5.5 Biolegend 
Granzyme B GB12 APC Invitrogen 
T1/ST2 FITC DJ8 mdBioproducts 
MULT-1 237104 PE R&D systems 
 
2.11.2 Staining of cell surface antigens  
Single cell suspensions from BAL, lung, spleen and LNs, were stained in staining 
buffer (PBS containing 1% FCS and 0.01% sodium azide).  Live and Dead Aqua 
(Invitrogen) staining was carried out in PBS according to the manufacturer’s 
instructions. To reduce non-specific binding, cells were incubated with Fc block (BD 
Biosciences) for 15 mins at 4oC.  Cells were then stained with cell antibodies for 25 
mins at 4oC, followed by twice washing with staining buffer and fixation in CellFixTM 
(BD Biosciences).  Flow cytometric acquisition was performed using a FACS 
FortessaTM (BD Biosciences) on Diva software, collecting a minimum of 50,000 live 
and single events. Analysis was carried out using FlowJo software. Dead cells were 
excluded on the basis of live and dead staining and doublets were excluded by means 
of FSC-W versus FSC-A.    
2.11.3 Intracellular staining (ICS) of cytokines 
For ICS, cells were first stimulated with PMA (100 ng/ml) and ionomycin (1µg/ml) 
(Sigma) in the presence of GolgiStop (BD Biosciences) for 4 hrs before surface 
staining as described above. After surface staining cells were fixed and washed in 1x 
permeablisation buffer (Cytoperm, BD Biosciences).  Afterwards, cells were 
incubated in permeablisation buffer for 5 mins. Cells were then incubated for 15 mins 
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with Fc block and then washed and stained with antibodies against cytokines diluted 
in permeablisation buffer.  Cells were then washed in permeablisation buffer and 
resuspended in staining buffer.  Some cells were stained for fluorescence minus one 
(FMO) controls. 
2.11.4 Flow cytometric staining of granzyme B, RORγt and regulatory T cells 
In case of intracellular staining for granzyme B and RORγt, cells were not stimulated 
but stained for surface markers first before being fixed. Cells were then 
permeabalised and Fc block was added for 10 mins to the cells before staining for 
granzyme B or RORγt. The samples were run and analysed as described above.  
Tregs were detected using the CD4+CD25+Foxp3+ staining kit from eBiosciences 
according to the manufacturer’s instructions. In brief, cells were stained with surface 
markers as described above and were fixed and permeabalised before staining for 
Foxp3. Flow cytometric analysis was performed as described above. 
2.12 Protein measurement 
2.12.1 Enzyme linked immunosorbent assay (ELISA) for serum IgE   
Serum IgE kit (OptEIA) was purchased from BD Biosciences and performed 
according to manufacturer’s instructions. Briefly, flat bottomed high binding 96 well 
plates (Costar, NY, USA) were coated ON with 100µl/well of anti-mouse Ab diluted 
to the appropriate concentration in coating buffer.  Wells were blocked using 
blocking buffer followed by washing. Samples or standards (recombinant protein 
diluted in assay buffer to the appropriate range) were added in duplicate and 
incubated for 2 hrs RT or ON at 4oC. After incubation, wells were washed (x4) and 
then incubated with working detector (detection Ab + streptavidin-HRP) for 1 hr.  
Plates were washed and TMB substrate (Neogen, USA) was added to each well.  The 
colourimetric reaction was stopped by the addition of 2N H2SO4 and optical density 
(OD) readings at 450nm were measured using a spectrophotometer (Softmax Pro, 
USA) within 30 mins.  
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HDM specific IgE was measured by coating plates with 100µl/well 50µg/ml HDM in 
carbonate buffer ON at 4oC. Wells were blocked for 2 hrs at RT. Serum samples were 
added to wells in duplicates and incubated ON at 4oC. Plate was washed and 2µg/ml 
biotin conjugated mouse anti-IgE Ab was added to the wells and incubated for 1 hr at 
RT. Plate was then washed and 100µl streptavidin-HRP was added to each well and 
incubated for 30 min at RT. Plate was then washed and TMB substrate was added to 
wells and incubated at RT until colour developed. Reaction was stopped with 0.19M 
H2SO4 and read at 450nm. The data was analysed using GraphPad Prism where the 
concentrations of mediators in the samples were calculated from the standard curve. 
Mediator-buffer combinations are outlined in Table 2.1. 
2.12.2 Bradford assay 
BAL protein measurement was carried out using the Bradford assay. Briefly bovine 
serum albumin (BSA) protein standards were made with concentrations from 2mg/ml 
to 0.1mg/ml in buffer (PBS and 5mM EDTA). 5µl of standard or BAL samples were 
added to each well in duplicates using a 96-well plate. 250µl of Bradford reagent 
(Sigma) was added to each well and the plate was briefly placed on a shaker. The 
absorbance was read at 595nm using a manufacturer spectrophotometer (using 
Softmax Pro software, Molecular Devices, USA). Analysis was performed on 
Graphpad Prism as described above. 
2.12.3 Lactose Dehydrogenase (LDH) assay 
LDH concentration in the BAL was used as a measure of lung cell damage. The 
enzymatic assay was performed according to manufacturer’s instructions (Abcam 
UK). Briefly, positive controls and standards provided were added to a 96-well plate 
in duplicate. 10µl of samples were added in duplicates and the volume was made up 
to 50µl using assay buffer. 50µl of reaction mix (containing diluted substrate mix 
solution) was added to each well. The OD was measured at T1 at 450nm using 
manufacturer spectrophotometer (Softmax Pro). The plate was then incubated at 37oc 
for 30 mins and the plate was read again at T2. Data was analysed by calculating 
ΔA450.  
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ΔA450=A2-A1 
Background OD was subtracted from all readings and the standard curve to obtain B. 
for each sample B= standard curve reading – background. 
Total LDH activity of each sample was then calculated as below: 
LDH activity=B x sample dilution/(T2-T1) x sample volume. 
T1=time of reading 1 
T2=time of reading 2 
B=NADH amount that was generated between T1 and T2 
2.13 Cytotoxicity and killing assay  
A cytotoxicity assay was performed using isolated lung NK cells and RMA-s target 
cells. Lung NK cells from HDM challenged mice or control mice treated with PBS or 
RSV were isolated. Lung vasculature was perfused and a single cell suspension was 
prepared as described earlier. NK cells were isolated using magnetic activating cells 
sorting (MACS) separation columns (Miltenyi Biotech) and an NK cell negative 
selection kit according to the manufacturer’s instructions (Miltenyi Biotech).  
RMA-s were grown in complete media and stained with 5µM Cell Trace Violet dye 
(Invitrogen) according to manufacturer’s instructions.  Cells were added to two V-
bottomed 96-well plates at E:T  (effector: target) ratios of 10:1, 5:1 and 1:1.   
To measure degranulation, one plate was incubated with PE conjugated Ab to 
CD107a for 2 hrs at 37oc.  After the incubation period, cells were washed and stained 
for NK cells using conjugated monoclonal antibody (mAbs) to NKp46.  
To measure killing activity of NK cells, the other plate was incubated for 4 hrs and 
then cells were stained with 350µl of FACS buffer containing 7-ADD. Both plates 
were analysed on a BD Fortessa. Cytotoxicity of NK cells was determined in the first 
plate by measuring CD107a expression on NK cells and killing of target cells was 
measured in the second plate by assessing 7-AAD (7-Aminoactinomycin D) uptake 
into target cells, identified using the violet dye. 
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2.14 Histology of lung tissue 
After removal from the animal, one lobe of lung (second lobe on the right) was 
inflated with PBS and fixed in 10% normal buffered formalin for 24 hrs and 
transferred in 70% ethanol until processed.  Specimens were paraffin embedded, and 
transverse sectioned (4µm) onto glass slides.  Embedding, sectioning and staining 
with haematoxylin & eosin were performed by histologist Lorraine Lawrence. Images 
were recorded using a 10x objective lens (Zeiss Axioscope.A1).  
2.15 Polymerase Chain Reaction (PCR) analysis  
Lung tissue was snap frozen in liquid nitrogen for later analysis. Lung tissue was 
homogenized in 350µl of RLT buffer containing 1% β-mercaptoethanol, using a 
TissueLyser (Qiagen). Total RNA was isolated using an RNeasy mini kit (Qiagen) 
using the automated Qiacube machine (Qiagen). RNA concentration and purity were 
determined on a nanodrop (Thermoscientific) and reverse transcription was carried 
out using the high-capacity cDNA kit (Applied Biosystems). Reverse transcriptase-
PCR (RT-PCR) was performed on Applied Biosystems 7500 real-time PCR system, 
using Taqman universal PCR master mix (Applied Biosystems). FAM-TAM-labelled 
probes and primer sets (Applied Biosystems) were used to measure expression of 
murine MULT-1 (ulbp1), Rae-1 family members (rae1δ and rae1ε are expressed in 
C57BL/6 mice), KC (cxcl1) and CCL2 (ccl2). Fold change in expression of mRNA 
was quantified by the 2-ΔΔCt method using GAPDH (VIC-TAM labelled probe) as an 
internal control (Applied Biosystems). PCR for the RSV L gene was performed, as 
described before [406], normalised to 18s gene expression and copy number 
determined using an RSV L gene containing plasmid as a standard [370].  
2.16 Data analysis  
Data is expressed as mean + SEM.  Data was not assumed to be normally distributed 
and statistical significance between groups was tested using a non-parametric Mann-
Whitney U Test. PCR data was considered as normally distributed and ANOVA was 
used to assess significance. For RSV weight loss 2 way ANOVA was used.  p value 
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of <0.05 was accepted as significant.  Graph generation and statistical analysis was 
performed by using GraphPad Prism software (Version 5.00, San Diego, CA) and 
flow cytometry data analysed using FlowJo (Version 7.6.1, USA). 
2.17 Supplementary tables to materials 
 
Table 2. General buffers and reagents 
Reagent Content Application Company 
7-amino-
actinomycin (7-
AAD) 
Reconstituted to 1mg/ml 
(See manufacturer’s 
instruction) 
Flow cytometry Sigma 
ACK lysis buffer 
0.15 M NH4Cl, 1mM 
KHCO3, 0.1 mM Na2EDTA 
at pH 7.2. 0.2µm filtered 
Depletion of red 
blood cells 
Sigma 
BAL media PBS with 5mM EDTA 
Bronchoalveolar 
lavage  
Invitrogen 
Cell dissociation 
solution 
 0.5% Trypsin-EDTA in PBS Cell culture Gibco 
Coating buffer PBS ELISA PAA 
Collagenase 
Type XI concentration 0.45 
mg/ml in PBS containing 
10% FCS. Final concentration 
of 50µg/ml 
Lung digestion Sigma 
CountBright 
Absolute Counting 
Beads 
Counting beads 
Cell count by 
Flow cytometry 
Invitrogen 
D-PBS Dulbecco's sterile PBS 
Cell culture, in 
vivo use 
PAA 
ELISA blocking 
solution 
10% FCS in PBS ELISA 
PAA, 
Biosource 
ELISA stop 
solution 
2 N H2SO4 ELISA Sigma 
ELISA wash 
buffer 
0.05% Tween20 in PBS, pH 
7.2-7.4 
ELISA Sigma 
FACS buffer 
1% BSA, 0.1% NaN3, 2mM 
EDTA in PBS, 0.2µm filtered 
Flow cytometry 
Sigma, 
Invitrogen 
Fc block  Anti - CD16/32 Flow cytometry 
BD 
Biosciences 
Fixation and 
permeabilisation 
buffer 
No details from manufacturer. 
Flow cytometry  
(intracellular 
staining) 
BD, 
eBiosciences 
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GolgiStop 
Contains Monensin (protein 
transport inhibitor) 
Flow cytometry 
(intracellular 
staining) 
BD 
Biosciences 
LIVE/DEAD 
fixable stain 
(Aqua) 
Aqua dye Flow cytometry Invitrogen 
Lysis buffer 
25mg/ml protease K (Sigma, 
UK), 0.5M EDTA, 1M Tris, 
5M NaCl, 10% SDS 
Genotyping 
(DNA) 
Sigma, 
Invitrogen 
MACS buffer 
0.5% BSA, 2mM EDTA in 
PBS, pH 7.2 
Cell sorting 
Sigma, 
Invitrogen 
PCR mastermix 
for RSV L-gene 
No information from 
manufacturer 
PCR Qiagen 
Streptavidin 
peroxidase 
Strepavidin peroxidase 
conjugate 
Plaque assay Sigma 
Tetramethyl 
benzidine (TMB) 
3,3’,5,5;- 
Tetrmethylbenzidine 
ELISA Invitrogen 
TE buffer 
10 mM Tris-HCl, 1mM 
EDTA, pH 8 
Genotyping 
(DNA) 
Sigma 
Trypan Blue 
solution 
0.4% Trypan Blue stain 
Viable cell 
count 
Sigma 
 
Table 3. Media and Media supplements 
Reagent Composition Application Company 
RPMI-1640 
medium 
See manufacturer's information 
sheet 
Cell culture PAA 
Fetal calf serum 
(FCS) 
Heat inactivated fetal bovine 
serum 
Cell culture Biosource 
L-glutamine 200µM Cell culture Invitrogen 
Penicillin-
Streptomycin 
100U/ml and 100µg/ml Cell culture Invitrogen 
 
2.18 Gating strategy for lymphocyte analysis by flow cytometry 
BAL and lung lymphocytes (CD4, CD8, NK and γδT cells) were analysed by flow 
cytometry. Cells were gated on FSC-A and FSC-W to exclude doublets and also 
live/dead stain was used to exclude dead cells. Following a lymphocyte gate based on 
FSC-A and SSC-A, CD4 cells were identified as CD3+CD4+ cells and CD8 cells as 
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CD3+CD8+. NK cells were gated on CD3-NKp46+ cells. γδT cells were gated on 
CD3+γδTCR+ cells.  
 
 
Figure 2.1. An example of the gating strategy for lung lymphocyte flow cytometry data: Mice 
were challenged with HDM (25µg) i.n. for 3 times a week for 3 weeks. Lungs were collected 24 
hrs after the last HDM challenge and stained for FACS analysis. a) Singlets were selected by 
means of FSC-A and FSC-W gating. b) BAL and lung cells were stained with Live and Dead stain 
to exclude dead cells. c) Lymphocytes were gated according to FSC/SSC. CD4 (d), CD8 (e), NK 
(f) and γδT (g) cells were gated according to FMO (fluorescence minus one) controls. 
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Chapter Three – Characterisation of NKp46+ Cell 
Activation in the HDM Model of Allergic Airway 
Inflammation 
3.1 Introduction 
The role of NK cells in viral infection and Th1 immunity has been well studied; 
however the role of NK cells in allergic disease has garnered less attention.  
 
Both clinical and mouse studies indicate the importance of NK cells in allergy and 
asthma. Defects in NK cell functions such as a reduction in IFN-γ production and 
a decreased capability to promote and sustain Th1 responses were shown in 
peripheral blood NK cells from asthmatic allergic patients, with increased 
cytotoxicity [345, 356, 407, 408]. In addition there is evidence using ex-vivo 
PBMC, that NK cell cytokine production is altered in allergic asthma with a 
higher frequency of Th2 cytokine producing NK cells than IFN-γ [309, 347, 349]. 
More recently, there is evidence that NK cell activation and interaction with other 
immune cells is defective in allergic patients [296, 309, 316]. Moreover in mouse 
models of allergic asthma, NK cell depletion by anti-NK1.1 and anti-ASGM1 Ab 
administration inhibited BAL and lung eosinophilia and Th2 cell infiltrate [361, 
363]. Interestingly there is also evidence that NK cells are important in promoting 
resolution of allergic inflammation by targeting inflammatory immune cells [365]. 
However none of the evidence above determines the mechanisms by which NK 
cells contribute to allergic asthma. Furthermore, in terms of depletion studies, the 
tools used such as depleting Abs are not specific to NK cells [364].  
 
Here we aim to define and characterise the phenotype of NK cells in a HDM 
induced murine model of allergic inflammation of the lung using NKp46 as a 
marker found to be on all NK cells at all stages of development [222]. 
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We first aimed to do this by performing a time course study. NK cells have been 
shown to promote and sustain Th1 responses in the LN by early production of 
IFN-γ [320]. We questioned whether NKp46+ cells contribute to initiation of Th2 
responses in this model or are important for shaping adaptive responses. 
3.2 Aims 
1. To establish and set-up the HDM model in house and study the inflammatory 
responses to HDM 
2. To study the role of NKp46+ cells in the HDM model using a time course 
study 
3. To characterise the phenotype and role of NKp46+ cells at early and/or late 
time points 
4. To characterise status of activation of NKp46+ cells in the HDM model 
(cytotoxicity)  
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3.3 Results 
3.3.1 Time course study- Characterisation of HDM model 
To characterise the phenotype, activation and receptor expression of NKp46+ cells 
in allergic inflammation, and to determine the involvement and importance in 
early stage (sensitisation) or later stage of allergic inflammation, a time course 
study was carried out. We chose to employ the HDM model as this is a clinically 
relevant model and shows features similar to human disease [409]. 
 
BALB/c mice were challenged for 3 days per week for up to 3 weeks by 
intranasal instillation of 25µl of a 1mg/ml solution of whole HDM allergen extract 
in PBS. A group of mice were given 1 dose of HDM and another group were 
given 4 doses of HDM. All mice were culled 24 hrs after the last challenge. Each 
HDM group has a corresponding PBS group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Time course study: BALB/c mice were challenged with 25µg HDM (i.n.). One group 
received HDM, 3 times a week for 3 weeks, another group of mice were challenged 4 doses of 
HDM and the last group received only 1 dose of HDM. All were culled 24 hrs post last challenge. 
Each group had corresponding PBS groups. 
 
3.3.1.1  BAL, lung and MLN total cell numbers increase with HDM challenge 
At each time point BAL, lung, MLN and spleen were collected and processed to 
be counted by flow cytometry. Total cells counts revealed that in mice challenged 
 
 
            25 µg HDM or PBS                                      
CULL 
Group 2, 4 doses  
Group 1, 9 doses  
Group 3, 1 dose  
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with HDM, BAL (Figure 3.2a) and MLN (Figure 3.2c) total cells numbers 
increase significantly throughout the experimental time course of HDM challenge. 
Lung (Figure 3.2b) total cell numbers only increased after 9 challenges however 
this was not significant in this experiment.  Spleen (Figure 3.2d) total cell 
numbers showed no significant changes. 
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Figure 3.2. BAL, lung, MLN and spleen total cell numbers: BALB/c mice were challenged with 
HDM (25µg) (HDM 9) or PBS (i.n.). Alternatively, mice received 4 (HDM 4) or one (HDM 1) 
dose. BAL (a), lungs (b), MLN (c) and spleen (d) were collected 24 hrs post last HDM challenge 
and processed for analysis by flow cytometry. (n=6 mice per group; arithmetic mean+SEM. 
*p≤0.05,** p≤0.01, ns=not significant, compared to PBS). 
 
3.3.1.2 BAL cell infiltration with HDM challenge 
To characterise the nature of the inflammatory infiltrate into the airways, BAL 
cells were collected at different time points and differential counts performed on 
cytospins. The proportion of both BAL eosinophils (Figure 3.3a) and lymphocytes 
(Figure 3.3g) increased dose dependently with increasing doses of HDM. 
However the proportion of macrophages (Figure 3.3c) decreased with increasing 
doses of HDM. The proportion of neutrophils (Figure 3.3e) increased significantly 
at one dose of HDM but this gradually declined with increasing doses of HDM. 
BAL eosinophil (Figure 3.3b), neutrophil (Figure 3.3f) and lymphocyte (Figure 
3.3h) numbers increased dose dependently with HDM challenge compared with 
a b 
c d 
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PBS mice. BAL macrophage numbers (Figure 3.3d) appeared to increase with 
HDM challenge but were only significant at the last time point (HDM9).  
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Figure 3.3. BAL differential cells: BALB/c mice were challenged with HDM (25µg) or PBS i.n. 
3 times a week for 3 weeks (HDM 9). Alternatively, mice received 4 (HDM 4) or one (HDM 1) 
dose. BAL cells were collected 24 hrs post last HDM challenge. BAL cells processed and counted 
on cytospins. Percentage and total number of eosinophils (a-b), macrophages (c-d), neutrophils (e-
f) and lymphocytes (g-h) are shown. (n=6 mice per group; arithmetic mean+SEM. ** p≤0.01, 
ns=not significant, compared to PBS). 
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3.3.1.3  BAL CD4 cells increase in number with increasing doses of HDM 
To characterise the T helper cell response to HDM, BAL and lung cells collected 
at different time points were stained for CD4 and intracellular cytokines and were 
analysed by flow cytometry. The proportion of BAL (Figure 3.4a) and lung 
(Figure 3.4c) CD4+ lymphocytes increased with HDM doses, was significantly 
elevated after 4 doses of HDM and remained high at 9 doses of HDM. Although 
BAL CD4+ lymphocyte numbers (Figure 3.4b) increased significantly in a dose 
dependent manner, lung CD4 numbers (Figure 3.4d) were significantly higher at 9 
doses only.  
 
The percentage and number of BAL IL-4 producing CD4 cells (Figure 3.5a-b) 
increased dose dependently with increasing doses of HDM, and although the 
percentage of lung IL-4 producing CD4 cells (Figure 3.5g) were increased with 
HDM, lung IL-4 producing CD4 numbers (Figure 3.5h) did not increase 
significantly. Similarly, the percentage and number of IL-13 producing CD4 cells 
increased in the BAL (Figure 3.5c-d) but this was only significant in the lung at 
later time points (Figure 3.5i-j).  
 
The percentage of BAL IFN-γ producing CD4 cells (Figure 3.5e) only increased 
after 4 doses of HDM and appeared to then reduce at 9 doses.  However the total 
cells numbers of BAL IFN-γ producing CD4 (Figure 3.5f) increased dose 
dependently with HDM challenge compared to PBS. Lung IFN-γ producing CD4 
cells (Figure 3.5k-l) increased both in percentage and numbers with increasing 
doses of HDM. There was no significant change in spleen CD4 cell numbers or 
cytokine expression (data not shown).  
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Figure 3.4. Number and percentage of BAL and lung CD4 cells: BALB/c mice were challenged 
with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks (HDM 9). Alternatively, mice received 
4 (HDM 4) or one (HDM 1) dose. BAL and lung cells were collected 24 hrs post last HDM 
challenge and processed to be analysed by flow cytometry for percentage (left column) and total 
cells numbers (right column) of BAL (a-b) and lung (c-d) CD4 cells. (n=6 mice per group; 
arithmetic mean+SEM. *p≤0.05,** p≤0.01, ns=not significant, compared to PBS). 
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Figure 3.5. Number and percentage of 
BAL and lung cytokines producing 
CD4 cells: BALB/c mice were 
challenged with HDM (25µg) or PBS 
i.n. 3 times a week for 3 weeks (HDM 
9). Alternatively, mice received 4 
(HDM 4) or one (HDM 1) dose. BAL 
(a-f) and lung cells (g-l) were collected 
24 hrs post last HDM challenge and 
processed to be analysed by flow 
cytometry for percentage (left column) 
and total cell numbers (right column) of 
IL-4 (a&b, g&h), IL-13 (c&d, i&j) and 
IFN-γ (e&f, k&l) producing CD4+ cells. 
(n=6 mice per group; arithmetic 
mean+SEM. *p≤0.05,** p≤0.01, ns=not 
significant, compared to PBS). 
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3.3.1.4  NKp46+ cell profile in BAL, lung and MLN after HDM challenge 
To determine when and where NKp46+ cells were recruited during the response to 
HDM, the percentage and number of BAL, lung, LN and spleen NKp46+ cells 
were analysed by flow cytometry. The percentage and number of BAL (Figure 
3.6a-b) and lung NKp46+ (Figure 3.6c-d) cells increased slightly at early doses 
and only significantly increased after 9 doses of HDM. The percentage of NKp46+ 
cells in LN (Figure 3.6e) decreased after the first dose of HDM and further 
decreased with increasing doses of HDM. However LN NKp46+ cell numbers 
(Figure 3.6f) increased at 4 doses of HDM and remained significantly high at 9 
doses. Spleen NKp46+ cells in percentage and numbers did not change with HDM 
challenge (data not shown). 
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Figure 3.6. Number and percentage of NKp46+ cells: BALB/c mice were challenged with HDM 
(25µg) or PBS i.n. 3 times a week for 3 weeks (HDM 9). Alternatively, mice received 4 (HDM 4) 
or one (HDM 1) dose.  BAL (a-b), lung (c-d), LN (e-f) and spleen cells were collected 24 hrs post 
last HDM challenge and processed to be analysed by flow cytometry. (n=6 mice per group; 
arithmetic mean+SEM. ** p≤0.01, ns=not significant, compared to PBS). 
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3.3.1.5  BAL NKp46+ cells produce IL-4 and IL-13 as well as IFN-γ with 
increasing doses of HDM challenge 
We aimed to investigate the cytokine production by NKp46+ cells in the lung and 
the airway following HDM challenge. Interestingly, we found that NKp46+ cells 
produced IL-4 and IL-13 following HDM challenge. The percentage and number 
of IL-4 (Figure 3.7a-b, g-h) and IL-13 (Figure 3.7c-d, i-j) producing BAL and 
lung NKp46+ cells increased significantly after 4 doses of HDM and remained 
elevated throughout the time course of HDM challenge. The percentage and 
number of IFN-γ producing NKp46+ cells in BAL (Figure 3.7e-f) and lung (Figure 
3.7k-l) also increased with 4 doses of HDM and further increased with increasing 
HDM challenge. 
3.3.1.6 Granzyme B expression increases in BAL and lung NKp46+ cells with 
increasing doses of HDM challenge 
To investigate NKp46+ cell activation following HDM challenge, granzyme B 
production was measured on NKp46+ cells by flow cytometry following HDM 
challenge. 
BAL and lung NKp46+ cells granzyme B (Figure 3.8a-b) production increased 
with one dose of HDM however this was not statistically significant in the BAL. 
In both BAL and lung granzyme B production in NKp46+ cells was significantly 
elevated at 4 and 9 doses of HDM. 
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Figure 3.7. Number and percentage of 
BAL cytokine producing NKp46+ 
cells: BALB/c mice were challenged 
with HDM (25µg) or PBS i.n. 3 times a 
week for 3 weeks (HDM 9). 
Alternatively, mice received 4 (HDM 4) 
or one (HDM 1) dose. BAL (a-f) and 
lung (g-l) cells were collected 24 hrs 
post last HDM challenge and processed 
to be analysed by flow cytometry for 
percentage (left column) and total cell 
numbers (right column) of IL-4 (a&b, 
g&h), IL-13 (c&d, i&j) and IFN-γ 
(e&f, k&l) producing NKp46+ cells. 
(n=6 mice per group; arithmetic 
mean+SEM. *p≤0.05,** p≤0.01, ns=not 
significant, compared to PBS). 
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Figure 3.8. BAL and lung granzyme B expression: BALB/c mice were challenged with HDM 
(25µg) or PBS i.n. 3 times a week for 3 weeks (HDM 9). Alternatively, mice received 4 (HDM 4) 
or one (HDM 1) dose. BAL and lung cells were collected 24 hrs post last HDM challenge and 
processed to be analysed by flow cytometry. BAL (a) and lung (b) granzyme B was measured by 
Mean fluorescence intensity (MFI). Representative flow cytometry plots of lung NKp46+ cells 
expressing granzyme B in mice treated with 9 doses of PBS or HDM (c). (n=6 mice per group; 
arithmetic mean+SEM. ** p≤0.01, ns=not significant, compared to PBS). 
 
3.3.2 NK cell cytotoxicity following HDM challenge 
A functional cytotoxicity assay was performed using isolated lung NK cells 
following HDM challenge using RMA-s cell as targets. For a positive control, 
lung NK cells from mice infected with RSV were isolated at day 4 post infection 
(Figure 3.9a). At E:T ratio of 1:1, although smaller than RSV response, there was 
a significant increase in killing (the percentage of RMA-s cells positive for 
7AAD) in HDM treated NK cells compared to naïve mice (Figure 3.9b-c). At an 
E:T ratio of 0.5:1 there was a significant increase in the degranulation of NK cells, 
measured by CD107a expression, in NK cells from HDM treated mice compared 
to naïve mice (Figure 3.9d). 
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Figure 3.9. NK cells cytotoxicity: BALB/c mice were challenged with HDM (25µg) i.n. 3 times a 
week for 3 weeks BAL and lung cells were collected 24 hrs post last HDM challenge. A group of 
mice were infected with RSV (1x106 PFU) and culled at day 4 post injection. Lung cells were 
isolated by MACS sorting and placed on a plate with violet dye stained RMA-s cells. Procedure is 
summarised in (a). Percentage of RMA-s cells positive for 7AAD at E:T ratio of 1:1 (b), % of 
lysis of RMA-s cells (c) and percentage of degranulation of NK cells by CD107a expression (d).   
(n=6 mice per group; arithmetic mean+SEM. *p≤0.05,** p≤0.01, compared to naïve; +++ p≤0.001 
RSV compared to naive). 
b 
c d 
a 
Page 84 of 194 
 
3.4. Discussion 
The role of NK cells in allergic inflammation and asthma is still unclear. There 
are a few studies carried out in murine models using OVA as allergen to study NK 
cells and their role in allergic asthma. In these studies, NK cells are depleted by 
means of antibodies to NK1.1 and ASGM1, which are also present on other cells 
[361, 363]. We chose to use HDM as allergen which is a known cause of domestic 
asthma and in animal models causes a robust airway inflammation and 
remodelling similar to the changes seen in asthmatics [409]. HDM can be 
delivered by local administration and unlike OVA does not require the need for 
adjuvant.  
 
We aimed to characterise NKp46+ cells in the HDM model of allergic 
inflammation. We performed a time course study to investigate the dynamics of 
NKp46+ cells at early time points (innate responses) and later time points 
(adaptive responses) of the disease model. We used NKp46 as a marker of NK 
cells as it is expressed on all NK cells at all stages of development. It should be 
noted that NKp46 is also found on type-3 innate lymphocytes and this is discussed 
further in Chapter 7. Of these, only conventional NK cells are cytotoxic and 
express granzyme B. 
 
We have shown, as stated in the literature [405], that continuous exposure to 
inhaled HDM leads to allergic inflammation of the lung in mice.  We have shown 
a dose dependent increase in total airway (BAL) and lung cells following HDM 
challenge (Figure 3.2a-b). We have also shown a 60% BAL eosinophilia as well 
as increases in other inflammatory cells in the airway in mice treated with HDM 
(Figure 3.3 & Figure 3.5h). There is a significant increase in numbers of Th2 
cytokine producing CD4 cells both in BAL and lung (Figure 3.4). In addition, 
although small, there is an increase in numbers of IFN-γ producing CD4 cells 
following HDM challenge (Figure 3.5e-f, k-l). There was no increase in total cell 
numbers in spleen or any changes in their cytokine production (Figure 3.2d). This 
indicates that the inflammatory response to HDM inhalation is a local response 
rather than systemic.  
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Interestingly, this study revealed that numbers of NKp46+ cells increase in the 
airway following HDM challenge (Figure 3.6a-b). BAL NKp46+ cells followed a 
similar trend to that of eosinophils, which support the hypothesis that NKp46+ 
cells may regulate airway eosinophilia [363]. In addition the Th2 responses seems 
to precede the increase in numbers and activation of NKp46+ cells and therefore 
NK cells do not appear to be important at early time points and might contribute 
to the allergic inflammation at later time points. Contrary to data reported by Ple 
et al. [363] and what is observed in Th1 immunity [320]  the percentage of 
NKp46+ cells in MLN (Figure 3.6e) was reduced with increasing doses of HDM. 
It has been shown before that during Th1 responses NK cells travel to the LN and 
are early source of IFN-γ and are important for initiation of Th1 responses [320].  
However in this model of the Th2 response, although NKp46+ cell numbers 
increase in the LNs following HDM challenge, their numbers at 1 dose of HDM is 
not significantly different to PBS treated mice. 
 
We wondered if NKp46+ cells could produce IL-4 and contribute to initiation of 
Th2 immunity [410]. However following the time course study, we did not 
observe IL-4 production by NKp46+ cells in the LN which again indicated that 
NKp46+ cells may not play a role at early time points of allergic inflammation. 
We aimed to investigate the cytokine production of NK cells in a Th2 
environment in the lung, which has not previously been studied. In fact, to our 
knowledge, Th2 cytokine production by NK cells has not previously been 
demonstrated in vivo in allergic responses, but only in ex-vivo cytokine cultured 
cells. In addition to producing IFN-γ (Figure 3.7e-f, k-l), NKp46+ cells can also 
produce Th2 cytokines in the lung following HDM challenge (Figure 3.7a-d, g-j). 
Both BAL and lung NKp46+ cells produce IL-4 and IL-13 with increasing doses 
of HDM. Production of Th2 cytokines by NK cells in the gut has been shown 
before [319], however production of these cytokines by NKp46+ cells has never 
been reported in the lung. 
 
We had initially hypothesised that NK cells might become impaired and less 
cytotoxic in allergic inflammation and this could be the reason that asthmatic are 
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more prone to respiratory viral infection. In addition to this there is evidence in 
the literature that production of type I IFNs, which lead to activation of NK cells 
in viral infection, is reduced in asthmatic patients [355, 375]. However we 
observed a marked increase in granzyme B production with increasing doses of 
HDM (Figure 3.8). Interestingly there is evidence in the literature showing that 
granzyme B is elevated in asthmatic’s airway [359, 360]. Increase in granzyme B 
is a marker of cytotoxicity and upon this observation; we decided to investigate 
the state of activation and cytotoxicity of NK cells in the HDM model.  
Using a functional assay we measured NK cell cytotoxicity and killing activity 
following HDM challenge and we have shown that NK cells appear to become 
more cytotoxic (Figure 3.9c-d). This data together with increased granzyme B 
indicated that NK cells are activated and become more cytotoxic following HDM 
challenge.  
In summary our data suggests a model in which NKp46+ cells contribute to Th2 
immunity by producing Th2 cytokines such as IL-4, which we have demonstrated 
for the first time in allergic lung inflammation. Therefore, we decided to 
investigate, more thoroughly, the phenotype of NKp46+ cells in allergic 
inflammation and present this data in Chapter 7. 
Additionally, NK cells appear to get activated and become more cytotoxic 
following HDM challenge. Following the above observation we aimed to 
investigate the function of NK cell activation and cytotoxicity and consequently 
decided to look at the role of NKG2D, a major activatory receptor on NK cells, in 
allergic inflammation of the lung.  
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Chapter Four – Role of NKG2D in the HDM model 
4.1 Introduction 
In our previous observation from the time course study, NK cells appear to 
become more activated and more cytotoxic following HDM challenge.  NK cells 
mediate their cytotoxic activity through a balance of signals from many activatory 
and inhibitory receptors. 
 
NKG2D is a major activatory receptor on all mature NK cells, however it is also 
expressed on NKT cells and subsets of γδ and αβ T cells [234, 235].  As well as 
mediating the cytotoxicity function of NK cells, NKG2D recognises ligands from 
the H60, MULT-1 and the Rae-1 families  in mice and  human MICA or MICB 
and ULBP1-6, which are induced in response to stress, DNA damage and on 
transformed cells such as tumours or virally infected cells [238, 239]. NKG2D has 
been implicated in tumour clearance, graft rejection, atherosclerosis, 
autoimmunity and infection [239, 242-246, 411] however its role in allergic 
inflammation or asthma is still not known. In murine models, activation of skin 
intraepithelial lymphocytes via NKG2D can promote systemic atopy [257].  In 
severe asthma, peripheral blood NK cells express high levels of NKG2D which 
correlates with blood eosinophilia [356]. Furthermore, NKG2D ligands MICA 
and ULBP-2 are elevated in the serum of children with respiratory symptoms of  
HDM allergy [357].   
 
The above evidence in the literature and our earlier observation of increased 
cytotoxic activity in NK cells by HDM (Chapter 3) lead us to explore the role of 
NKG2D expression by NK cells in the induction and control of atopic lung 
disease.  
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4.2 Aims 
1. To determine the role of the NKG2D receptor in allergic inflammation of the 
lung using the HDM model of allergic inflammation in NKG2D KO mice as 
well as using anti-NKG2D mAb 
2. To determine the ability of NKG2D deficient mice to mount an NK cell 
response in the lungs by determining the role of the NKG2D receptor in the 
RSV model of respiratory infection. 
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4.3 Results 
4.3.1 The role of NKG2D in allergic lung inflammation 
To study the role of NKG2D in allergic inflammation of the lung, NKG2D KO 
mice were treated with 25µg of HDM or 25 µl PBS three times a week for three 
weeks.  
 
 
 
 
 
4.3.1.1  Lung and airway cell infiltration in NKG2D KO mice after HDM 
challenge 
Following HDM challenge, there was a significant increase in lung peribronchial 
inflammation as shown by H&E staining (Figure 4.1a) and this was significantly 
lower in the KO mice. There was a significant increase in BAL total cells in WT 
mice following 9 doses of HDM (Figure 4.1b); however this was significantly 
lower in the NKG2D KO mice. There was no significant difference in baseline 
inflammatory response in WT PBS treated mice and KO PBS treated mice (Figure 
4.1b). 
 
The percentage and number of BAL eosinophils following HDM challenge was 
significantly lower in NKG2D KO compared to WT mice (Figure 4.1c-d). 
Although the percentage of BAL neutrophils was not significantly lower in terms 
of total cell numbers, neutrophils were lower in NKG2D KO mice compared to 
WT mice (Figure 4.1c-d). BAL lymphocyte numbers were significantly lower in 
the KO mice (Figure 4.1d) but this reduction failed to reach a statistically 
significant percentage (Figure 4.1c). Although the percentage of macrophages was 
changed in NKG2D KO mice (Figure 4.1c), there was not a significant change in 
BAL macrophage numbers (Figure 4.1d). 
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Figure 4.1. Lung histology, BAL cell proportions and numbers in NKG2D KO mice: NKG2D 
KO mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. BAL cells 
and lung sections were collected 24 hrs after the last HDM challenge. Lung sections were stained 
with H&E (a). Total cell count (b) was performed by flow cytometry. BAL cells were processed 
and counted on stained cytospin preparations. Percentage (c) and total cell numbers (d) of 
eosinophils, neutrophils, lymphocytes, and macrophages are shown. (n=6 mice per group; 
arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above the two 
groups). 
a 
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4.3.1.2 BAL but not lung lymphocyte numbers were reduced in NKG2D KO 
mice treated with HDM 
To characterise the adaptive responses in NKG2D KO mice challenged with 
HDM we studied BAL and lung lymphocyte profiles in these mice. Following 
flow cytometric analysis of lymphocytes (CD4, CD8, γδT, and NK cells) in BAL 
and lung, the percentage and number of these lymphocytes were determined. 
There was a significant increase in both BAL and lung percentage and the number 
of CD4 cells following HDM challenge in WT mice (Figure 4.2a-b & i-j). 
Although there was no change in the percentage of BAL CD4, total cell numbers 
in NKG2D KO mice treated with HDM were less than WT mice. There was not a 
significant reduction in lung CD4 cells both in percentage and number in the 
NKG2D KO mice (Figure 4.2 i-j).  
 
There was a significant increase in both percentage and number of BAL CD8+ 
cells in WT mice treated with HDM. Although percentage of BAL CD8+ cells did 
not alter, the total cells numbers were significantly lower in NKG2D KO mice 
treated with HDM. There was not a significant increase in the percentage and 
number of lung CD8+ cells with HDM both in WT and KO mice (Figure 4.2 c-d & 
k-i). 
 
There was a significant increase in both the percentage and number of NKp46+ 
cells in BAL of WT mice treated with HDM and there was significantly lower 
BAL NKp46+ percentage and total cell numbers in NKG2D KO mice. There was 
not a significant increase in the percentage and number of lung NKp46+ with 
HDM both in WT and KO mice (Figure 4.2 e-f & m-n). 
 
Whilst there was no change in the percentage of γδT cells in the BAL of mice 
treated with HDM, there was a significant increase in the numbers in the BAL in 
WT mice treated with HDM. The number of γδT cells was significantly lower in 
NKG2D KO mice treated with HDM compared to WT. In the lung, there was no 
significant increase in the percentage or number of lung γδT cells with HDM both 
in WT and KO mice (Figure 4.2 g-h & o-p). 
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Figure 4.2. BAL and lung lymphocytes in NKG2D KO mice: NKG2D KO mice were 
challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. BAL (left panel) and lung 
(right panel) cells and were collected 24 hrs after the last HDM challenge. BAL and lung cells 
were analysed by flow cytometry. Percentage (left columns) and total number (right columns) of 
CD4+ (a&b,i&j), CD8+ (c&d,k&l), NKp46+ (e&f,m&n) and γδT cells (g&h,o&p) are shown. 
(n=6 mice per group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by 
a bar above the two groups). 
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4.3.1.3 Th2 responses following HDM challenge are lower in NKG2D KO 
mice 
To investigate the importance of NKG2D in Th2 responses induced by HDM, IL-
4 and IL-13 producing CD4+ cells were analysed by flow cytometry. BAL 
percentage and number of both IL-4 (Figure 4.3 a-b) and IL-13 (Figure 4.3 c-d) 
increased significantly in WT mice treated with HDM and this was significantly 
lower in NKG2D KO mice treated with HDM. Although there was a significant 
increase in IFN-γ producing CD4 cells both in percentage (Figure 4.3e) and 
number (Figure 4.3f) following HDM challenge in WT mice, this was 
significantly lower in the numbers of IFN-γ producing CD4 in the NKG2D KO 
mice. Interestingly there was a slight increase in the percentage of IFN-γ 
producing cells in the NKG2D KO mice. There was not a significant change in 
lung Th2 responses following HDM challenge in WT mice (data not shown).  
 
To determine if lack of NKG2D would influence the production of serum IgE in 
response to HDM, serum total IgE and HDM specific IgE was measured in the 
NKG2D KO mice. There was a significant increase in total serum IgE and HDM 
specific IgE levels in WT mice treated with HDM and this was significantly lower 
in NKG2D KO mice treated with HDM compared to WT (Figure 4.3g-h). 
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Figure 4.3. BAL and lung cytokine producing CD4 cells and total serum IgE in NKG2D KO 
mice: NKG2D KO mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 
weeks. BAL cells were collected 24 hrs after the last HDM challenge. BAL cells were analysed by 
flow cytometry. Total serum IgE was measured by ELISA. Percentage (left column) and total 
number (right column) of IL-4 (a&b), IL-13 (c&d), IFN-γ (e&f), total serum IgE (g) and HDM 
specific IgE (h) are shown. (n=6 mice per group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, 
ns=not significant, indicated by a bar above the two groups). 
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4.3.1.4 NK cells are less activated in NKG2D KO mice 
To determine whether NKG2D is involved in the activation of NK cells 
challenged with HDM, granzyme B (Figure 4.4a&c) and CD69 (Figure 4.4b&d) 
expression in WT and NKG2D KO NK cells was measured. Both CD69 
expression and granzyme B levels were significantly lower in NKG2D KO mice 
compared to WT mice treated with HDM. 
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Figure 4.4. Lung NK cells CD69 and granzyme B expression in NKG2D KO mice: WT and 
NKG2D KO mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. 
Lung cells were collected 24 hrs after the last HDM challenge. Lung NK cells were analysed by 
flow cytometry. Expression of granzyme B (a&c) and CD69 (b&d) is shown.  (n=6 mice per 
group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above 
the two groups). 
 
4.3.2 NKG2D blocking mAb (MI6) 
As our data with the NKG2D KO mice suggested that NKG2D was an important 
regulator of the inflammatory response to HDM, we wished to determine whether 
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blockade of this receptor could prevent allergic inflammation and whether it could 
reduce the extent of inflammation once established. To use the Ab 
prophylactically, WT mice were treated with 200µg NKG2D blocking mAb or 
isotype control (i.p) 2 days before starting HDM challenge and this was followed 
by weekly doses of 100µg of mAb. 
 
 
4.3.2.1 Treatment with NKG2D blocking mAb reduced the proportion of 
airway eosinophils but did not significantly reduce other inflammatory 
responses induced by HDM 
Blocking the NKG2D receptor by mAb (MI6) did not significantly reduce the 
inflammatory responses to HDM in WT mice. Both BAL and lung total cells in 
mice treated with MI6 were reduced, however this was not statistically significant 
from WT HDM treated mice (Figure 4.5a-b). Similarly, the percentage and 
number of BAL differential cells (macrophages (Figure 4.5c-d), lymphocytes 
(Figure 4.5e-f) and neutrophils (Figure 4.5g-h)) reduced slightly but were not 
statistically significant. Although the percentage of BAL eosinophils was 
significantly reduced in WT mice treated with MI6, the reduction in the total 
number of eosinophils was not statistically significant (Figure 4.5i-j).  
Other inflammatory parameters such as lymphocytes and Th2 responses were 
similar to BAL total cells and BAL differentials, where there was a slight 
reduction by MI6 treatment but this change was not statistically significant (data 
not shown).  
Page 98 of 194 
 
BAL macrophages
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
50
100
150
**
**
ns
%
BAL macrophages
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
50
100
150
**
**
ns
ce
lls
 x
 1
0
3
BAL lymphocytes
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
10
20
30
** **
ns
%
BAL lymphocytes
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
50
100
150
200
**
**
ns
c
e
lls
 x
 1
0
3
BAL neutrophils
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
5
10
15
**
**
ns
%
BAL neutrophils
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
50
100
150
**
**
ns
ce
lls
 x
 1
0
3
BAL eosinophils
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
20
40
60 **
**
*
%
BAL eosinophils
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
200
400
600
**
**
ns
ce
lls
 x
 1
0
3
BAL total cells
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0.0
0.2
0.4
0.6
0.8
1.0 **
**
ns
C
el
ls
 x
 1
0
6
Lung total cells
PB
S
HD
M
 +
 Is
o
HD
M
 +
 M
I6
0
2
4
6
ns
ns
ns
C
el
ls
 x
 1
0
6
a b
c d
e f
g h
i j
 
Figure 4.5. BAL and lung total cells and BAL differential cells in mice treated with NKG2D 
blocking mAb (MI6): WT C57BL/6 mice were injected with 200µg of  NKG2D blocking mAb or 
isotype control, 2 day prior to HDM challenge followed by weekly injection of 100µg (i.p.). Mice 
were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. BAL (a) and lung (b) 
cells and were collected 24 hrs post last HDM challenge. BAL (a) and lung (b) total cells were 
counted on flow cytometry. BAL cells were applied to cytospins and counted. Percentage (left 
column) and total number (right column) of macrophages (c&d), lymphocytes (e&f), neutrophils 
(g&h) and eosinophils (i&j) are shown. (n=6 mice per group; arithmetic mean+SEM. *p≤0.05, ** 
p≤0.01, ns=not significant, compared to PBS unless indicated by a bar above the two groups). 
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4.3.3 RSV infection in NKG2D KO mice 
To determine whether the response observed in NKG2D KO mice is specific to 
HDM challenge, or due to a global reduction in NK cell responsiveness or the 
ability to mount inflammatory responses in the lung, we used the RSV model of 
respiratory infection. NKG2D KO and WT mice were treated to 106 PFU RSV 
(i.n) or HEp2 supernatant controls. Mice were culled 4 days post infection. 
 
 
 
 
 
4.3.3.1 There was no significant difference in the WT and NKG2D KO mouse 
response to RSV both in weight loss and viral load 
There was significant weight loss at day 1 post infection in both WT and NKG2D 
KO mice treated with RSV compared to corresponding HEp2 controls. However 
there was no significant difference in weight loss between NKG2D KO and WT 
mice treated with RSV (Figure 4.6a). Similarly there was no significant difference 
in viral load measured by PCR for viral L-gene in NKG2D KO and WT mice 
infected with RSV (Figure 4.6b). 
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Figure 4.6. Weight loss and viral load in NKG2D KO mice following RSV infection: WT and 
NKG2D KO mice were infected with RSV (106 PFU) or HEp2 supernatant i.n. Mice were weighed 
daily (a) and culled 4 days post infection. The right top lobe of the lung was snap frozen and used 
to measure L-gene copy number (viral load) by qPCR (b). (n=5-6 mice per group; arithmetic 
mean+SEM. *p≤0.05, ** p≤0.01, ***p≤0.001, ns=not significant, indicated by a bar above the two 
groups). 
 
4.3.3.2 There was no significant difference in total cell numbers or 
composition of the inflammatory infiltrate in the airway and lungs of 
RSV treated WT and NKG2D KO mice 
There was a significant increase in BAL total cells in both WT and NKG2D KO 
mice infected with RSV; however there was no difference in BAL total cell 
numbers between NKG2D KO and WT mice (Figure 4.7a). There was no 
significant increase in lung inflammatory responses at 4 days post infection in 
either WT or NKG2D KO mice (Figure 4.7b). 
There was a significant reduction in the percentage of BAL macrophages in WT 
and NKG2D KO mice infected with RSV and this corresponded with an increase 
in percentage of lymphocytes and neutrophils (Figure 4.7c). However there was 
no significant difference in the percentage or numbers of BAL macrophages, 
lymphocytes or neutrophils in RSV infected WT and NKG2D KO mice (Figure 
4.7c-d). 
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Figure 4.7. BAL and lung cells in NKG2D KO mice infected with RSV: WT and NKG2D KO 
mice were infected with RSV (106 PFU) or HEp2 supernatant i.n. BAL (a) and lung (b) cells and 
were collected 4 days after infection. BAL (a) and lung (b) total cells were counted by flow 
cytometry. BAL cells were applied to cytospins and counted. Percentage (c) and total number (d) 
of macrophages, lymphocytes, and neutrophils are shown. (n=5-6 mice per group; arithmetic 
mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above the two groups). 
 
4.3.3.3  There is no significant difference in the NK cell response and 
activation in WT and NKG2D KO mice infected with RSV 
The percentage and number of BAL NKp46+ cells increased significantly in both 
WT and NKG2D KO mice; however there were no significant differences 
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between the two groups (Figure 4.8a-b). Similarly, the percentage and number of 
IFN-γ producing NKp46+ cells were increased by RSV infection in both WT and 
NKG2D KO mice but there were no differences between the two groups (Figure 
4.8c-d). CD69 expression (Figure 4.8e) and granzyme B (Figure 4.8f) production 
as markers of NK cell activation were also increased with RSV in both groups, 
with no difference between WT and KO mice. 
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Figure 4.8. BAL NKp46+ cells in NKG2D KO mice infected with RSV: WT and NKG2D KO 
mice were infected with RSV (106 PFU) or HEp2 supernatant i.n. BAL cells were collected 4 days 
post infection. BAL NKp46+ cells were analysed by flow cytometry. Percentage and number of 
BAL NKp46+ (a&b) and IFN-γ+ NKp46+ cells (c&d) and CD69 (e) and granzyme B expression 
(f) are shown. (n=5-6 mice per group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not 
significant, indicated by a bar above the two groups). 
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4.3.3.4  There is no significant difference in BAL CD4 and CD8 responses in 
RSV infected WT and NKG2D KO mice 
The percentage and number of BAL CD4 cells increased significantly in both WT 
and NKG2D KO mice infected with RSV but there was no difference between the 
two groups (Figure 4.9a-b). Similarly the percentage and number of the IFN-γ 
producing CD4 cells increased in response to RSV in both WT and KO mice but 
there were no significant difference between the two (Figure 4.9c-d).  
The percentage and number of BAL CD8 cells were also increased in response to 
RSV in both WT and NKG2D KO mice; however there were no differences 
between the two groups (Figure 4.9e-f). In addition, the percentage and number of 
IFN-γ producing CD8+ lymphocytes was increased in response to RSV in both 
groups but there was no significant change between WT and NKG2D KO mice 
(Figure 4.9g-h). 
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Figure 4.9. BAL CD4 and CD8 cells in NKG2D KO mice infected with RSV: WT and NKG2D 
KO mice were infected with RSV (106 PFU) or HEp2 supernatant i.n. BAL cells and were 
collected 4 days post infection. BAL CD4 (left panel) and CD8 (rigt panel) cells were analysed by 
flow cytometry. Percentage and number of BAL CD4 (a&b) and IFN-γ+ CD4 cells (c&d), 
percentage and number of BAL CD8 (e-f) and IFN-γ+ CD8 cells (g-h) are shown. (n=5-6 mice per 
group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above 
the two groups). 
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4.4 Discussion  
We have shown in Chapter 3 that NKp46+ cells are activated and become more 
cytotoxic following HDM challenge. This observation led us to investigate the 
major activatory receptor NKG2D in allergic inflammation of the lung as this 
receptor is involved in activation of NK cells by its engagement to its ligand. We 
employed the HDM model in NKG2D KO mice. We observed that airway cell 
numbers (Figure 4.1b), and more specifically airway eosinophils were reduced by 
60% in NKG2D KO mice treated with HDM compared to WT controls (Figure 
4.1c-d). In addition we observed a significant reduction in lung peribronchial 
inflammation in NKG2D KO mice by histological studies (Figure 4.1a). 
Furthermore, other inflammatory cells such as CD4, CD8, γδT cells as well as 
NKp46+ cells were all significantly lower in numbers in the airways in the KO 
mice compared to WT mice treated with HDM (Figure 4.2). In addition all Th2 
responses measured by IL-4 and IL-13 production in CD4 cells as well as total 
serum IgE and HDM specific IgE were significantly less in the KO mice (Figure 
4.3).  
 
We then aimed to determine whether activation of NK cells in the HDM model is 
dependent on NKG2D. We measured granzyme B and CD69 expression levels in 
both WT and NKG2D KO and demonstrated that NK cells appear to be less 
activated in NKG2D KO mice (Figure 4.4). This indicates that activation of NK 
cells in HDM challenged mice could be at least partially dependant on NKG2D as 
lack of this receptor in the KO mice leads to less CD69 and granzyme B 
expression, both of which are markers of activation in NK cells. 
 
We next aimed to block the inflammatory responses in WT mice treated with 
HDM by using NKG2D blocking Ab as this could have potential therapeutic 
implications. WT mice were treated with NKG2D blocking Ab (MI6) and culled 
following the last HDM challenge. Although we observed a reduction in total 
cells numbers and inflammatory parameters, this change was not statistically 
significant due to the spread of data (Figure 4.5). We employed the dosing 
regimen commonly used for this Ab in the literature [266]; however we were not 
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able to determine whether the Ab administered intraperitoneally would block this 
receptor in the lung. We tried the treatment with Ab prophylactically and well as 
therapeutically, however both dosing regimens produced similar results. It 
remains to be established if dosing regimen, route of administration and 
increasing the power of the study by increasing mouse numbers per group, would 
improve the outcome of this study.  
 
NKG2D KO mice used in our study exhibit only minor alteration in their NK cell 
receptor repertoire and respond normally to MCMV infection [412], and therefore 
have a very similar phenotype to WT mice. Nevertheless, the attenuated 
inflammatory responses in NKG2D deficient mice in response to HDM could 
reflect an alteration in NK cell responsiveness or in immune responses in the lung. 
To address this and to determine whether the response in NKG2D KO mice is 
HDM specific, we infected mice with RSV and examined the viral load and 
immune response 4 days after infection. In this model, NK cells are recruited to 
the lungs and peak at day 4 after infection and promote the development of type-1 
adaptive immunity [343, 413]. We detected no differences in weight loss and viral 
load (Figure 4.6), as measured by copies of the RSV L-gene at 4 days after 
infection, which is the peak of viral load in this model, between the two groups. 
Furthermore, there were no differences in responses to RSV infection in terms of 
total inflammatory cell recruitment into the airways and the nature of the 
inflammatory infiltrate (Figure 4.7). NKp46+ cell numbers in the airways and their 
IFN-γ production was unaltered in NKG2D KO mice compared to WT mice 
(Figure 4.8). Development of the CD4+ or CD8+ lymphocyte response was 
similarly unaltered (Figure 4.9). In addition, we measured all the above 
parameters at 7 days after infection as this is the peak of adaptive responses to 
RSV. However there were no significant differences in inflammatory responses 
and viral load between WT and NKG2D KO at this time point (data not shown). 
This data  demonstrates  that  unlike HDM  allergen  challenge,  following a  
respiratory  viral   infection, NKG2D deficient mice are able to mount a robust  
inflammatory  response in the  lung, recruit NK cells and control viral infection. 
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Together this data indicates a pro-inflammatory role for NKG2D in allergic 
inflammation. In the following chapter we determine whether NKG2D is 
expressed on cells other than NK cells in this model and specifically determine 
the role of NK cell NKG2D in allergic inflammation of the lung. 
Page 107 of 194 
 
d 
 
 
 
 
 
Chapter Five 
 
Page 108 of 194 
 
Chapter Five – Determining the Cellular Specificity of 
NKG2D Expression Required for Allergic Inflammation 
5.1 Introduction 
We have shown that NK cells are activated and increase their granzyme B 
production following multiple HDM challenges (Chapter 3). We have also shown 
that NKG2D promotes allergic inflammation in the lung and lack of this receptor 
leads to a dampening down of all inflammatory responses in HDM challenged 
mice (Chapter 4). NKG2D is expressed on NK cells as well as other cells of the 
immune system including CD4, CD8, γδT and NKT cells [234, 235]. Therefore 
we wished to determine whether NK cells intrinsic expression of NKG2D drives 
allergic inflammation or whether it is the expression of this receptor on other cells 
that is important.  
To address this question we carried out adoptive transfer studies. We hypothesised 
that transfer of WT NKG2D expressing cells into NKG2D KO mice would 
determine which cells are responsible for the importance of this receptor in 
allergic inflammation.  
 
Additionally, there is evidence in the literature that granzyme B is elevated in the 
airway of allergen challenged asthma patients [359, 360]. Our data, together with 
this evidence lead us to investigate the importance of NK cell intrinsic granzyme 
B in allergic inflammation of the lung. 
5.2  Aims 
1. To determine what proportion of  NKG2D expressing cells are NK cells 
2. To determine whether adoptive transfer of WT NK cells into NKG2D KO 
mice would restore the inflammatory response to the WT phenotype 
3. To determine the importance of granzyme B in NK cells by adoptive transfer 
of granzyme B KO NK cells into NKG2D KO mice 
4. To determine the importance of other NKG2D expressing cells, by adoptively 
transferring these cells expressing NKG2D into the NKG2D KO mice 
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5.3 Results 
5.3.1 Determining which lymphocyte subsets express NKG2D in allergic 
lung inflammation  
To determine what lymphocyte populations expressed NKG2D in the mouse lung, 
WT mice were challenged with 9 doses of HDM and lung cells processed and 
stained as described previously.  We showed that only cells with low SSC, which 
would include lymphocytes, but not granulocytes or alveolar macrophages, 
express NKG2D using SSC vs NKG2D (Figure 5.1a).  
 
Cells were gated on live, singlet, lymphocytes and then gated on NKG2D. We 
then determined the proportion of NKG2D+ cells which were CD4+ T cells, CD8+ 
T cells, γδ T cells, NKT cells and NK cells. Only 3% of NKG2D positive cells 
were CD4+ T cells (CD3+CD4+), 7% were CD8+ T cells (CD3+CD8+), 4% were γδ 
T cells (CD3+ γδTCR+), 5% were NKT cells (CD3+NK1.1+) and 80% were NK 
cells (CD3-NKp46+) (Figure 5.1b). 
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Figure 5.1. Lymphocyte subsets expressing NKG2D: Representative flow cytometry plots of 
mice challenged with 9 doses of HDM. Lung cells were processed and stained for CD3, CD4, 
CD8, γδTCR, NK1.1 and NKp46. Lung cells were gated on singlets and live cells and NKG2D 
expression is shown against SSC (a). Lung cells (b) were gated on singlets and live lymphocytes. 
NKG2D expressing lymphocytes are shown: 3% of NKG2D positive cells are CD4 (CD3+CD4+), 
7% are CD8 (CD3+CD8+), 4% are γδT cells (CD3+ γδTCR+), 5% are NKT (CD3+NK1.1+) and 
80% are NK cells (CD3-NKp46+). 
 
5.3.2 Adoptive transfer of WT NK cells and granzyme B KO NK cells 
Once we determined that 80% of NKG2D positive cells were NK cells we aimed 
to determine whether NKG2D expression on NK cells was sufficient to promote 
allergic inflammation. In addition, we aimed to determine the role of granzyme B 
in NK cells. We transferred 0.5x106 WT spleen NK cells or granzyme B KO NK 
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cells into NKG2D KO mice (i.v) 24 hrs before starting the HDM challenge. To 
control for effects of sorting and transfer of cells, KO NK cells were transferred to 
KO mice. 
 
 
 
5.3.2.1 Purity of sorted cells determined by flow cytometry 
Splenic CD3-NKp46+ cells were stained with an Ab to NKp46 and sorted by flow 
cytometry. Figure 5.2 shows the purity of the sorted cells which was typically 97-
99%. Cells were then counted and the viability was typically above 97%. 
 
 
 
Figure 5.2. Purity of sorted cells: A single cell suspension of spleen cells was prepared and cells 
were stained with CD3 and NKp46. Cells were sorted by flow cytometry and CD3-NKp46+ cells 
were collected. The plot shows the purity of cells checked following sorting. 
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5.3.2.2 Adoptively transferred NK cells reach the lung and are present in the 
lung 24 hrs after the last HDM challenge 
To determine that NK cells sorted and transferred intravenously had reached the 
lung and were present during the experiment, cells were tracked by their 
expression of NKG2D as the hosts receiving these cells were deficient in 
NKG2D. We stained and gated on CD3-NKp46+ cells and then looked for cells 
that were positive for NKG2D. Almost all NKp46+ cells were NKG2D positive in 
a wild type naïve mouse. NKG2D KO mice lacked NKG2D on all cells including 
NK cells however, once WT NK cells which express this receptor are injected in 
the mice, 11% of NK cells were positive for NKG2D, indicating that WT NK and 
granzyme B deficient NK cells (these cells express NKG2D)  reached the lung 
and were present during allergic inflammation (Figure 5.3). 
 
Figure 5.3. Tracking of adoptively transferred cells: Representative flow cytometry plots of 
mice treated with 9 doses of HDM following adoptive transfer of WT or granzyme B KO NK 
cells. Transferred cells were tracked by expression of NKG2D on NK cells.  
 
5.3.2.3 Airway inflammation is restored by adoptive transfer of WT NK cells, 
but not granzyme B KO NK cells, into NKG2D KO mice 
To determine the influence of adoptive transfer on airway inflammatory responses 
to HDM in NKG2D KO mice, total cell numbers in the airway (BAL) and lungs 
were determined. BAL cell numbers significantly increased following HDM 
challenge in WT mice and, as shown before, this was significantly lower in 
NKG2D KO mice. However following transfer of WT NK cells into NKG2D KO 
mice BAL total cell numbers were completely restored to WT levels.  
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Transfer of granzyme B KO NK cells (which express NKG2D on their surface), 
did not restore the airway inflammatory responses (Figure 5.4a). 
 
The proportion of airway cells which were macrophages reduced in WT mice 
treated with HDM and this was higher in NKG2D KO mice treated with HDM as 
shown before. Adoptive transfer of WT NK cells into NKG2D KO mice reduced 
the percentage of macrophages to WT levels but no change was observed by 
transfer of granzyme B KO cells (Figure 5.4b).  
 
The percentage of lymphocytes (Figure 5.4d), neutrophils (Figure 5.4f) and most 
importantly eosinophils (Figure 5.4h) were increased significantly following 
HDM challenge but this was significantly lower in NKG2D KO mice. Adoptive 
transfer of WT NK cells into NKG2D KO mice restored the inflammatory 
response to HDM in KO mice. Adoptive transfer of granzyme B KO NK cells into 
NKG2D KO mice did not restore the airway inflammatory responses.  
 
Total cell numbers of macrophages (Figure 5.4c), lymphocytes (Figure 5.4e), 
neutrophils (Figure 5.4g), and eosinophils (Figure 5.4i) were increased in WT 
mice following HDM challenge and were significantly lower in NKG2D KO 
mice. Adoptive transfer of WT NK cells restored these cell numbers back to WT 
levels. Transfer of granzyme B KO NK cells did not restore these inflammatory 
responses. 
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Figure 5.4. Airway inflammatory responses in NKG2D KO mice following adoptive transfer 
of WT and granzyme B KO NK cells: Spleen CD3-NKp46+ cells were sorted by flow cytometry. 
NKG2D KO mice received (i.v) 0.5x106 WT or gzmb-/- sorted cells 24 hrs before HDM challenge. 
WT or NKG2D KO mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 
weeks. BAL cells were collected 24 hrs after the last HDM challenge. BAL total cells were 
analysed by flow cytometry (a). BAL cells were processed by cytospins and counted under the 
microscope. Percentage (left column) and total number (right column) of macrophages (b&c), 
lymphocytes (d&e), neutrophils (f&g), and eosinophils (h&i) are shown. (n=6 mice per group; 
arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, compared to WT PBS unless 
indicated by a bar above the two groups). 
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5.3.2.4 Adoptive transfer of WT NK cells but not granzyme B KO NK cells 
into NKG2D KO mice restores the lung inflammatory responses to HDM 
To determine whether transfer of WT NK or granzyme B KO NK cells into 
NKG2D KO mice would restore inflammation in the lung following HDM 
challenge, lung sections were stained with H&E. The lung sections show a 
significant increase in inflammatory cells in the lung following transfer of WT 
NK cells into NKG2D KO mice but not granzyme B KO NK cells (Figure 5.5). 
 
 
 
Figure 5.5. Lung inflammation to HDM in NKG2D KO mice following adoptive transfer of 
NK cells: Spleen CD3-NKp46+ cells were sorted by flow cytometry. NKG2D KO mice received 
(i.v) 0.5x106 WT or gzmb-/- sorted cells 24 hrs before HDM challenge. WT or NKG2D KO mice 
were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. Lung collected 24 hrs 
after the last HDM challenge. Lung sections were stained with H&E. 
 
5.3.2.5  Adoptive transfer of WT NK cells, but not granzyme B KO NK cells, 
into NKG2D KO mice restores BAL and lung lymphocyte numbers to the 
WT phenotype 
To determine whether transfer of WT NK or granzyme B KO NK cells would 
restore the inflammatory lymphocyte responses to HDM in NKG2D KO mice, 
BAL and lung cells were analysed by flow cytometry to look at the profile of 
different lymphocytes. The percentage of BAL CD4+ and CD8+ lymphocytes 
increased significantly in WT mice challenged with HDM and this was slightly 
increased in the NKG2D KO mice, however this was not significant. This increase 
was then restored to WT levels in NKG2D KO mice that received WT NK cells 
but not in KO mice receiving granzyme B deficient NK cells (Figure 5.6a-c). 
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BAL CD4 and CD8 total cell numbers increased significantly in WT mice 
challenged with HDM and were lower in NKG2D KO mice challenged with 
HDM. Adoptive transfer of WT NK cells but not granzyme B KO NK cells 
restored CD4 and CD8 numbers to WT levels (Figure 5.6b-d). 
 
Both BAL NK cells percentage and numbers increased significantly with HDM 
challenge in WT mice and this was lower in NKG2D KO mice. Transfer of WT 
NK cells into NKG2D KO mice elevated the percentage and number of NK cells 
back to WT levels. This was not observed with transfer of granzyme B KO NK 
cells (Figure 5.6e-f). 
 
Although there was no significant change in the percentage of BAL γδT cells, 
there was a significant increase in total cell numbers of these cells in WT mice 
challenged with HDM. This number was significantly lower in NKG2D KO mice 
and we were able to restore this number by transferring WT NK cells but not with 
NK cells deficient in granzyme B (Figure 5.6g-h). 
 
There was no significant change in the percentage of lung CD4+ and CD8+ cells 
(Figure 5.6i-k); however the total number of lung CD4+ cells followed the same 
trend as the BAL CD4+ cells (Figure 5.6j). Although lung CD8+ total cell numbers 
showed a similar trend to BAL CD8+ cells this was not significant due to the 
spread of data (Figure 5.6l). 
 
Both the percentage and total cell number of NK cells significantly increased in 
WT mice following HDM challenge and although these numbers were lower in 
NKG2D KO mice, we were able to restore this response by transfer of WT NK 
cells. Transfer of granzyme B KO NK cells did not restore this response (Figure 
5.6m-n). There was no change in lung γδT cells between each group (Figure 5.6o-
p) 
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 Figure 5.6. BAL and lung lymphocytes in NKG2D KO mice adoptively transferred with WT 
NK cells: Spleen CD3-NKp46+ cells were sorted by flow cytometry. NKG2D KO mice received 
(i.v) 0.5x106 WT or gzmb-/- sorted cells 24 hrs before HDM challenge. WT or NKG2D KO mice 
were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. BAL (left panel) and 
lung (right panel) cells and were collected 24 hrs after the last HDM challenge. BAL and lung 
cells were analysed by flow cytometry. Percentage (left columns) and total number (right columns) 
of CD4+ (a&b,i&j), CD8+ (c&d,k&l), NKp46+ (e&f,m&n) and γδT cells (g&h,o&p) are shown. 
(n=6 mice per group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, compared to 
WT PBS unless indicated by a bar above the two groups). 
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5.3.2.6 Th2 responses are restored to WT levels in NKG2D KO mice 
receiving WT NK cells 
To determine the influence of adoptive transfer on Th2 responses to HDM in 
NKG2D KO mice, IL-4 and IL-13 producing CD4 cells were measured by flow 
cytometry. The proportion and number of IL-4 and IL-13 producing BAL CD4 
cells were significantly increased following HDM challenge in WT mice (Figure 
5.7a-d). However this was significantly lower in NKG2D KO mice. Both the 
percentage and number of these cells were restored almost to WT levels in 
NKG2D KO mice receiving WT NK cells. Transfer of granzyme B KO NK cells 
into NKG2D KO mice failed to restore total numbers of IL-4 and IL-13 producing 
CD4+ cells.  
 
Although there seems to be a slight increase in the percentage of BAL IFN-γ 
producing CD4+ cells in NKG2D KO and KO mice receiving granzyme B KO NK 
cells, these cell total numbers were lower in NKG2D mice and were elevated in 
KO mice receiving WT NK cells. Transfer of granzyme B KO cells did not 
change the phenotype of NKG2D KO mice in their production of IFN-γ by BAL 
CD4 cells (Figure 5.7e-f). There were no significant changes observed in lung 
Th2 responses (data not shown).  
 
To determine whether the lack of IgE response can be restored in NKG2D KO 
mice by transfer of NKG2D expressing NK cells, serum total IgE and HDM 
specific IgE was measured. Both total IgE and HDM specific IgE were absent 
NKG2D KO mice, however transfer of WT NK cells in NKG2D KO mice 
challenged with HDM, lead to an increase in IgE levels. Transfer of granzyme B 
KO NK cells into NKG2D KO did not elevate the IgE levels and IgE levels in 
these mice were as low as PBS treated mice (Figure 5.7g-h). 
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Figure 5.7. Th2 inflammatory responses to HDM in NKG2D KO mice receiving WT or 
granzyme B KO NK cells: Spleen CD3-NKp46+ cells were sorted by flow cytometry. NKG2D 
KO mice received (i.v) 0.5x106 WT or gzmb-/- sorted cells 24 hrs before HDM challenge. WT or 
NKG2D KO mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. 
BAL cells were collected 24 hrs post last HDM challenge and were analysed by flow cytometry. 
Percentage (left columns) and total number (right columns) of IL-4 (a&b), IL-13 (c&d), IFN-γ 
(e&f) CD4 cells and serum total IgE and HDM specific IgE (g&h) are shown. (n=6 mice per 
group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, compared to WT PBS 
unless indicated by a bar above the two groups). 
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5.3.3 Adoptive transfer of CD3 positive cells 
To determine whether expression of NKG2D on CD3+ lymphocytes could restore 
allergic inflammation in our model, we transferred WT CD3+ cells into NKG2D 
KO mice.  Spleen CD3+ cells sorted by flow cytometry contain CD4, CD8, γδT 
and NKT cells.  
 
 
 
 
 
5.3.3.1 Inflammatory responses to HDM are not restored with adoptive 
transfer of WT CD3+ cells in NKG2D KO mice 
Adoptive transfer of WT CD3+ cells into NKG2D KO mice did not restore the 
inflammatory responses to HDM in the KO mice. BAL total cells were 
significantly increased by HDM in WT mice and this was lowered in NKG2D KO 
mice. Transfer of WT CD3+ cells did not increase the BAL total cells (Figure 
5.8a).  
In addition, BAL eosinophil, neutrophils, macrophages and lymphocytes 
percentage and number were not altered in NKG2D KO mice that received WT 
CD3+ cells (Figure 5.8b-i). All the other inflammatory markers such as 
lymphocytes and Th2 responses were also unaltered in NKG2D KO in following 
transfer of WT CD3+ cells (data not shown). 
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Figure 5.8. Airway inflammatory responses to HDM in NKG2D KO mice receiving WT CD3 
cells: Spleen CD3+ cells were sorted by flow cytometry. NKG2D KO mice received (i.v) 0.5x106 
cells 24 hrs before HDM challenge. WT or NKG2D KO mice were challenged with HDM (25µg) 
or PBS i.n. 3 times a week for 3 weeks. BAL cells were collected 24 hrs after the last HDM 
challenge and were analysed by flow cytometry for total cell numbers (a). BAL cells were 
processed by cytospins and counted under the microscope. Percentage (left columns) and total 
number (right columns) of eosinophils (b&c), neutrophils (d&e), macrophages (f&g) and 
lymphocytes (h&i) are shown. (n=6 mice per group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, 
ns=not significant, compared to WT PBS unless indicated by a bar above the two groups). 
Page 122 of 194 
 
5.4 Discussion 
We have shown that NK cells are activated and increase production of granzyme 
B following HDM challenge in the lung (Chapter 3). Additionally, we have shown 
that NKG2D is important for driving the allergic inflammation to HDM, as lack of 
this receptor leads to overall dampening down of inflammatory responses 
(Chapter 4). Next, we aimed to determine in which cells of the immune system 
NKG2D expression and granzyme B production is important in allergic 
inflammation. To answer this question, we first planned to determine the 
proportion of NKG2D positive cells in the lung. NKG2D is only expressed on 
hematopoietic cells including CD4, CD8, NKT, γδT and NK cells as well as some 
macrophages in the mouse [235, 236]. We showed that 80% of NKG2D+ 
lymphocytes in the lung in allergic inflammation are NK cells (Figure 5.1). This 
supported our initial hypothesis that NK cells are important in allergic 
inflammation.  
 
To demonstrate that it is NK cell intrinsic NKG2D expression and granzyme B 
production that promote allergic inflammation, we transferred WT NK cells into 
NKG2D KO mice. We also transferred granzyme B KO NK cells (which express 
NKG2D on the surface (Table 4) to assess whether NK cells require granzyme B 
for their role in allergic inflammation. We had previously shown increases in 
cytotoxicity in NK cells challenged with HDM (Chapter 2) and there is supporting 
evidence in the literature that granzyme B is elevated in the airway of allergen 
challenge asthmatics patients [359, 360].  
 
We have shown that adoptive transfer of WT NK cells which express NKG2D 
restored all inflammatory responses to HDM in NKG2D KO mice to WT levels. 
BAL differential cell numbers (Figure 5.4), Th2 responses as well as IgE levels 
(Figure 5.7) were restored to WT levels with transfer of WT NK cells into the KO 
mice. We have shown in Chapter 4 that NKG2D KO mice cannot mount an 
immune response to HDM and this response is specific to HDM as they are able 
to respond to RSV infection.  
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Lack of inflammatory responses to HDM in NKG2D KO mice indicates the 
importance of this receptor in promoting allergic inflammation. We have shown in 
this chapter that it is expression of this receptor on NK cells that drives the 
inflammatory responses to HDM. Interestingly we were able to show that NK 
cells require both NKG2D and granzyme B to perform their role in allergic 
inflammation as transfer of granzyme B KO NK cells into NKG2D KO mice did 
not restore the phenotype.  BAL total cells (Figure 5.4), airway inflammatory cells 
(Figure 5.4), and Th2 responses (Figure 5.7) were not restored to WT levels in 
NKG2D mice receiving granzyme B KO NK cells, despite expressing NKG2D on 
the surface. 
 
Interestingly, transfer of WT CD3 cells which includes CD4, CD8, γδT, and NKT 
cells did not restore the inflammatory responses to HDM in NKG2D KO mice 
(Figure 5.8); further proving that expression of NKG2D on NK cells and not on 
CD3+ lymphocytes promotes allergic inflammation. 
 
The importance of granzyme B as an effector molecule suggests cytotoxic 
mechanisms may play a role. NK  cells  could regulate  allergic inflammation  by  
killing  activated T cells,  DCs  or  respiratory epithelial cells [266, 309, 314, 414-
417]. Alternatively, granzyme B can regulate inflammation by other mechanisms, 
for example, IL-1α which has undergone proteolysis by granzyme B can promote 
allergic airway inflammation [418-420]. We therefore aimed to find the NK cells’ 
targets and mechanism of action in allergic inflammation. 
 
 
 
 
 
 
 
 
Page 124 of 194 
 
Table 4. Summarising the adoptive transfer studies and the outcome of each 
experiment 
 
Experiment Cells NKG2D Granzyme 
B 
Allergic 
inflammation? 
Wild type mice NK cells 
CD3+ 
lymphocytes 
+ 
+ 
+ 
+ 
YES 
NKG2D KO NK cells 
CD3+ 
lymphocytes 
- 
- 
+ 
+ 
NO 
NKG2D KO 
+ WT NK cells 
NK cells 
CD3+ 
lymphocytes 
+ 
- 
+ 
+ 
YES 
NKG2D KO 
+ granzyme B KO 
NK cells 
NK cells 
CD3+ 
lymphocytes 
+ 
- 
- 
+ 
NO 
NKG2D KO 
+ CD3+ 
lymphocytes 
NK cells 
CD3+ 
lymphocytes 
- 
+ 
+ 
+ 
NO 
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Chapter Six
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Chapter Six – Mechanisms of NK Cells Action in Allergic 
Inflammation 
6.1 Introduction 
We have shown for the first time that NK cells promote allergic pulmonary 
inflammation in response to HDM allergen, by mechanisms dependent on NK cell 
intrinsic expression of the major activating receptor NKG2D and granzyme B. 
Here we aimed to determine the mechanisms by which NK cells are involved in 
promoting allergic inflammation through NKG2D and granzyme B. 
We have shown that NK cell cytotoxicity activity is increased following HDM 
challenge and granzyme B production is increased in these cells, indicating these 
cells are possibly interacting with target cells and removing them through 
cytotoxic activity. 
We first aimed to find the NKG2D ligand in the lung as we hypothesised that NK 
cell cytotoxic activity is initiated through engagement of this receptor with its 
ligand expressed on the target cell. Mouse NKG2D ligands are MULT-1, Rae-1 
and H60 [421]. However H60 is not transcribed in C57BL/6 mice [422]. 
 
With adoptive transfer studies (Chapter 5) we showed that lack of granzyme B 
and NKG2D on NK cells prevents allergic inflammation, therefore we 
hypothesised that these cells might be lysing some regulatory cells, for instance 
Tregs or regulatory DCs. In fact selective lysis of Tregs by NK cells has been 
demonstrated before [415].  
 
However we also hypothesised that NK cells could promote allergic inflammation 
by killing epithelial cells which might express the NKG2D ligand. Expression of 
the NKG2D ligand on mouse and human epithelial cells has been shown before 
[266, 411, 423]. We hypothesised if epithelial cells were expressing the NKG2D 
ligand in response to HDM, activated NK cells could kill these cells, which in 
return would lead to break down of the epithelial barrier. Damage to the epithelial 
barrier increases the access of inflammatory DCs to allergen and this could be the 
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reason for the low inflammatory responses in mice lacking NKG2D or NK cells 
lacking granzyme B. Additionally, epithelial damage could lead to the release of 
IL-33 which is expressed in the nucleus of non-hematopiotic cells [112]. IL-33 
has been shown to be critical for activation of ILC2 and initiation of allergic 
inflammation [92, 424, 425].  
 
Interestingly there is evidence that granzyme B might have extracellular 
proteolytic activity as well as cytotoxicity [418, 419]. There is evidence in the 
literature that granzyme B can convert pro-IL-1α to the active form [420]. IL-1α 
has been shown to control allergic sensitisation to HDM [46].  
 
We have summarised the above hypotheses in the graphic below: 
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6.2 Aims 
1. To locate the NKG2D ligands in the lung in HDM challenged mice 
2. To determine whether NKG2D is important in innate or adaptive response to 
HDM 
3. To establish whether NK cells alter the level of IL-1α in HDM model 
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6.3 Results 
6.3.1 NKG2D ligand expression in the lung is increased after 9 doses and 1 
challenge with HDM 
To find the mechanisms by which NKG2D promotes allergic inflammation, we 
looked for NKG2D ligands MULT-1 (ulbp1) and the Rae-1 family in the lung. 
Snap frozen lung tissue was processed and NKG2D ligand gene expression was 
measured by qPCR in the whole lung. After 9 doses of HDM, MULT-1 
expression significantly increased in WT mice. Interestingly there was also a 
significant increase in MULT-1 expression in NKG2D KO mice challenged with 
HDM (Figure 6.1a). There was no increase in gene expression of Rae-1 family 
members as detected with a pan-specific primer/probe set (Figure 6.1b). 
Following this observation we measured MULT-1 gene expression after 1 dose 
HDM to determine how early the ligand is expressed in the lung of HDM 
challenged mice. There was a significant increase in MULT-1 gene expression 
following one HDM challenge (Figure 6.1c). There was no change in Rae-1 
expression (Figure 6.1d). 
6.3.2 NKG2D does not regulate early inflammatory responses to HDM 
Following observations above that the NKG2D ligand is expressed following one 
dose of HDM, we looked at the importance of NKG2D in early inflammatory 
responses to HDM. Mice were challenged with one dose of HDM and early 
inflammatory markers were measured. There was a significant increase in 
neutrophil chemo-attractant CXCL1 gene expression in both WT and NKG2D 
KO mice challenged with one dose of HDM and there was no significant 
difference between WT and NKG2D KO mice (Figure 6.2a). There was also a 
significant increase in early pro-inflammatory chemokine CCL2 gene expression 
in both WT and NKG2D KO mice (Figure 6.2b). Similarly there was a significant 
increase in BAL neutrophil and NK cell numbers in both WT and NKG2D KO 
mice and there was no significant difference in WT and KO responses (Figure 
6.2c-d). 
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Figure 6.1. NKG2D ligand in the lung: WT and NKG2D KO mice were challenged with HDM 
(25µg) or PBS i.n. 3 times a week for 3 weeks (a&b) or with a single dose of 70µg HDM (i.n.) 
(c&d). Lung was collected 24 hrs after the final HDM challenge and processed for qPCR analysis. 
MULT-1 (ulbp-1) and Rae-1 gene expression were measured. (n=5-6 mice per group; arithmetic 
mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above the two groups). 
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Figure 6.2. NKG2D in innate responses to HDM: WT and NKG2D KO mice were challenged 
with a single dose of HDM (70µg) or PBS (i.n.). Lung tissue was collected 24 hrs after HDM 
challenge and processed for qPCR analysis. CXCL1 (KC) (a) and CCL2 (b) gene expression was 
measured. Cytospin preparations and flow cytometry were used to count airway neutrophils (c) 
and NK cells (d). (n=5-6 mice per group; arithmetic mean+SEM, ** p≤0.01, *** p≤0.001, ns=not 
significant, indicated by a bar above the two groups). 
 
6.3.3 IL-1α is not expressed in C57BL/6 mice following HDM challenge 
To determine whether NK cells alter the level of IL-1α, we aimed to measure IL-
1α production following HDM challenge. We measured IL-1α gene expression in 
WT and NKG2D KO mice challenged with 9 doses of HDM. There is no increase 
in gene expression of IL-1α in WT or NKG2D KO mice at least in the C57BL/6 
model (Figure 6.3). Furthermore, we were unable to measure IL-1α protein levels 
in the BAL of mice treated with HDM in C57BL/6 mice (data not shown). IL-1α 
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gene expression increased in BALB/c mice challenged with HDM (personal 
communication with Laura Lambert (PhD student)).  
In addition, we measured soluble granzyme B in the BAL of mice challenged with 
HDM and were unable to detect this (data not shown). 
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Figure 6.3. IL-1α gene expression in HDM model in C57BL/6 mice: WT and NKG2D KO mice 
were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. Lung was collected 24 
hrs after HDM challenge and processed for qPCR analysis. IL-1α gene expression was measured. 
(n=5-6 mice per group; arithmetic mean+SEM, ns=not significant, indicated by a bar above the 
two groups). 
 
6.3.4 Epithelial barrier  
To measure the integrity of the epithelial barrier following HDM challenge, we 
measured BAL protein levels and LDH levels in the BAL of mice challenged with 
9 doses of HDM, as readouts of leakage of serum proteins into the airways and of 
cell death, respectively. BAL protein levels were increased significantly in WT 
mice and although this was lower in NKG2D KO mice, this difference was not 
significant (Figure 6.4a). LDH which is a marker of cell damage was significantly 
increased in WT mice challenged with HDM but there was no difference between 
WT and NKG2D KO mice (Figure 6.4a). 
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Figure 6.4. BAL protein and LDH levels: WT and NKG2D KO mice were challenged with HDM 
(25µg) or PBS i.n. 3 times a week for 3 weeks. BAL was collected 24 hrs after HDM challenge 
and BAL protein levels (a) and LDH activity (b) was measured. (n=5-6 mice per group; arithmetic 
mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, indicated by a bar above the two groups). 
 
6.3.5 There is no significant difference in antigen uptake of DCs in WT and 
NKG2D KO mice 
We hypothesised that NK cells interaction with the epithelium could lead to an 
increased ability of antigen to cross this barrier and be taken up by APC. To 
measure antigen uptake by DCs in WT and NKG2D KO mice, AF647 conjugated 
OVA was given i.n. with or without HDM and antigen content of DCs in the 
MLN was determined 24 hrs post challenge.  
 
 
 
Antigen uptake in DC in the MLN was measured by flow cytometry in WT and 
NKG2D KO mice. The gating strategy is shown in Figure 6.5. Total number of 
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OVA+ cells and OVA+ DCs in the MLN were determined.  DCs were defined as 
F4/80-CD11c+MHC II+ cells. 
There was no significant difference in the percentage or number of OVA+ cells in 
WT and NKG2D KO mice (Figure 6.6a-b). Furthermore, there was no difference 
in the numbers of OVA+ DCs in WT and NKG2D KO mice (Figure 6.6c-d). In 
conclusion, it appears that antigen uptake is not influenced by NKG2D. 
 
 
 
Figure 6.5. Gating strategy for OVA+ DCs in MLN: WT and NKG2D KO mice were challenged 
with AF647 conjugated OVA i.n. with or without HDM (50µg) and mice were culled 24 hrs post 
challenge.  MLN were collected and single cell suspension was processed and analysed on flow 
cytometry. Following exclusion of dead and doublets cells, cells were gated on AF647+ (OVA+). 
Alternatively, DCs were gated on F4/80- MHC II+ and CD11c+ and antigen uptake in these cells 
was measured by expression of AF647. Representative flow cytometry plots are shown.
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Figure 6.6. Antigen uptake by DCs in WT and NKG2D KO mice: WT and NKG2D KO mice 
were challenged with AF647 conjugated OVA i.n. with or without HDM (50µg) and mice were 
culled 24 hrs post challenge.  MLN were collected and single cell suspension was processed and 
analysed on flow cytometry. Following exclusion of dead and doublets cells, cells were gated on 
AF647+ (OVA+) and percentage (a) and total cell numbers (b) is shown. Alternatively, DCs were 
gated on F4/80- MHC II+ and CD11c+ and antigen uptake in these cells was measured by 
expression of AF647. Percentage (c) and total numbers (d) of DCs are shown. (n=5-6 mice per 
group; arithmetic mean+SEM. *p≤0.05, ** p≤0.01, ns=not significant, compared to WT PBS 
unless indicated by a bar above the two groups). 
 
6.3.6 NKG2D ligand MULT-1 is upregulated on Foxp3+ regulatory T cells 
in allergic inflammation   
To identify which cells in the lung express MULT-1, we stained epithelial cells as 
well as other inflammatory cells in WT mice challenged with 9 doses of HDM 
and measured MULT-1 expression by flow cytometry. Staining for granulocytes, 
alveolar macrophages, tissue macrophages, DCs, epithelial cells, B cells, CD8, 
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γδT, NK, NKT cells revealed that these cells do not increase MULT-1 expression 
following HDM challenge (Figure 6.7a). However there was a significant increase 
in CD4 cells expression of MULT-1 following HDM challenge (Figure 6.7a&b). 
Further analysis of this population showed that activated CD4+ cells 
(CD4+CD25+) are not expressing MULT-1 (Figure 6.7a&c), however 
CD4+CD25+Foxp3+ cells (Tregs) showed an increase in MULT-1 expression 
(Figure 6.7a&d). 
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Figure 6.7. MULT-1 expression of immune cells: WT mice were challenged with HDM (25µg) 
or PBS i.n. 3 times a week for 3 weeks. Mice were culled 24 hrs post challenge. Lung tissue was 
collected, single cell suspensions prepared and cells stained for granulocytes (Ly6G+), alveolar 
macrophages (CD11c+F4/80+), tissue macrophages (F4/80+CD11b+CD11c-), DC (F4/80-CD11c+), 
epithelial cells (CD45-EpCAM+), B cells (CD19+), CD8 (CD8+), γδT (CD3+ γδTCR+), NKT 
(CD3+NK1.1+), NK (CD3-NKp46+), CD4 (CD4+), activated CD4 (CD4+CD25+) and Tregs 
(CD4+CD25+Foxp3+). Cells were analysed by flow cytometry. Representative flow cytometry 
plots are shown (a). MULT-1 expression by MFI is shown (b-d). (n=5-6 mice per group; 
arithmetic mean+SEM. ** p≤0.01, ns=not significant, compared to PBS). 
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6.4 Discussion 
We determined that NK cells promote allergic inflammation through NKG2D and 
granzyme B expression. We aimed to further define the mechanisms by which NK 
cells are involved in allergic inflammation. We reasoned that NK cells could 
promote allergic inflammation by direct interaction with cells expressing the 
NKG2D ligand. Consequently we looked for NKG2D ligand expression in the 
lungs of mice treated with HDM. We found that the MULT-1 (ulbp-1) gene is 
upregulated in both WT and NKG2D KO mice following 9 doses of HDM (Figure 
6.1a). This indicates that NKG2D ligand expression following HDM challenge is 
independent of the NKG2D receptor as NKG2D KO mice are also able to express 
the ligand in response to HDM. Interestingly, we have shown that MULT-1 
expression is upregulated as early as 24 hrs after one dose of HDM (Figure 6.1c). 
Upon this observation we considered whether NKG2D is important in early 
responses to HDM. We had previously shown that NK cells do not appear to be 
important at early time points of inflammatory responses to HDM (Chapter 3, 
Figure 3.6). Further analysis of early inflammatory markers such as CXCL1 
(neutrophil chemoattractant) and CCL2 (early proinflammatory chemokine) 
demonstrated that although these markers are increased following one dose of 
HDM in the lung, there is no significant difference between WT and NKG2D KO 
mice (Figure 6.2a-b). Furthermore neutrophils, which are the first infiltrating cells 
in the airway after one dose of HDM, increased significantly in both WT and 
NKG2D KO mice (Figure 6.2c). Although we see differences in NK cell numbers 
with 9 doses of HDM between WT and NKG2D KO mice (Chapter 4, Figure 4.2), 
there is no difference in NK cell numbers between WT and NKG2D KO mice 
after 1 dose of HDM (Figure 6.2d). In addition, we were unable to find IL-1α 
gene or protein as an early inflammatory marker in the lung of C57BL/6 mice 
challenged with HDM (Figure 6.3).  In summary, NKG2D does not appear to 
regulate the early innate response to HDM challenge in the airways. 
 
We hypothesised that epithelial cells express the NKG2D ligand in response to 
HDM. Expression of the NKG2D ligand by epithelial cells has been shown by 
others [266, 411, 423] and there is evidence that expression of this ligand by 
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epithelial cells can lead to atopy [257]. It is not clear how HDM is able to induce 
this ligand in these cells, however we hypothesised that if epithelial cells express 
this ligand, this would lead to lysis of these cells by NK cells expressing the 
NKG2D receptor and breakdown of the epithelial barrier. Although we were able 
to show an increase in BAL protein levels in mice treated with HDM and an 
increase in LDH levels as marker of cell damage, we were unable to show any 
significant change between WT and NKG2D KO mice (Figure 6.4).   
We had also hypothesised that expression of the NKG2D ligand on epithelial cells 
could render them as targets for NK cells lysis and this could possibly lead to 
release of IL-33. IL-33 is well known for its effect on ILC2 and initiation of Th2 
responses. However it is not yet clear how this cytokine is released. The reason 
for this is that IL-33 is not secreted from cells and is expressed in the nucleus of 
non-hemopoietic cells [112] and is possibly released in large amounts as result of 
cell death. Interestingly a recent paper has shown that epithelial repair factor 
(Trefoil factor 2) which is released as a result of injury, induces IL-33 production 
and leads to airway inflammation in HDM model of asthma [426]. This supports 
the idea that IL-33 release might happen as a results of epithelial damage. Despite 
this we were not able to show ligand expression on epithelial cells and Lambrecht 
et al. also reported failure to detect dying cells following HDM administration 
[46, 427].  
 
Additionally, we aimed to measure antigen uptake by DCs that could increase 
following epithelial barrier compromise. We hypothesised there would be 
reduction in antigen uptake in NKG2D deficient mice due to the inability of NK 
cells to interact and lyse epithelial cells and this could be one of the reasons there 
is lower inflammatory responses in these mice. However there was no significant 
difference in antigen uptake by DCs between WT and NKG2D KO (Figure 6.6). 
Together this data indicates that NK cells and NKG2D do not appear to play a 
role in innate responses to HDM and suggest that NKG2D is exerting its influence 
on the adaptive phase of the allergic response. 
Following this observation we aimed to investigate which cells express the 
NKG2D ligand (protein) following HDM challenge. We stained for lung immune 
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cell subsets and looked for MULT-1 expression by flow cytometry. Expression of 
the NKG2D ligand MULT-1 is increased on Tregs in the lung (Figure 6.7d). 
However although MULT-1 expression was only upregulated on Tregs following 
HDM, some cells such as macrophages, DCs and epithelial cells show MULT-1 
expression (MFI) in both PBS and HDM. This raises the question of whether 
these cells are targets of NK cells through NKG2D activation if they 
constitutively express MULT-1. We are only able to answer this question if other 
NK cell receptor ligands expression were measured on these cells, as NKG2D 
induced activation of NK cells can be inhibited if the target cells express 
inhibitory  ligands [236, 428]. Nonetheless upregulation of MULT-1 on Tregs 
could render them as a target for NK cell lysis. 
 
We demonstrated in Chapter 3 that NK cells become more cytotoxic in response 
to HDM and there is evidence that NK cells can limit the extent of the T cell 
response to infection  via  cytotoxic  killing  of  activated effector T cells [314].  
In man and mouse,  polyclonally  activated  T cells  were shown to increase  
expression of NK cell activating ligands, which renders  them  susceptible to NK 
cell lysis  [414] and  selective lysis of regulatory T cells  by NK cells  has been 
demonstrated [415]. MULT-1 expression on Tregs suggests a mechanism in 
which NK cells kill Tregs via NKG2D. As Tregs are crucial in controlling HDM 
induced allergic  inflammation, this  would  lead to an increase  in  respiratory  
inflammation [429]. 
 
Further work is required to determine whether NK cells directly lyse Tregs in 
response to HDM and whether this mechanism is dependent on NKG2D. 
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Chapter Seven - NKp46+ Cells in the Lung are Comprised 
of RORγt+ and RORγt-. 
7.1 Introduction 
In Chapter 3 we show that NKp46+ cells produce Th2 cytokines in HDM 
challenged mice. Consequently we aimed to investigate the phenotype of these 
NKp46+ cells in the lung. 
NKp46 is expressed on conventional NK cells and ILC3. ILC are an emerging 
family of lymphocytes that are shown to be effectors and regulators of innate 
immunity. Recently ILCs have been classified into three groups based upon 
transcription factor and cytokine expression [118]. Group 1 ILCs include 
conventional NK cells that predominantly produce IFN-γ [377-379]. ILC2 are IL-
5 and IL-13 producing cells in the gut and lung in allergic inflammation and 
helminth infection [92, 113]. Group 3 ILCs include LTi cells and ILC3 [219].  
 
ILC3 are prevalent in the gut, and express RORγt [381]. NKp46+ expressing ILC3 
produce IL-22 [382-384] guard against commensal and pathogenic bacteria [382, 
393, 394]. LTi cells which are necessary for the formation of LNs during 
embryonic development are NKp46- and also produce IL-17 and IL-22, therefore 
possibly mediating immunity to microbes [383]. 
 
Mouse ILC3 cells are different from conventional NK cells as they do not express 
Ly49 and do not produce perforin.  ILC3 also do not produce IFN-γ in response to 
IL-12 and IL-18 instead they produce IL-22 in particular, in response to IL-23 
[382, 388, 389]. ILC3 differ to LTi cells by expressing NKp46 but not producing 
IL-17. 
The role of ILC3 in the lung is not known, however IL-22 producing ILC have 
been shown to be important in the innate immune response to bacterial infection 
both in the gut and lung [394, 430]. Interestingly, it has been shown that IL-13 
producing ILCs from humans which express RORγt can produce IL-22. It has also 
been shown that ILCs from the tonsil, when stimulated with IL-23 and IL-2, 
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produce IL-22 but not IL-13, whereas when stimulated with IL-2 and TLR2 
agonist produce IL-13, which indicates that not only ILCs are plastic but also are 
influenced by their environment in their cytokine production [384]. Although 
ILC2 have been shown to produce Th2 cytokines, there is no evidence of ILC3 
ability to produce Th2 cytokines in the lung. Thus we aimed to characterise 
NKp46+ ILCs in the lung, to establish their phenotype and to study their activation 
in allergic airway disease and determine whether the Th2 cytokine producing 
NKp46+ cells are in fact ILC3 cells. 
7.2 Aims 
1. To phenotype NKp46+ cells in the lung of naïve and HDM challenged mice 
2. To identify which ILCs are the source of Th2 cytokines in allergic 
inflammation 
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7.3 Results 
7.3.1 Lung NKp46+ cells are comprised of RORγt+ and RORγt- populations 
To determine the phenotype of NKp46+ cells in the respiratory system, naive 
airway and lung tissue cells were compared to MLN and spleen NKp46+ cells. In 
the airways, the majority of CD3-NKp46+ cells were RORγt+ (Figure 7.1b), 
whereas in the lung and MLN both RORγt+ and RORγt- populations were present 
(Figure 7.1c-d). Conventional NK cells are the predominant NKp46+ population 
in the spleen and here all NKp46+ cells were RORγt- cells (Figure 7.1e). We 
demonstrated expression of the IL-7 receptor subunit, CD127 on NKp46+RORγt+ 
cells, suggesting these cells were ILC3 (Figure 7.1f).  
 
 
 
 
Figure 7.1. NKp46+ cells are comprised of RORγt+ and RORγt- cells in the lung: WT BALB/c 
mice were culled and lungs were collected. Single cell suspensions were processed and cells were 
stained for NKp46 and RORγt expression. Cells were analysed by flow cytometry. Representative 
flow cytometry plots are shown (a). Following exclusion of doublet dead cells, CD3-NKp46+ cells 
were gated on RORγt. BAL (b) lung (c) MLN (d) and spleen (e) cells are shown. CD127 
expression is shown on lung RORγt+ cells (f). 
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7.3.2 Phenotype of NKp46+ cells in the lung and MLN 
To determine the phenotype of NKp46+RORγt+ cells in the lung, cells from PBS 
and HDM challenged mice were stained for different surface markers and 
compared to MLN cells. In the lung, both PBS and HDM challenged mice 
expressed DX5 on NKp46+ RORγt+ and NKp46+ RORγt- cells (Figure 7.2a). 
  
In the MLN the proportion of DX5+ NKp46+ RORγt+ was lower (Figure 7.2i). 
Interestingly in both lung and MLN, NKp46+ RORγt+ cells were NKG2D and 
granzyme B negative (Figure 7.2b&c-j&k). Although in the lung expression of 
Ly49G was observed on both NKp46+ RORγt+ and NKp46+ RORγt- (Figure 7.2d), 
in MLN only NKp46+ RORγt- expressed Ly49G (Figure 7.2i).  
In addition lung NKp46+ RORγt+ cells do not appear to express CD11b and 
CD27, however NKp46+ RORγt- cells which have conventional NK cells 
phenotype express CD11b and CD27 (Figure 7.2e-f). MLN NKp46+ RORγt+ cells 
express CD27 but not CD11b (Figure 7.2m-n).  
Interestingly lung and MLN NKp46+ RORγt+ cells express high levels of T1/ST2 
(Figure 7.2g&o). Furthermore, almost all lung NKp46+ RORγt+ cells express c-kit 
(Figure 7.2h) but the proportion of NKp46+ RORγt+ cells in MLN that express c-
kit is lower (Figure 7.2p). 
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Figure 7.2. NKp46+ RORγt+ cells phenotype in the lung: WT BALB/c mice were challenged 
with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. Mice were culled 24 hrs post challenge 
and lung (left columns) and MLNs (right columns) were collected. Single cell suspensions were 
prepared and cells were stained for NKp46 and RORγt expression and other surface markers. Cells 
were analysed on flow cytometry. Representative flow cytometry plots of CD3-NKp46+ cells for 
expression of DX5 (a&i), NKG2D (b&J), granzyme B (c&k), Ly49G (d&i), CD11b (e&m), 
CD27 (f&n), T1/ST2 (g&o), c-kit (h&p) against RORγt are shown.  
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7.3.3 Numbers of airway NKp46+RORγt+ cells increase following HDM 
challenge 
In the airways, both RORγt+ and RORγt- cell numbers increased significantly 
following HDM challenge (Figure 7.3a), although the proportion of NKp46+ cells 
which were RORγt+ decreased (Figure 7.3b) due to a larger influx of the 
conventional RORγt- NK cells into the airway. Similarly the proportion of the 
RORγt+ cells decreased in the lung following HDM challenge (Figure 7.3d); 
however the total number of these cells did not change in the lung (Figure 7.3c). 
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Figure 7.3. Airway NKp46+ RORγt+ cells increase with HDM: WT BALB/c mice were 
challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. Mice were culled 24 hrs 
post challenge and BAL and lungs were collected. Single cell suspensions were prepared and cells 
were stained for NKp46 and RORγt expression and were analysed on flow cytometry. BAL and 
lung total cells (a&c) and proportion of NKp46+ cells which were RORγt+ (b&d) are shown. (n=5-
6 mice per group; arithmetic mean+SEM. ** p≤0.01, ns=not significant, compared to PBS). 
 
Page 147 of 194 
 
7.3.4 NKp46+RORγt+ cells are a source of Th2 cytokines in HDM 
challenged mice 
To determine which NKp46+ cells are the source of Th2 cytokines in HDM 
challenge, we stained NKp46+RORγt+ and NKp46+RORγt- cells for Th2 cytokines 
and IL-22. NKp46+RORγt+ produce IL-4 and IL-13 following HDM challenge 
(Figure 7.4a-b) and do not appear to be a source of IFN-γ (Figure 7.4c). However 
NKp46+RORγt- cells produce IFN-γ following HDM challenge (Figure 7.4c). 
NKp46+RORγt+ cells also produce IL-22 following HDM challenge, 
NKp46+RORγt- cells do not appear to produce IL-22 (Figure 7.4d). 
 
 
Figure 7.4. NKp46+ RORγt+ cells produce Th2 cytokines following HDM challenge: WT 
BALB/c mice were challenged with HDM (25µg) or PBS i.n. 3 times a week for 3 weeks. Mice 
were culled 24 hrs post challenge and BAL and lungs were collected. Single cell suspension was 
processed and cells were stained for NKp46 and RORγt. Intracellular staining for IL-22 and Th2 
cytokines was performed. Cells were analysed on flow cytometry. Representative flow cytometry 
plot of lung CD3-NKp46+ cells for IL-4 (a), IL-13 (b), IFN-γ (c) and IL-22 (d) production against 
RORγt are shown. Proportion of cytokine producing RORγt+ cells are shown at the bottom of each 
flow cytometry plot. (n=5-6 mice per group; arithmetic mean+SEM. * p≤0.05, ** p≤0.01, ns=not 
significant, compared to PBS). 
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7.4 Discussion 
We demonstrated in Chapter 3 that NKp46+ cells in the lung produce Th2 
cytokines following HDM challenge. Production of Th2 cytokines by NK cells 
have been shown before [352, 353, 431-434]. The human data for production of 
Th2 cytokines by NK cells (defined as CD56+) were produced following 
stimulation ex vivo in isolated PBMC, whereas in the mouse NK cells were 
analysed ex vivo and defined as DX5+ cells. Hoshino et al. showed both human 
and mouse NK produce IL-13 and IL-5 in the absence of IFN-γ and stimulated 
with IL-2 in vitro  [431]. In addition, McDermott et al. showed IL-13 production 
by interepithelial DX5+ NK cells in intestinal nematode infection [319]. We 
defined NK cells by NKp46 and showed Th2 production in the lung by these 
cells. However NKp46 is expressed on conventional NK cells and on ILC3 which 
are RORγt+.   
 
We have shown that in naive airways the majority of CD3-NKp46+ cells were 
RORγt+ cells (Figure 7.1b), whereas in the lung and MLN both RORγt+ and 
RORγt- populations were present (Figure 7.1c-d). In the spleen, the NKp46+ 
population only contained RORγt- cells (Figure 7.1e), as expected for 
conventional NK cells which are the only NKp46+ population found at this site 
[435]. The presence of an NKp46+RORγt+CD127+ population of ILCs in the lung 
(Figure 7.1f) suggested that these were type-3 ILCs, whereas the NKp46+RORγt-
CD127- cells are suggestive of conventional NK cells. As ILC3 have not been 
previously characterised in the lung, we aimed to further phenotype their surface 
marker expression to allow comparison with the conventional NK cell. 
 
Consistent with a conventional NK cell phenotype, lung and MLN 
NKp46+RORγt- cells expressed the major NK cell activating receptor, NKG2D 
and granzyme B (Figure 7.2b-c & j-k). The NKG2D receptor and granzyme B 
were absent in ILC3 (NKp46+RORγt+) cells (Figure 7.2b-c & j-k). This is in 
contrast to the NKG2D+ phenotype reported for CD3-NKp46+ cells in the gut 
[382, 388, 389]. As conventional NK cells mature, they lose CD27 expression and 
gain CD11b expression, and we found these different stages of maturation present 
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in lung conventional RORγt-NKp46+ cells (Figure 7.2e-f). These markers were 
largely absent from NKp46+RORγt+ cells, although a proportion of RORγt+ cells 
in MLN were CD27+ (Figure 7.2n). This is similar to the phenotype reported for 
gut NKp46+ cells [382, 388, 389]. Although MLN NKp46+RORγt+ cells were c-
kit- (Figure 7.2p), both BAL and lung NKp46+RORγt+ cells were c-kit+ (Figure 
7.2h), which was also reported for gut NKp46+ ILCs [388, 389]. 
 
Furthermore in the lung both RORγt- and RORγt+ NKp46 cells exhibited 
heterogeneity in their Ly49G expression (Figure 7.2d), in the MLN RORγt+ cells 
were Ly49G- (Figure 7.2i). In the MLN all cells were DX5+ (Figure 7.2i), as 
would be expected for conventional NK cells. Surprisingly not all NKp46+RORγt- 
cells were DX5+. Furthermore, a proportion of RORγt+ cells in the lung were 
DX5+ (Figure 7.2a). Low levels of DX5 expression were reported on Peyer’s 
patches and gut, but not on lamina propria NKp46+ cells [388, 389].  
 
Interestingly, NKp46+RORγt+ cells were positive for the IL-33 receptor, T1/ST2 
(Figure 7.2g&o). As T1/ST2 is expressed on cells involved in type-2 responses, 
this may be a mechanism by which these cells are activated in allergic lung 
inflammation. Interestingly, we observed both RORγt+ and RORγt- cell numbers 
increased significantly following HDM challenge in the airways (Figure 7.3a&c). 
Following ICS, we demonstrated NKp46+RORγt+ cells are a source of Th2 
cytokines (Figure 7.4a-b) and IL-22 (Figure 7.4d) following HDM challenge, 
whereas IFN-γ was limited to the RORγt-NKp46+ conventional NK cells (Figure 
7.4c). There is some evidence that under certain circumstances ILC3 cells may 
reduce their RORγt expression and acquire the ability to produce IFNγ, perhaps 
indicating a transition from ILC3 to ILC1 [392] and demonstrating the phenotypic 
plasticity of this ILC subset. 
 
In summary, we have shown for the first time that lung NKp46+ cells are 
comprised of two populations; conventional NK cells which are CD3-
NKp46+RORγt- and CD3-NKp46+RORγt+ cells which have a similar phenotype to 
ILC3. In homeostasis the majority of airway NKp46+ cells are RORγt+ ILC3. 
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NKp46+RORγt- cells express both NKG2D and granzyme B and are the source of 
IFN-γ in the lung whereas NKp46+RORγt+ cells do not express NKG2D, 
granzyme B and IFN-γ, instead they are CD127+ and can produce IL-22. Overall, 
lung NKp46+RORγt+ ILC exhibit a phenotype which is similar, but which differs 
slightly to that described for gut ILC3s. The difference observed in our study in 
phenotype of ILC3 and the published data on ILC3 in the gut could be due to 
strain differences as the published data is carried out on C57BL/6 mice and here 
we used BALB/c mice. 
 
Further understanding of these cells and intervention studies would determine the 
role of ILC3 in the lung and in allergic inflammation. 
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Chapter Eight – Conclusion and Future Work 
In this thesis we show for the first time that NK cells promote allergic airway 
inflammation in response to HDM, by mechanisms dependent on NK cell intrinsic 
expression of NKG2D and granzyme B. In addition we demonstrated that lung 
NKp46+ cells are comprised of RORγt+ and RORγt- and NKp46+ RORγt+ cells 
possibly contribute to allergic inflammation to HDM by producing Th2 cytokines. 
 
8.1 NK cells NKG2D and granzyme B are critical in allergic 
airway inflammation  
NK cells are a first line of defence against viral infections; however the role of 
these cells in allergic airway disease is still unclear. The small numbers of 
published studies on these cells in allergic airway disease have only been carried 
out in conventional murine asthma models such as OVA induced airway 
inflammation. Although OVA models are well established, they are believed to be 
less clinically relevant and require a use of adjuvant and systematic sensitisation 
before local challenges. In addition, the studies carried out by others have only 
depleted NK cells by means of antibodies such as anti-NK1.1 and anti-ASGM1, 
which are also present on other cells [361, 363]. These potential off-target effects 
mean that these studies are inconclusive [45, 304, 364, 436-438]. 
 
We chose to use the HDM model of allergic lung inflammation as this model is 
well cited within the literature and HDM is a major cause of domestic asthma. In 
animal models HDM causes a robust airway inflammation and remodelling 
similar to that seen in asthmatics [43, 405, 409], following local administration 
without the need for adjuvant. 
 
We aimed to characterise NK cells in allergic inflammation of the lung and study 
NK cell phenotype and dynamics in this model. We carried out a time course 
study to examine NK cell responses at different times during establishment of the 
allergic response. 
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In the time course study, continuous intranasal exposure to HDM led to Th2 
immunity and inflammation with a significant recruitment of inflammatory cells 
into the airways. Eosinophil numbers peaked at week 3 after 9 doses of HDM. We 
observed a dose dependant increase in airway and lung CD4 cells. We 
demonstrated that lung CD4+ cells produce IL-4 and IL-13 and in the airways 
CD4+ lymphocytes produce IFN-γ, as well as Th2 cytokines. However the IL-4 
production was far more significant than the IFN-γ. Although LN cell numbers 
increased significantly throughout the time course, there was no change in spleen 
total cell numbers which indicated the immune response to HDM is a local rather 
than a systemic response.  
 
We observed IL-4 production by CD3-NKp46+ cells in the time course study. We 
then questioned, if as seen in Th1 immunity where NK cells travel to LN and are 
early source of IFN-γ for T cell polarisation [320], NK cells could be an early 
source of IL-4 within the LNs and contribute to initiation of Th2 immunity. 
Although the percentage of NK cells in MLN was reduced with increasing doses 
of HDM, the total cell numbers increased after 4 doses of HDM.  Contrary to 
what is reported by Ple et al. [363] and what is observed in Th1 immunity [320],  
the number of NK cells did not increase at early time points, suggesting that NK 
cells are not involved in initiation of Th2 immunity. Increases in NK cell numbers 
in the lung follows the same trend as Th2 cells and eosinophils and this could 
imply a relationship between NK cell activation and eosinophilia. Interestingly a 
recent paper showed that in a resolution model of allergic inflammation, NK cell 
numbers in the mLN reduce at the peak of inflammation but then increase during 
the resolution period, when eosinophilia and Th2 cells decrease. Furthermore, 
depletion of NK cells delayed resolution of inflammation, further indicating the 
possible regulatory role for NK cells [365].  
 
We had also hypothesised that in Th2 environments NK cells might become less 
cytotoxic and speculated whether this is the reason that asthmatics are more prone 
to respiratory viral infections. To our surprise, NK cells in the BAL produce 
significant amounts of granzyme B following HDM challenge.  Therefore we 
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carried out functional cytotoxicity assays and further demonstrated that NK cells 
are cytotoxic following HDM challenge. Our observations led us to investigate the 
role of NKG2D in allergic inflammation by using NKG2D KO mice as NKG2D is 
a major activatory receptor mediating the cytotoxic function of NK cells.  
Allergic inflammation was severely attenuated in mice deficient in NKG2D 
compared to WT mice treated with HDM, exhibiting lower cell infiltration and 
reduced Th2 responses. 
 
NK cells get activated through many mediators in Th1 immunity such as 
cytokines [294-297] however it is not clear how NK cells get activated during 
allergic inflammation and during Th2 immunity. 
There is evidence that NK cells are activated through the CD16 receptor and upon 
IgE stimulation, show cytotoxicity against IgE coated target cells. This could 
result in cytokine and chemokine release and contribute to IgE mediated allergic 
inflammation [439]. Furthermore, IL-4 induced cytotoxic activity in NK cells has 
also been demonstrated by others. In this study cytotoxic activity and expression 
of perforin and granzyme B were enhanced by activation of memory Th2 cells 
and IL-4 production by these cells was critical for the anti-tumour effect of NK 
cells against OVA expressing tumour cells [440]. NK cells also express TLR 
receptors and it cannot be disregarded that they get activated by TLR stimulation 
[441]. 
Although we were not able to rule out activation by cytokines or TLRs in our 
study, one mechanism could be through activation of NKG2D. We show in 
NKG2D KO mice that their expression of CD69 and granzyme B production is 
less than WT mice treated with HDM. Furthermore the numbers of NK cells are 
also less in NKG2D KO mice, but whether NKG2D activation is involved in 
recruitment of NK cells in the lung remains to be established. Interestingly we 
saw upregulation of MULT-1 expression following administration of a single dose 
of HDM and this was independent of the presence of NKG2D, as we observed the 
same levels of expression in NKG2D KO mice. Upregulation of the ligand as 
early as 1 dose, could be a mechanism by which NK cells get activated. 
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We asked whether NKG2D was important for the adaptive or the innate response 
to HDM allergen. After a single challenge with HDM extract, we see no 
differences in the inflammatory response in NKG2D deficient mice, suggesting 
that NKG2D is exerting its influence on the adaptive phase of the allergic 
response. This is in addition to the earlier data we had from a time course study 
suggesting that NK cells are involved in later adaptive responses to HDM and not 
important at early innate responses. 
 
We observed no difference in the phenotype of NKG2D KO mice compared to 
WT mice in the absence of HDM challenge and although there is supporting 
evidence in the literature [412], we decided to test these mice in a different 
inflammatory condition. RSV infected NKG2D mice exhibited the same 
inflammatory responses as WT mice and NKG2D was not required for immune 
responses to respiratory viral infection. Therefore the response we see in NKG2D 
KO mice is not due to their phenotype or their NK cell development but it is a 
specific response to HDM. 
 
We then aimed to establish which cells expressing NKG2D are important in 
allergic inflammation as NKG2D is expressed on many cells including NKT, γδT, 
CD4 and CD8 cells [234, 235]. First we showed that in the lung 80% of NKG2D+ 
lymphocytes are NK cells. Secondly, we transferred WT NK cells in NKG2D KO 
mice and demonstrated that adoptive transfer of WT NK cells into NKG2D KO 
mice restored the inflammatory response to HDM almost 100% back to WT 
levels. In our studies we used NKp46 to isolate NK cells for adoptive transfer as 
in the spleen, this marker is exclusively expressed on NK cells [435] thus 
conclusively demonstrating that NK cells promote allergic lung inflammation in 
our model. In addition to the transfer of WT NK cells we transferred granzyme B 
deficient NK cells into NKG2D KO mice. Interestingly we observed that transfer 
of these cells did not restore the response further indicating that NK cell 
cytotoxicity is driving allergic inflammation. 
Furthermore, transfer of CD3+ cells did not restore the inflammatory responses to 
HDM, indicating that the selective expression of NKG2D on NK cells is critical 
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for enhancing lung inflammation in response to HDM allergen, and they do this 
via both NKG2D and granzyme B production.   
 
The importance of granzyme B as an effector molecule suggests cytotoxic 
mechanisms play a role in NK cell regulation of the adaptive response. NK cells 
can limit the extent of the T cell response to infection via cytotoxic killing of 
activated effector T cells [314]. In man and mouse, polyclonally activated T cells 
increase expression of NK cell activating ligands, which renders them susceptible 
to NK cell lysis [414].  
 
Although we found NKG2D ligand MULT-1 gene expression in the lung as early 
as 1 dose and also 9 doses of HDM, because MULT-1 is constitutively expressed 
at mRNA levels [239], we aimed to show the protein expression of this ligand on 
the target cells.  
 
NKG2D ligand MULT-1 was found to be upregulated on lung Tregs identifying 
them as potential targets for NK cell lysis and suggesting a mechanism in which 
NK cells kill Tregs via NKG2D.  
As regulatory T cells are crucial in controlling HDM induced allergic 
inflammation, this would lead to an increase in respiratory inflammation [187]. 
Interestingly in asthma, regulatory cells such as Tregs appear to be reduced [190, 
442] and NKG2D ligand expression on Tregs have also been reported [415], 
whether these cells are targets of NK cells in allergic airway inflammation and 
whether consequently this would lead to susceptibility to RSV infection remains 
to be studied.  
 
We were not able to demonstrate how Tregs upregulate MULT-1 in response to 
HDM, however there is evidence in the literature which indicates TLR activation 
could lead to NKG2D ligand expression. In mouse peritoneal macrophages 
stimulation of TLR4 by LPS lead to upregulation of Rae-1 in these cells [265] and 
TLR4 engagement on renal tubular epithelial cells also lead to expression of 
NKG2D ligands on these cells [260].  As HDM extract contains LPS, it can be 
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postulated that a similar mechanism is involved in upregulation of MULT-1 on 
Tregs in our model. 
There is also evidence in the literature that regulatory T cells from patients with 
allergic asthma are susceptible to granzyme B mediated cytotoxicity, which 
correlates with clinical severity [443]. Granzyme B can regulate inflammation by 
non-cytotoxic mechanisms [46, 418-420]; however we were not able to 
demonstrate this role in our model.  
 
Our data suggests a model in which Tregs which otherwise dampen down Th2 
responses and eosinophilia, upregulate the NKG2D ligand in response to HDM 
and consequently become the target of NK cells which have also upregulated 
NKG2D and granzyme B as a result of exposure to HDM. Activated NK cells lyse 
Tregs and this leads to removal of a regulatory mechanism and therefore leads to 
inflammation such as eosinophilia (Figure 8.1). 
 
 
Figure 8.1. Proposed mechanism of NK and Treg interaction in HDM model. 
 
In support of our data, natural killer activity is high in the peripheral blood of 
people with asthma [345, 407, 408] and in severe asthma NK cells exhibit 
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increased expression of CD69 and NKG2D. Interestingly expression levels of 
these surface molecules correlate with the percentage of blood eosinophils [356]. 
Furthermore, patients with allergic asthma have elevated levels of granzyme B 
expressing NK cells and granzyme B protein in the airways following allergen 
challenge [359, 360]. Intriguingly the NKG2D ligands MICA and ULBP-2, are 
elevated in the serum of children with HDM allergy [357]. Furthermore genome 
wide meta-analysis identified 6p21.33 locus near HLA-C and MICA strongly 
associated with allergic asthma [358]. Interestingly, a recent paper also reports a 
proinflammatory role for NK cells in development of allergic airway disease 
[444]. This study, in which allergic lung inflammation is induced by OVA, show 
an increase in NK cells in the airway and depletion of NK cells lead to reduction 
in airway inflammation. Interestingly, although they show a role for NK cells in 
shaping T cells response in allergic inflammation, they conclude this is not due to 
cytotoxic function of NK cells as perforin KO mice develop allergic inflammation 
similar to WT mice. 
 
Asthma has enormous health care expenditure associated with it due to 
exacerbation resulting in major morbidity and mortality [445]. In addition many 
patients do not respond to therapy [129], Thus NK cell activation via NKG2D and 
their granzyme B production may be important new therapeutic targets in asthma 
and allergic disease. 
 
8.1.1 Future work 
In our studies we were not able to determine how NK cells get activated in 
allergic inflammation. Studying the release of cytokines and different NK cell 
receptor upregulation could demonstrate what controls their activation. Use of 
TLR KO mice could determine whether NK cells activation is compromised in the 
absence of particular receptors.  
 
Our results suggest that NK cells can directly regulate the T cell response by 
killing Tregs. This would result in an increase in inflammation in the presence of 
effective NK cell killing, which is consistent with our observations in NKG2D 
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KO mice. To determinate the mechanism by which NK cells influence Tregs, full 
characterisation of NK cell ligands expression on these cells in allergic 
inflammation is required. Although upregulation of activating ligands may cause 
Tregs to become NK cell targets, loss of inhibitory ligands such as Qa-1 could 
also be a potential mechanism [306]. In addition, by means of in vitro killing 
assays direct killing of Tregs by NK cells can be demonstrated. Furthermore to 
demonstrate NKG2D dependant killing of these cells, anti-NKG2D can be used in 
this assay. In vivo transfer of labelled Tregs into mice which have been challenged 
with HDM can demonstrate if these cells are targets and undergo lysis.  
We have conclusively demonstrated that NK cell granzyme B expression is 
needed for the actions of NK cells, however, non-cytotoxic functions of granzyme 
B could also play a role. To determine whether cytotoxic function of granzyme B 
is involved in NK cells function in allergic inflammation, perforin deficient mice 
can be used. Perforin is required for cytotoxic function of NK cells. Transfer of 
perforin deficient NK cells into NKG2D KO mice would determine if 
inflammatory responses are dependent on the cytotoxic function of NK cells. 
 
We were unable to fully replicate our KO data with the use of anti-NKG2D Ab 
and we believe this is mainly due to dosing regimen and optimisation of the 
protocol. Further work is required to determine which protocol and dose is 
required. The outcome of this could have important implications in potential 
therapeutic target of NKG2D in treatment of asthma.  
 
Finally, due to time and resource constraints we were not able to acquire human 
data to support our observation in mice. Studying NK cells in human has 
limitations which include the inability to access substantial material from the 
exact site of disease, the reliance on peripheral blood samples and the severe 
restrictions on interventional experimentation. However our work can lead to 
future studies in patients that would determine the role of NK cells in various 
asthma phenotypes.  
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8.2 ILC3 are present in the lung and are the source of Th2 
cytokines 
In our time course study we observed Th2 cytokine production by NKp46+ cells 
and although there is evidence of Th2 cytokine production by NK cells in the 
literature we aimed to phenotype these cells in the lung. We found that NKp46+ 
cells were comprised of RORγt+ and RORγt- and they are phenotypically 
different. NKp46+RORγt+ population expressed the IL-7 receptor subunit CD127, 
suggesting these cells were ILC3. The lung and airway NKp46+RORγt- population 
were CD127- and express NKG2D and granzyme B, therefore we believe this 
population to be conventional NK cells [222, 392].  
 
Further characterisation of lung NKp46+RORγt+ cells revealed a phenotype which 
is similar to what is described as ILC3s. Interestingly, lung NKp46+RORγt+ cells 
were positive for the IL-33 receptor; T1/ST2 a marker associated with ILC2 cells 
however ILC2 do not express RORγt. Whether lung ILC3 get activated via 
T1/ST2 receptor during allergic inflammation remains to be studied. 
 
Both NKp46+ RORγt+ and RORγt- cell numbers increased significantly in the 
airway following HDM challenge. We demonstrate that NKp46+RORγt+ cells are 
a source of Th2 cytokines IL-4, IL-13 and IL-22 following HDM challenge, 
whereas conventional NK cells only produced IFN-γ. Others have reported 
production of type-2 cytokines by DX5+ and NK1.1+ cells in the gut in helminth 
infection and our data suggest this source may be ILC3 [319, 389, 431, 446, 447]. 
In human PBMCs, production of Th2 cytokines by CD56 cells was also reported 
[347, 349, 353, 431]. Interestingly, although NK cells in human express CD56, 
this marker is also found on human IL-22 producing ILCs [397, 448, 449].  
 
Crellin et al demonstrated that tonsillar RORγt+CD127+ cells stimulated ex vivo 
can produce IL-5 and IL-13. Although the relationship between these cells and the 
cells we find in the lung is not clear, it suggests that there is a human counterpart 
for the Th2 cytokine producing RORγt+ mucosal cells [384]. Interestingly the 
human blood ILC2 defined by CRTH2 and CD161 expression also expressed low 
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levels of RORγt [126]. These cells were shown to produce IL-22 and IL-13, 
therefore supporting our observation of Th2 production by ILC3, which are not 
known to produce Th2 cytokines. 
 
Production of IL-22 and Th2 cytokines by ILC3 in our model is intriguing as IL-
22 is mostly known to be anti-inflammatory and protective especially to epithelial 
cells [450, 451]. However, IL-22 has also been shown to be pro-inflammatory 
[396]. IL-22 is shown to be required during sensitisation to OVA and IL-22 
administration has been shown to reduce allergic lung inflammation in mice [400, 
402]. Interestingly a recent paper has shown an immunopathogenic role for IL-22 
in a mouse model of chronic fungal allergy [403]. 
 
In summary, we show that ILC3 cells produce Th2 cytokines in allergic 
pulmonary inflammation, demonstrating a previously unappreciated subset of 
ILC3 and identifying a novel innate source of type-2 cytokines. In asthma, similar 
characteristics are observed in RORγt+IL-17+CD4+ T cells which co-produce Th2 
cytokines, and thus mirror the ILC phenotype we report [452, 453].  
 
8.2.1 Future work 
Our preliminary data needs to be supported with further studies of these cells in 
the lung. We have used Ab against RORγt to examine these cells by flow 
cytometry. To confirm our observation, RORγt reporter mice can be used which 
would allow isolation of these cells by flow cytometry, measurement of different 
cytokines and transcription factor gene expression. Furthermore isolation of these 
cells would allow in vitro manipulation of these cells to determine their activation 
and polarisation by different cytokines such as IL-33. In vitro expansion of these 
cells would be useful as they can be adoptively transferred in genetically modified 
mice to determine the importance of their cytokine production in allergic 
inflammation, in the absence of other cells' expression of that cytokine, such as 
IL-4 and IL-13. As an alternative approach mice selectively lacking Th2 cytokines 
such as IL-4 in NKp46+ cells can be used by means of back crossing Cre (under 
NKp46 promoter) mice with floxed mice on a specific cytokine. 
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Studying these cells in another Th2 environment such as helminth infection would 
determine whether this is a unique differentiated cell type found only in the lung 
or whether gut derived NKp46+ cells also produce Th2 cytokines. 
 
Due to lack of biological resources, it is not yet possible to carry out intervention 
studies such as selective depletion of these cells. Others have tried complicated 
methodologies to study these cells in the gut. Sawa et al [454] compared RAG-/- 
(no T and B cells, but would have both conventional NK and ILC3) to RAG-/-
RORγt-/- (no T, B or RORγt+ cells, but should have conventional NK cells). 
Vonarbourg et al [392] used RAG-/- mice and used antibodies which deplete 
different combinations of cNK, LTi and ILC3 cells. In their work, the application 
of anti-ASGM1 resulted in the depletion of most cNK cells, whereas LTi cells and 
ILC3 cells were unaffected. Anti-NK1.1 depleted LTi and cNK cells but not ILC3 
and anti-Thy1 injections led to the depletion of virtually all innate lymphocyte 
populations. However none of the Abs described above are selective for these 
cells and further understanding these cells would lead to development of ways to 
study their function. 
 
The production of type-2 cytokines by these cells is of particular relevance to lung 
disease where these cytokines are believed to underlie inflammation, exacerbation 
and remodelling associated with asthma. These cells could therefore represent a 
novel target for therapy in pulmonary inflammation. 
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Other works presented or published from this work: 
1. Finalist: MedImmune Abstract Competition 2011: 
The role of NK cells in a murine model of allergic inflammation  
Understanding the contribution of the innate immune system to the pathogenesis 
of asthma is an important and growing area of research. Asthmatics are more 
prone to respiratory viral infections and NK cells are a first line of defence against 
infections. Although there is evidence for a role for NK cells in allergic airway 
disease, it is not known whether NK cell responses are altered by allergic 
inflammation or the mechanisms that might underlie the NK cell’s effects in 
asthma. 
We aim to test the following linked hypotheses:  
– Different NK cell functions (cytokine production and cytotoxicity) control 
allergic airway disease.  
– Allergic inflammation influences NK cell phenotype and function with 
consequences for respiratory viral infection.  
We employed a model of murine allergic airway inflammation in which mice are 
dosed 3 times a week for 3 weeks with HDM (house dust mite) extract and culled 
24 hour after the last HDM challenge. 
We demonstrated that numbers of NK cells in the BAL (bronchoalveolar lavage) 
increase following HDM challenge and this change follows a similar trend to 
BAL eosinophils and Th2 cells, suggesting a proinflammatory role for NK cells, 
which is in support of literature. We have demonstrated for the first time in 
allergic lung inflammation that pulmonary NK cells contribute to Th2 immunity 
by producing Th2 cytokines such as IL-4. We performed a time-course study and 
showed that the activating receptor NKG2D and granzyme B production on NK 
cells increase significantly following HDM challenge.  Furthermore we have 
shown by means of functional assays (killing assay and LAMP-1 expression) NK 
cells become more cytotoxic. 
Preliminary studies using the HDM model in NKG2D KO mice show a dramatic 
reduction in the extent of the inflammatory response in the absence of this 
receptor. Reduction in BAL cell infiltration and lung NK cells, as well as 
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granzyme B and cytokine production in lung NK cells in NKG2D KO mice, 
suggests an important role for this receptor in allergic inflammation.  
Future studies will determine the mechanisms by which NK cells and NKG2D can 
regulate allergic inflammation. The outcomes of this research are expected to 
clarify on the role of NK cells in allergen induced airway inflammation, which 
will provide new insight into control of human allergic reactions and 
susceptibility to respiratory viral infection in asthmatic patients. 
 
2. ATS 2013 Poster Presentation: 
Am J Respir Crit Care Med 187;2013:A2680 
 
The Role of NK Cells in Allergic Inflammation of the Lung 
Introduction: NK cells are innate cells of the immune system and constitute 10% 
of lung lymphocytes. Increasing evidence implicates innate immunity in the 
pathogenesis of asthma and although there is evidence of a role for NK cells in 
development of allergic inflammation, the mechanisms by which NK cells 
contribute to allergy is not known. Understanding these mechanisms could have 
therapeutic implications for asthma. 
Hypothesis: NK cells contribute to allergic inflammation of the lung through 
their major activating receptor NKG2D. 
Method: We aimed to determine the phenotype of NK cells in allergic 
inflammation by employing a murine model in which mice are dosed 3 times a 
week for 3 weeks with house dust mite (HDM) extract and culled 24 hours after 
the last HDM challenge. In addition NKG2D knockout (KO) mice were used to 
determine the importance of this receptor in this model. 
Result: We performed a time-course study and demonstrated that numbers of NK 
cells in the bronchoalveolar lavage (BAL) increase over the course of HDM 
challenge and this follows a similar trend to BAL eosinophils and Th2 cells. We 
showed that the major activating receptor NKG2D and granzyme B production by 
NK cells increase significantly following HDM challenge. Furthermore we have 
shown by means of functional assays (LAMP-1 expression) NK cells become 
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more cytotoxic. In addition we have shown upregulation of the NKG2D ligand 
(MULT-1) in the lung of the mice treated with HDM. 
In order to determine the importance of the NKG2D receptor in allergic 
inflammation we tested the HDM model in NKG2D KO mice. We showed a 
dramatic reduction in the extent of the inflammatory response in the absence of 
this receptor. We observed approximately 60% reduction in BAL eosinophilia, 
Th2 responses and serum IgE production. To determine the requirement for 
NKG2D expression on NK cells, we adoptively transferred WT NK cells into 
NKG2D KO mice, which restored allergic inflammatory responses to HDM. In 
addition we showed that NK cell function in allergic inflammation is granzyme B 
dependant, as adoptive transfer of granzyme B-/- NK cells did not restore the 
response to HDM. 
Conclusion: We have identified a novel mechanism by which NK cells contribute 
to allergic inflammation in the lung. The NKG2D receptor on NK cells promotes 
allergic inflammation and this function is dependent on NK cell cytotoxicity. 
 
3. Journal of Allergy and Clinical Immunology:  
2014 March;133(3):827-835. doi: 10.1016/j.jaci.2013.09.048 
 
Natural killer cell NKG2D and granzyme B are critical for allergic 
pulmonary inflammation 
Background: The diverse roles of innate immune cells in the pathogenesis of 
asthma remain to be fully defined. Natural killer (NK) cells are innate 
lymphocytes that can regulate adaptive immune responses. NK cells are activated 
in asthma; however, their role in allergic airway inflammation is not fully 
understood. 
Objective: We investigated the importance of NK cells in house dust mite 
(HDM)-triggered allergic pulmonary inflammation. Specifically, we aimed to 
determine the role of the major NK-cell activating receptor NKG2D and NK-cell 
effector functions mediated by granzyme B. 
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Methods: Allergic airway inflammation was induced in the airways of mice by 
repeated intranasal HDM extract administration and responses in wild-type and 
NKG2D-deficient mice were compared. Adoptive transfer studies were used to 
identify the cells and mechanisms involved. 
Results: Mice that lacked NKG2D were resistant to the induction of allergic 
inflammation and showed little pulmonary eosinophilia, few airway TH2 cells, and 
no rise in serum IgE after multiple HDM-allergen exposures. However, NKG2D 
was not required for pulmonary inflammation after a single inoculation of 
allergen. NKG2D-deficient mice showed no alteration in responses to respiratory 
virus infection. Transfer of wild-type NK cells (but not CD3+ cells) into NKG2D-
deficient mice restored allergic inflammatory responses only if the NK cells 
expressed granzyme B. 
Conclusions: These studies established a pivotal role for NK-cell NKG2D and 
granzyme B in the pathogenesis of HDM-induced allergic lung disease, and 
identified novel therapeutic targets for the prevention and treatment of asthma. 
 
 
 
